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This work describes investigations into the synthesis of new potential multimodal agents for 
medical imaging of cancer cells. For this purpose, two approaches were used: (i) based on 
novel fluorescent nanohybrids based on iron oxide nanoparticles, and (ii) based on a 
symmetric tripodal core that can be functionalised, giving rise to bifunctional chelating 
molecular and nanocomposite agents. Each Chapter of this thesis describes the synthesis and 
characterisation of the different components of the desired probes. The cellular viability of the 
as-prepared imaging agents was evaluated using different cell lines (e. g., PC-3, EMT6 and 
FEK-4) and assays, such as MTT and crystal violet. Laser scanning confocal microscopy 
investigations were carried out on the new fluorescent conjugates synthesised hereby to study 
their localisation within cancer cells.   
 
Chapter 1 describes the context of this work, starting with a background of cancer and tumour 
hypoxia, and including overviews of different imaging modalities particularly applied to 
diagnosis, staging and follow-up of prostate cancer (PET, SPECT, MRI, confocal and epi-
fluorescence microscopy, FLIM and TCSPC). The synthesis and development of some 
radioisotopes for use in PET/SPECT imaging is detailed. The use of imaging probes based on 
thiosemicarbazide derivatives is described together with their advantages, due to the 
importance of this type of compounds in tumour hypoxia detection and multimodality imaging 
potential. Moreover, the use of iron oxide nanoparticles as scaffolds for biomedical and 
nanomedicine applications, with special importance for magnetic resonance imaging, is 
reviewed. Finally, the use of bombesin, a GRP-targeting peptide, as a vector for the recognition 
of cancer cells and its incorporation into imaging probes is discussed.  
 
Chapter 2 describes synthetic approaches towards the functionalisation of a tripodal symmetric 
organic core containing –CH2Br units used as starting material. Novel fluorophores based on 
BODIPY were synthesised and characterised hereby, together with other compounds including 
different linkers. The most promising fluorescent molecules synthesised and characterised 
hereby were tested in PC-3 cells using single and two-photon laser scanning confocal 
microscopy, and their cell viability was evaluated by means of MTT assays. Furthermore, two 
deferoxamine-based molecules were synthesised and radiolabelled with zirconium-89. 
 
Chapter 3 describes the synthesis of a peptide sequence (the [7-13] bombesin fragment, of 
interest for cancer cells targeting) using solid-phase peptide synthesis, and the attempts to 
incorporate this into the fluorescent tripodal molecule synthesised in the previous chapter. 
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Moreover, the synthesis of a deferoxamine-bombesin conjugate as a new chelator for main 
group and transition metals is reported herein. 
 
Chapter 4 describes the synthesis of novel thiosemicarbazide-based ligands, some structural 
investigations using NMR spectroscopy and the single crystal X-ray diffraction data collected 
to fully characterise the main new molecules emerging from this study. The complexation tests 
to incorporate several metals from main group and transition metals (e. g., Zr(IV), Ga(III) and 
Cu(II)) and the results obtained are reported. The behaviour of the ligands in three different 
cell lines was assessed via crystal violet assays, and their IC50 values calculated after 24, 48 
and 72 hours of incubation in cells. 
 
Chapter 5 describes the synthesis and characterisation of novel imaging probes based on 
benign iron oxide nanoparticles coated with a silica shell. These were functionalised with two 
types of fluorophores: quantum dots (Cd0.1Zn0.9Se) and a potential hypoxia targeting unit, and 
three radiolabelling methods using gallium-68 were developed. An alternative system based 
on citric acid-coated iron oxide nanoparticles and functionalised with a BODIPY derivative was 
synthesised. The most promising nanocomposites in terms of kinetic stability were tested in 
PC-3 cells, using single and two-photon laser scanning confocal microscopy to study their 
fluorescent properties. Their cell viability was tested in PC-3 cells using MTT assays over a 
range of conditions and timescales. 
 
Chapter 6 constitutes a summary of the work carried out and results found during this thesis 
and includes some proposals for future work based on the research findings described here. 
 
Chapter 7 contains all the experimental details and characterisation data for the compounds 
described in this thesis. 
 
The Appendices provide supporting spectroscopic evidence and X-ray diffraction data for the 
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Chapter 1. Introduction 
1.1. Background 
Cancer is one of the top ten causes of death in the world in the 21st century. According to a 
cancer statistics report from the World Health Organization (WHO), in the year 2012, 14.1 
million adults were diagnosed with cancer, and from these, 8.2 million (58.2%) died from 
cancer worlwide.1 Hence, the importance for increased research in drug discovery in order to 
diagnose and treat cancer is clear.2-4 
 
It has been proven that the earlier the stage at which the tumour is diagnosed, the higher the 
patient’s survival rate will be. This is clearly illustrated in Chart 1.1, which shows prostate 
cancer diagnosis and the 5-year survival rate by stage from a study carried out in men between 
2006 and 2012 in the United States. 
 
Chart 1.1. Prostate cancer diagnosis and 5-year survival rate by stage, 2006 – 2012. Data obtained 
from reference 5.  
 
As seen from Chart 1.1, until recently around 80% of prostate cancers were diagnosed at the 
localised stage, allowing 100% of those patients to survive in a 5-year term. Around 12% of 
cases were localised at the regional stage, with the tumour at a spreading stage (adjacent), 
and then the survival rate in a 5-year term was still 100%. Finally, only 4% of patients were 
diagnosed at a late stage, from which only 29% survived five years post-diagnosis. 
Consequently, it is easily seen that an early cancer diagnosis is equally important as the 
treatment for this, since an early diagnosis can improve the patients’ survival rate.  
 




Currently, four methods are being used in clinical practise to diagnose cancer:6-12 
- Blood or other sample testing techniques by targeting overexpressed molecules, such 
as sugars, fats, proteins, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). 
However, there is a lack of sensitivity and selectivity in the current testing reagents.13 
- Biopsy is the most common way to diagnose cancer, consisting in the collection of a 
tissue sample from the site of interest for a subsequent examination of the morphology 
and gene status. 
- Medical imaging (or molecular imaging) is useful in the cases when the location of a 
tumour in a specific site is difficult. Molecular imaging has the capacity to speed up the 
diagnosis process, and combined with blood sample testing it enables the location of a 
tumour and an early cancer detection.14 
- Endoscopy is generally applied at the middle or late stages of cancer diagnosis in 
combination with other imaging tools to confirm a cancer diagnosis, or with biopsy to 
collect a tissue sample for further investigations.14 
 
From all the above mentioned cancer diagnostic techniques, medical imaging is the one that 
is concentrating an important part of the research in this field. Medical imaging techniques 
commonly used in cancer diagnosis include X-ray computed tomography (CT scans), X-ray 
imaging, magnetic resonance imaging (MRI) and positron emission tomography (PET).15-17  
Similar to PET, single-photon emission computed tomography (SPECT) can also be used to 
detect pathologies, although its sensitivity is much lower than that of PET. All these techniques 
are based in the use of a source of energy (X-ray, magnetism, gamma or positron decay) to 
create a detailed view of the body in order to locate a tumour mass, and they can be used to 
detect all types of cancer.   
 
Many medical imaging methods are based on the use of radioisotopes (mainly positron and 
gamma emitters) as contrast agents. For example, PET uses positron-emitting radioisotopes 
such as 68Ga (t1/2 = 68.3 min), a popular radioisotope in clinical research. When 68Ga is 
anchored onto an adequate in vivo delivery vehicle in precancerous stages, it selectively 
concentrates around infected sites and areas of inflammation, and it can report on areas of 
rapid cell division. However, there are longer lived metallic isotopes which will most probably 
become more promising in future diagnostic imaging applications, since their longer circulation 
in vivo enhances the tumour/background ratio.18 One of these promising radioisotopes is 89Zr 
(t1/2 = 78.4 h), as will be described in the next sections.6 
 
As such, there is a need to develop new imaging contrast molecules which can selectively 
concentrate around the affected sites.  




1.2. Cancer and tumour hypoxia 
Hypoxia appears as a result of a disequilibrium between the supply and the consumption of 
oxygen in a number of different diseased tissues, including tumours. Areas with O2 tensions 
(pO2 values) ≤ 2.5 mmHg are considered hypoxic tissue areas. These areas can be found in 
a broad variety of human malignancies (e.g., breast, uterine, cervix, vulva, head and neck, 
prostate, rectum and lung cancer, brain tumours and malignant melanomas).19-28 Hypoxia 
starts at a very early stage during tumour development from a tumour diameter of just a few 
millimetres,29-32 and it is a characteristic feature of the environment found in advanced solid 
tumours. It has been proven that this can promote tumour progression and resistance to 
therapy. As such, tissue hypoxia is seen as a central factor for tumour aggressiveness and 
metastasis, independent of aspects such as tumour stage and nodal status.19, 29  
 
Hypoxia occurs in tissues as a consequence of inadequate blood supply, affecting tumour cell 
biology.29 In normal (healthy) tissues or organs, the O2 supply matches the metabolic 
requirements, while in locally advanced solid tumours, the O2 consumption rate of some cells 
can outweigh a restricted oxygen supply and result in the development of tissue areas with 
very low O2 levels.19 It has been found that 50-60% of locally advanced solid tumours may 
suffer from some hypoxic and/or anoxic tissue areas that are heterogeneously distributed 
within the tumour mass.19 
 
Non-invasive assessment of hypoxia is possible via imaging techniques such as PET or 
SPECT by detection of radiolabelled tracers or with MRI techniques. However, clinical 
experience using these methods in patients is so far very limited.19 
 
As mentioned before, cells in hypoxic regions are resistant to both radiotherapy and 
chemotherapy, so that hypoxia is a serious concern that moreover contributes to tumour 
progression.29, 30 This is thought to be caused by an absence of oxygen-based free radical 
processes that otherwise make cells sensitive to ionising radiation. Many studies have been 
carried out to stablish the relationship between tumour size and therapeutic sensitivity, and a 
size-dependent variation in hypoxic fractions was found. Studies on lung nodules of three 
different sizes showed that, while there was no evidence of necrosis on 0-5 mm3 nodules, both 
6 mm3 and 20 mm3 nodules contained substantial areas of dead cells, implying hypoxia. 
Consequently, hypoxia would be expected to scale with tumour size.33 Figure 1.1 shows a 
schematic description of hypoxic regions in malignant solid tumours.  
  




Even though nowadays there is much research invested in hypoxia and despite all the 
information collected in the past few decades, there are still many important questions to 
answer in order to develop the long-standing goal of exploiting tumour hypoxia as the best 
validated target in oncology.34 
 
Figure 1.1. Representation of a malignant solid tumour with its three differenced areas. The tissue area 
next to the blood vessel is normoxic as the supply and consumption of O2 is “normal”, as it should be in 
most healthy cells. The next area is hypoxic, having a deficit of O2. Finally, the last area is necrotic, 
which corresponds to dead cells. As seen in the arrows next to the different areas, therapy resistance is 
greater at necrotic and hypoxic areas, and O2 and nutrients arrive less effectively at these areas. 











1.3. Medical and optical imaging and its underlying basic 
 physicochemical concepts 
1.3.1. Positron emission tomography (PET) 
Positron emission tomography is a relevant technique among the ones commonly used in 
medical imaging for cancer diagnosis. PET is an imaging modality frequently used for 
screening, diagnosing and staging body tissues to identify or follow certain chronic conditions 
such as cancer and/or neurodegenerative diseases. Thanks to PET, it is possible to 
understand the fundamentals of the underlying biology of these diseases and to improve and 
discover new treatments.36-41 It has emerged as an imaging modality with excellent sensitivity 
for in vivo studies in the field of molecular imaging.42, 43 
 
This technique can be thought of as a small camera that can take photos of a subject of interest 
with an exposure time that goes from a few seconds to several minutes. This imaginary camera 
does not image visible light, instead it images high-energy gamma-rays that are emitted from 
the radioisotope present inside the subject. In this regard, it is possible to label biological 
molecules with a radioactive isotope: an isotope able to ultimately produce two gamma-rays 
by emitting a positron from its nucleus. This positron (the antimatter counterpart of an electron) 
eventually collides with a nearby electron and they annihilate each other in order to produce 
energy in the form of two very energetic gamma-rays (511 keV), which are emitted in opposite 
directions and placed at 180 degrees with respect to each other (Figure 1.2).44 
 
As such, every PET scan requires a positron-emitting radioisotope to be inserted into the body. 
The two main challenges in the synthesis of positron-emitting labelled compounds are: (i) the 
short half-lives of most of the common cyclotron-generated PET radioisotopes (Table 1.1), and 
(ii) the extremely low radioisotopic concentrations that are used (pM-nM).36, 45, 46 
 
Because of the extremely short half-lives of some of the positron-emitting isotopes used in 
PET, the chemistry that leads to the incorporation of the isotope into the parent molecule, and 
its subsequent introduction into the subject’s body needs to be as rapid as possible.44 
 
There is a wide variety of radioisotopes that can be employed for PET. Some of them are more 
commonly used: 15O, 13N, 11C and 18F; and others are less common: 14O, 64Cu, 62Cu, 124I, 76Br, 
82Rb and 68Ga. Most of these isotopes need to be produced in a cyclotron, but some of them 
– such as 68Ga and 82Rb – can be produced using a generator. Once labelled tracers are 




introduced into the subject, their distribution and concentration can be followed by PET 
imaging.44, 47 

















Among the isotopes listed in Table 1.1, 11C and 18F are the most commonly used due to their 
relatively longer half-lives. The half-lives of 13N and 15O are too short to carry out complex 
radiochemical syntheses of more than one reaction step. An example of the use of 15O is the 
radiolabelling of water, butanol and gases (CO, CO2) for inhalation studies.48 Regarding 13N, 
this radioisotope is incorporated into nitrite/nitrate and ammonia, and these labelled 
compounds can be used as starting materials to prepare other more complex labelled products 
(e.g., amino acids).49-51 
 
There are several criteria that tracers need to fulfil to be successfully used as imaging probes 
for PET. The most important one is that the positron-emitting isotope must be chemically linked 
to the molecule of interest and not easily dissociate. If it does dissociate, the radioisotope will 
be the one followed by PET imaging instead of the tracer. Consequently, it is important to 
choose a radiotracer with a high specificity for the target molecule since interaction of the 
radiotracer with other molecules could interfere with the aiming radioactive signal that is 
detected by the PET camera. It is also desirable to choose a radiotracer that has a high affinity 
for its target in order to obtain high-contrast PET images. Moreover, another important criterion 
is that the label must not significantly modify the biological properties of the parent molecule. 
Finally, the distribution of the radiopharmaceutical in the body should be related to the 
physiological response to measure functionality of the biochemical process under research.44, 
49, 52-54 
 
Nowadays, PET is being used in conjunction with other diagnostic techniques such as 
computed tomography (CT) in order to provide more detailed information about malignant 
(cancerous) tumours and other lesions. The combination of these two techniques is promising 
in the diagnosis and treatment of several types of cancer. 
 













Figure 1.2. Principle of positron annihilation. PET cameras can detect paired gamma rays (511 keV 
each), produced by the positron annihilations, that travel in opposite directions at 180o to each other. 
Hence, positron decay can be localised without collimation by using the principles of coincidence 
detection. Since PET cameras do not require collimators, they have a much higher count rate than 
SPECT systems. Adapted from reference 55. 
 
1.3.2. Single-photon emission computed tomography (SPECT) 
As well as positron emitters, there are isotopes that are beta-emitters (such as 3H and 14C). 
Beta-particles (electrons) do not travel significant distances in tissue and hence do not produce 
annihilation events, as positrons do. For this reason, beta-emitter isotopes are not of use for 
non-invasive imaging of living subjects. However, these kind of isotopes can also be used with 
tracers for imaging living subjects with a different type of camera (“gamma-cameras”), which 
do not require the production of two coincident gamma-rays. These type of cameras are 
employed in a process known as single-photon emission computed tomography, in which they 
are rotated around the subject to produce tomographic images. 
 
In comparison to SPECT, PET is at least ten times more sensitive, and positron-emitting 
isotopes produce less perturbation to the biochemical behaviour of the radiolabelled parent 
molecules because these can readily be substituted for naturally occurring atoms. SPECT 
systems have improved spatial resolution, although they lose in sensitivity. In conclusion, PET 
is a more powerful technique for imaging most molecular events (Table 1.2). Figure 1.3 shows 
brain images taken with PET and SPECT, respectively. 




Other beta-emitter isotopes are 99mTc, 111In and 123I. One advantage of SPECT when compared 
to PET is that in SPECT it is possible to use several different radiolabelled tracers at the same 
time because this technique can distinguish gamma-rays of different energies. Contrary to this, 
a PET camera takes images that reflect gamma-ray events with the same energy (in colour, 
whose scale reflects the concentration of the isotope).44, 56 
 
Table 1.2. Comparison of some aspects of PET and SPECT. 
 SPECT PET 
Used radioisotope Photon emitter Positron emitter 
Average half-life of isotopes Hours to days Seconds to minutes 
Examples of isotopes 99mTc, 201Tl, 131I, 111In, 123I, 133Xe 18F, 11C, 13N, 15O, 68Ga 
Spatial resolution x 3x 
Contrast resolution x 2x 
Signal noise:ratio x 2x 
Variety of ligands Poor Higher 
Availability Available Rare 
Cost Affordable Expensive 













Figure 1.3. Benzodiazepine receptor concentration shown in images, obtained using PET (middle) and 
SPECT (bottom). Adapted from reference 57. 




1.3.3. Magnetic resonance imaging (MRI) 
Magnetic resonance imaging is an imaging technique that relies on the naturally occurring 
magnetic properties of the abundant 1H nuclei in the water and fatty molecules in body tissues 
to produce detailed images of any part of the body. The hydrogen nuclei behave like a small 
magnetic bar, and under normal circumstances without the action of an external magnetic field, 
hydrogen atoms spin in the body in random directions with their axes randomly aligned. There 
are two energy values in the magnetic field for the 1H nucleus, corresponding to m = +1/2 and                  
m = -1/2. The first energy state is described by the spin function α, and the second one is 
described by the spin function β. There is an energy gap between these two energy levels, 
with β being the one with a higher energy in the presence of a magnetic field. 
 
In order to produce images using MRI, a strong magnetic field is applied (using an MRI 
scanner), and this makes the protons’ axes align in the magnetic field direction, either in the α 
or β energy states. This uniform alignment creates a magnetic vector oriented along the axis 
of the MRI scanner. When additional energy in the form of a radiofrequency is applied, some 
protons that are in the lower energy state have enough energy to transition to the higher energy 
state. Finally, when the radiofrequency source is turned off, the protons that have moved to 
the higher energy β position return to their original state (α), and this causes a signal (and a 
radio wave) to be emitted. This emitted energy sends a signal to a computer, which uses 
mathematical formulae to convert the signal into an image of anatomical details with high tissue 
contrast and high spatial resolution. It can provide information about the exact location of the 
protons in the body, and also distinguish between different types of tissues, due to the protons 
in different tissues realigning at different speeds and producing distinct signals. These steps 
are schematically shown in Figure 1.4.58, 59 
 
Compared to X-ray and computed tomography, MRI uses radiation in the radiofrequency range 
which does not cause any known biological damage when it passes through the tissues.59, 60 





Figure 1.4. Schematic representation of the different steps that occur to the hydrogen nuclei to create 
signals in MRI. 
 
1.3.4. Confocal and epi-fluorescence microscopy 
The invention of confocal microscopy is attributed to Marvin Minsky, who produced a 
microscope in 1955.61 The development of confocal microscopy was mostly driven by the aim 
of imaging biological events as they occur in living tissue (in vivo), and Minsky had the goal of 
imaging neural networks in unstained preparations of living brains. The principle of confocal 
microscopy discovered by Minsky, and patented in 1957, is used in all the modern confocal 
microscopes. Figure 1.5 illustrates this principle, which is the same as the one applied in epi-
fluorescence microscopy, and which is still the basic configuration of most modern confocal 
systems used for fluorescence imaging. Minsky's original configuration used a pinhole placed 
in front of a zirconium arc source as the point source of light.62 
 
Confocal microscopy presents many advantages when compared to conventional optical 
microscopy, such as the controllable depth of field, the elimination of image degrading out-of-
focus information, and the ability to collect serial optical sections from thick specimens.  
Confocal microscopy has become very popular in the past few years, due in part to the 
possibility of obtaining high-quality images from samples prepared for conventional optical 
microscopy. One of its major applications in the biomedical sciences involves imaging either 
fixed or living cells and tissues that have been labelled with a fluorescent probe.62, 63  
 




The major advantage of the confocal approach is that it uses spatial filtering in order to 
eliminate out-of-focus light or flare in specimens that are thicker than the plane of focus. 
Confocal microscopy uses point illumination where only a part or a point of the sample is 
excited at any one time. It uses a pinhole in an optically conjugate plane in front of the detector 
to eliminate out-of-focus information and produce better quality images compared with wide-
field images. In theory, only light from the focused focal plane reaches the detector. This is 
due to the attenuation of the light intensity, which rapidly falls off above and below the plane 
of focus as the beam converges and diverges. This reduces the excitation of molecules that 
are out of the focal plane, hence eliminating a lot of unwanted background signals. Any out-of-
focus light that enters the photo-detector normally has an intensity that is too weak to be 
detected. Moreover, any point of light that is in the focal plane but not at the focal point will be 
blocked by the pinhole screen.62, 64, 65  
 
Three-dimensional images can be made from scanning many thin sections through the sample 
to create numerous optical sections that can be stacked together to produce an image. 
Generally, in order to obtain higher resolution images, a laser is used as the excitation source 
because it provides discrete wavelengths with very high intensities as well as a point light 
source of illumination. Depending on the laser system used, the desired wavelength can be 
selected, enabling a wider range of fluorophore probes/labels to be utilised.62, 66, 67  
 
Figure 1.5 shows the basic configuration of a confocal microscope. As it can be seen, a laser 
is used to provide the excitation light. The laser light (blue) first reflects off a dichroic mirror, 
followed by two other mirrors, which scan the laser across the sample. Next, the dye in the 
specimen is excited by the laser light. It fluoresces, and the fluorescent emitted light (green) is 
descanned by the same mirrors that are also used to scan the excitation light (blue) coming 
from the laser. The emitted light then passes through the dichroic mirror and is focused onto 
the pinhole. The light that passes through the pinhole is measured by a detector (e.g., a 
photomultiplier tube). At a given instant, only one point of the sample is observed, so that there 
can never be a complete image of the sample. The detector of the microscope is attached to 
a computer, which builds up the image.62 
 





Figure 1.5. Schematic representation of the basic set-up of a confocal microscope. The light coming 
from the laser is scanned across the specimen by the scanning mirrors. Optical sectioning occurs as 
the light passes through a pinhole on its way to the detector. 
 
1.3.5. Two-photon fluorescence lifetime imaging microscopy (FLIM) and time-  
 correlated single-photon counting (TCSPC) 
Two-photon fluorescence microscopy has found applications in many fields of tissue research 
thanks to its deep tissue penetration and its limited photochemical damage.  
 
Figure 1.6 schematically shows the differences between one-photon (left) and two-photon 
(right) excitation techniques. In one-photon excitation, one photon from the light with the 
appropriate energy can excite the targeted molecule and raise its energy state from the ground 
energy state to an excited level. Once in the excited state, the molecule can relax to the lowest 
vibrational level in this state, and from there it can return to the ground state while emitting a 
photon. In contrast to this, the principle of a two-photon microscope is that, during the excitation 
process, two photons that have twice the wavelength and half the energy of one photon are 
absorbed simultaneously to excite the molecule and reach the same excited energy level. 
Another difference between these two modalities is that in a one-photon microscope, all the 
dye molecules along the beam-path outside the focal point (FP) are also excited and, for this 
reason, out-of-focus light needs to be eliminated using a pinhole. In a two-photon microscope, 
only the dye molecules that are within the FP are excited, while the fluorophores outside of the 




focal plane are not excited because the simultaneous two-photon absorption is only possible 
at the focal plane. For this reason, the pinhole that is used in laser scanning confocal 
microscopy is not required to obtain a sharp image from one plane in a tissue volume.68 Three-
dimensional analysis of deeper tissue with minimal loss of fluorescence and reduced 
phototoxicity is possible thanks to the properties of two-photon microscopy.69, 70 
 
Figure 1.6. Scheme representing the differences between one-photon excitation and two-photon 
excitation. (A) Jablonski diagrams, and (B) excitation of the specimen through a beam-path (FP: focal 
point). Adapted from reference 68. 
 
The fluorescence lifetime (FLT) is defined as the average time that a molecule remains in an 
excited state before returning to the ground state by emitting a photon, and is characteristic of 
each fluorophore. It is determined as the time when the intensity of the fluorophore decreases 
by 1/e, which is approximately 36%, from the initial excited energy value. FLT is an intrinsic 
characteristic of each fluorescent molecule and is independent of the fluorescence intensity 
and concentration. When the biological environment of a fluorescent molecule is changed 
(e.g., temperature, redox state, pH, or protein-binding state) this changes the FLT of that 
fluorophore. For this reason, fluorescence lifetime imaging (FLIM) is an imaging technique in 
(A) 
(B) 




which the contrast is based on the lifetime of the individual fluorophore rather than its emission 
spectrum.71  
 
FLIM techniques can be classified in two types: time-domain, by multidimensional time-
correlated single-photon counting (TCSPC), and frequency-domain. In TCSPC, the time 
between sample excitation by a pulsed laser and the arrival of the emitted photon at the 
detector is measured. TCSPC records the photon density over time, so that it is a one-
dimensional technique. Specifically, TCSPC uses a multidimensional time-correlated single-
photon counting process. The focused beam of a high frequency pulsed laser is used to scan 
the sample. Data recording is based on detecting single photons and determining the arrival 
times of the photons with respect to the laser pulses as well as the beam in the moment of 
photon detection. As a result, a three-dimensional data array representing the pixels of the 
two-dimensional scan is obtained, with each pixel containing photons in many time channels 
for consecutive times after the excitation pulses.71, 72  
 
The basic set-up of a FLIM instrument is shown in Figure 1.7, and it includes a pulsed laser 
source, a detector, a dichroic mirror to separate fluorescence signal from excitation light, a 
TCSPC unit to measure the time between excitation and fluorescence emission, and an 
objective to focus the excitation light into the sample and collect the fluorescence signal.68 
 
Figure 1.7. Schematic representation of the basic set-up of a two-photon microscope and fluorescence 
lifetime imaging. This is a simplified overview of this type of microscope. Adapted from reference 68. 




1.4. Radioisotopes and their aqueous chemistry 
1.4.1. Zirconium-89 
Zirconium-89 is a very promising radioisotope for PET imaging thanks to its unique properties, 
which will be described in this section, and this will also touch upon current methods applied 
in the production of this isotope using a cyclotron. 
 
(A) Zirconium and its properties 
Klaproth discovered zirconium (Zr) in 1789 as “zircon” in the form of orthosilicate ZrSiO4. The 
first time zirconium was isolated as a metal was in 1824 by Berzelius. For many years, Zr was 
used in industrial applications such as the fabrication of fake diamonds, but at that time the 
medical community had not yet paid much attention to this element and it was only used in its 
impure form, zircon. However, during the atomic testing period of the 1950s and 1960s, two 
isotopes of zirconium, 93Zr and 95Zr, appeared as relevant fission products. This led to the first 
studies of the radiochemistry of Zr, which were published in a National Academy of Sciences 
(NAS) report in 1960.73 
 
From having a relevant paper in fission/fall-out, scientists started investigating the biological 
distribution of 93Zr (t1/2 = 1.53 million years) and 95Zr (t1/2 = 65 days) radioisotopes in animals. 
These studies comprised parameters of relevance such as the biodistribution and toxicity of 
95Zr in rats or mice, and some interesting results came out, such as the observed high affinity 
of Zr to the bones by autoradiography and its low toxicity in rats. Due to these favourable 
properties, in the past few years zirconium has reached a relevant role as a potential positron 
emission tomography isotope for the labelling of monoclonal antibodies (mAbs) for in vivo 
cancer imaging.73-80 Some of the successful applications of 89Zr found in the last decades 
include the assessing of target expression, in vivo biodistribution and pharmacokinetics of 
antibodies in applications of cancer diagnosis, treatment planning and monitoring, and 
dosimetry.81-84 
 
Despite the successful in vivo results described above, the nuclear medicine community has 
taken a long time to embrace the potential of zirconium-89 due to the lack of efficient methods 
of separation from the 89Y target material and because of the difficult aqueous chelation 
chemistry.85  
 
(B) Properties of zirconium-89 
Zirconium-89 has a half-life of 78.4 h, the longest among all the β+ emitting radiometals 
currently available on the market, and allows imaging up to a week after the injection of a 89Zr-




based probe.81, 86 Moreover, it is compatible with the relatively slow blood clearance of most 
immunoglobulin G (IgG) antibodies used in radioimmunodiagnosis (t1/2 = 1-2 days).73 Other 
properties, such as its β+ decay ratio of 22.3% and its maximum energy of 897 keV, make it 
an ideal candidate for PET imaging (Figure 1.8). One disadvantage that should be taken into 
consideration is that its intense gamma emission (100% yield), with energy of 909 keV, dictates 
very careful calibration and set-up of the imaging equipment in order to obtain a good image 
quality.87 
 
Zirconium’s oxidation state is +4 and its preferred coordination number is 8, which makes 
hydrolysis likely to happen in aqueous solution.85 The hexa-aqua ion Zr(H2O)64+ can only exist 
at very low Zr concentrations, and in highly acidic aqueous solutions. In neutral solutions and 
in the absence of complexing agents, Zr species can be mostly found as a polynuclear and 
polymeric form.73, 88, 89 
 
Figure 1.8. (A) Decay scheme of 89Zr, and (B) some decay characteristics of 89Zr. Adapted from 
reference 90. 
 
(C) Radiosynthesis of zirconium-89 
It is possible to produce some isotopes of zirconium using a cyclotron as shown in the Table 
1.3 below. 
 
Table 1.3. Properties of some zirconium isotopes.91 t1/2 is the half-life of the radioisotopes; Iγ and Eγ refer 
to the intensity and energy of the γ emission, respectively; IEC denotes the intensity of the electron 
capture decay; Iβ+ is the intensity of the positron emission decay, and Emax(β+) and Eave(β+) designate the 
maximum and average energies of the decay by positron emission, respectively. 
Isotope t1/2 Iγ Eγ IEC Iβ+ Emax(β+) Eave(β+) 
86Zr 16.5 h 100% 241 keV     
88Zr 83.4 d 100% 390 keV     
89Zr 78.4 h 100% 909 keV 76.6% 22.3% 897 keV 397 keV 
 




These three isotopes can be produced using different nuclear reactions with particle energies 
between 5 and 85 MeV. Among the three of them, zirconium-89 is the most promising one for 
investigating new immunoPET agents to use in in vivo imaging of cancerous tumours, and to 
guide and plan radioimmunotherapy.91-93 
As shown in Figure 1.9, three principal routes can be used to produce 89Zr at accelerators, 
which are: 
1. The bombardment of 89Y with protons or deuterons, termed as 89Y(p,n)89Zr or 
89Y(d,2n)89Zr reactions. 
2. Alpha-induced nuclear reactions on Sr, resumed as natSr(α,xn)89Zr process. 
3. Neutron activation via 90Zr(n,2n)89Zr reaction.87, 91 
Figure 1.9. Scheme of the three paths that can be followed for the production of 89Zr. Adapted from 
reference 91. 
 
Among these three main production paths, (1) is the most popular due to yttrium being 
monoisotopic (isotopic abundance = 100%). This means that natural yttrium is comprised of 
only yttrium-89 and hence it does not require enrichment, which makes it a favourable target 
material and adds an extra advantage to the production of 89Zr with a proton biomedical 
cyclotron: the target does not require a costly, enriched target material.87, 91, 94 
 
New methods are being investigated to find more efficient ways to produce the new promising 
immunoPET target, 89Zr. Walther et al. have examined the production, separation and 
characterisation of this isotope, including supplementation of a commercial Cyclone 18/9 with 
a self-made solid target system (STS).95 Holland et al. have reported standardised methods 
for the routine production and isolation of high-purity and high-specific activity 89Zr using a 
small cyclotron with optimised conditions and a solid, commercially available 89Y-foil target.85 
Infantino et al. have optimised the widely used Monte Carlo simulation code FLUKA to 




prototype a solid target for the production of 89Zr by irradiation of a metallic 89Y target foil in a 
proton biomedical cyclotron through the reaction (1) described above.87 Moreover, the group 
of Marshall at the Positron Emission Tomography Imaging Centre (PETIC) in Cardiff has also 
worked on the optimisation of this process using an in silico model to reduce the amount of 
generated by-products such as 88Zr.96 Finally, in an example published by Safeghi et al., the 
production of 89Zr in an accelerator is reported via proton bombardment on sedimented 89Y2O3 
as a target.91  
 
(D) Ligands of relevance to 89Zr stabilisation 
Any biomolecular PET tracer needs to be able to form a stable radiometal chelate. Up to now, 
several efforts have been attempted to complex zirconium with many different aqueous 
chelators, of which deferoxamine B (DFO) has become the most successful and commonly 
used.97 Figure 1.10 shows three different chelators and the complexes formed with Zr4+. 
Although there are some differences between the three chelators, each structure shows a 
coordination number of eight.90 
Figure 1.10. Ligand structure, coordination scheme and currently published structure of some common 
chelators for Zr4+ and their complexes with the metal: DFT structure (Zr-DFO98), and crystal structures 
(Zr-DTPA99 and Zr-EDTA100). Adapted from reference 90. 
 




The reason of the success of deferoxamine as the most prominent Zr4+ chelator employed is 
that it is a hexadentate, bifunctional siderophore with three hydroxamate groups for chelating 
metals and a primary amine tail that can be modified by different reaction paths for conjugation 
to a biomolecule.101 Deferoxamine B is commercially available in the form of the iron chelator 
Desferal (DF), and it is a natural product; a microorganism-produced siderophore with 3 
hydroxamate groups.90, 102 
 
It is known that the presence of the three hydroxamate groups in DFO makes this molecule a 
suitable and effective chelator for Zr4+, and it is proven that the success of many of the 89Zr-
based PET imaging is thanks to the value of DFO as a chelator for this ion.90, 94, 103 Even though 
there is not a crystal structure of Zr-DFO, DFT-modelling of the metal complex suggests that 
it has a coordination number of eight, with two coordination sites on the zirconium ion occupied 
by H2O molecules, as can be seen in Figure 1.11.104 
Figure 1.11. Complexation reaction between [89Zr(C2O4)4]4- and DFO. Adapted from 
reference 77. 
 
Although DFO is the best known chelator for 89Zr, there is a growing need for the search of 
new and better ligands in order to form stable radiometal chelates with tuneable properties. It 
is believed that a better ligand than DFO can be found.105 The ideal chelator for this ion to allow 
stable Zr4+ chelation would be a ligand that satisfies two conditions: it should be octadentate 
and be oxygen-rich.90 A ligand satisfying these conditions would create a more stable, robust 
system for chelating Zr, and would help to minimise the problems found in PET imaging 
involving the complex 89Zr-DFO, namely the release of free 89Zr4+ in vivo and uptake by bones 
and other non-targeted organs of the body.90 This uptake is directly related to chelate 
instability, which releases 89Zr during the long circulation time of monoclonal antibodies.106, 107 
In order to solve these issues of non-specific accumulation in tissues and organs, some recent 




studies have investigated the modification of the conjugation chemistry used to link DFO to 
antibodies and the synthesis of more effective chelators.98, 104, 105, 108 
 
Once the 89Zr tracer is attached to a deferoxamine moiety, this ligand is conjugated to the 
antibody.109 Regarding this conjugation, two main methods are commonly used at the moment. 
One involves a succinic acid linker between the amino function of the DFO and an amino 
function on the antibody, and the other deals with a p-isothiocyanatobenzyl-deferoxamine 
derivative.73 Figure 1.12 shows a schematic view of the complex 89Zr-DFO attached to an 
antibody. 
 
Figure 1.12. Schematic overview of a 89Zr-labelled antibody using DFO as chelator. Adapted from 
reference 110.  
 
1.4.2. Gallium-68 
Gallium-68 as a positron emitter nuclide, recently available from generators, is of great interest 
in current medical imaging at a preclinical level due to some important advantages that will be 
explained in the next sections.  
 
(A) Gallium and its relevant properties for radioactive synthesis in water 
The radioisotope gallium-68 has a half-life of 67.7 min, which is compatible with the 
pharmacokinetics of most radiopharmaceuticals of low molecular weight such as antibody 
fragments, peptides and oligonucleotides. 68Ga decays to 89% under β+ decay into stable zinc-
68, and to 11% via electron capture. Its average positron energy, Eβ+, per disintegration of 740 
keV is ideal for PET imaging, providing a high spatial resolution.111-113 




The only stable oxidation state of gallium in aqueous solution is +3, being the three hydrated 
Ga3+ ion stable only under acidic conditions. Due to the almost exclusive formation of 
[Ga(OH)4]- ions, the solubility of this ion is high at physiological pH. However, hydrolysis to the 
insoluble compound Ga(OH)3 when its concentration exceeds the nanomolar level makes it 
less soluble in the pH range of 3-7.114-116 
 
Ga3+ complexes have a preferred coordination number of six, although some chelates can be 
four- or five-coordinated. The Ga3+ ion is a hard Lewis acid, and thus it forms 
thermodynamically stable complexes with ligands that are hard Lewis bases. These are 
ligands containing oxygen, nitrogen and sulphur donor atoms, but also softer functional groups 
have been found to be suitable for Ga3+, such as phenolate and thiol groups.114, 116, 117 
 
(B) Radiosynthesis of gallium-68 
In contrast to zirconium-89, gallium-68 is a generator-produced nuclide. Generators present 
some advantages like allowing clinical studies without an on-site cyclotron, or if cyclotron beam 
time is not available, and they can generate radionuclides and radioactive probes at any time 
on demand.111, 114 
 
Gallium-68 can be produced from a generator system that consists of an inorganic or organic 
matrix that immobilises the parent radionuclide, 68Ge. The pair 68Ge/68Ga is ideal for a 
generator strategy, due to the combination of the half-lives of these ions (t1/2 = 270.9 d and t1/2 
= 67.7 min for 68Ge and 68Ga, respectively), suitable for radiopharmaceutical synthesis. The 
preferred production path of 68Ge is via the (p,2n) reaction on gallium targets (Figure 1.13). In 
order to avoid break-through, a good separation system of the stationary mother (68Ge) from 
the soluble daughter (68Ga) is mandatory. Since the chemical properties of the two generated 
ions, Ge4+ and Ga3+ are sufficiently different, there are several different methods that allow 







Figure 1.13. Production of 68Ge by the (p,2n) reaction of 69Ga. Adapted from reference 114. 




(C) Ligands of relevance to the radiochemistry of gallium 
As mentioned before, the majority of chelators designed for Ga3+ are hexadentate, although 
several chelates that are reported to be stable in vivo have coordination numbers of four or 
five. Gallium forms complexes with bifunctional chelators, that is, ligands that have 
functionalities that allow covalent coupling to a targeting vector – such as peptides and 
antibodies – as well as binding of the metal cation.  
 
Deferoxamine B, the most commonly used chelator to form stable complexes with 89Zr, was 
one of the first molecules used in the radiolabelling of 68Ga3+, due to the resulting high 
radiochemical yield. However, whilst high radiolabelling yields occur at concentrations > 5 μM, 
at a nanomolar level (< 50 nM) DFO is not a good chelating agent for gallium.114, 118, 119 
 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is one of the best known 
chelators used for radiometals in an oxidation state of +3. Ga(DOTA)- is stable enough to be 
used in clinical practice. However, there is still another chelator for Ga3+ with a higher 
thermodynamical stability constant, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA). 
The high thermodynamic stability of the Ga3+ chelates with NOTA is due to the fact that the 
small cation perfectly fits in the cyclic cavity of the nine-membered triazamacrocyclic ligand, 
such that the chelator can encapsulate the metal ion with high efficiency. Figure 1.14 shows 
the structure of the ligands DOTA and NOTA.114 
Figure 1.14. Structural formula of common chelators for metallic radioisotopes: (A) DOTA, and (B) 
NOTA. (C) Structural formula of Ga(NODASA). Adapted from reference 114. 
 
Another very stable gallium chelator is 1,4,7-triazacyclononane-1-succinic acid-4,7-diacetic 
acid (NODASA), forming the complex Ga(NODASA), which also has the potential for 
biomolecule coupling using the prelabelling approach thanks to the free carboxylate group 
available, the other three carboxylates being protected by the metal ion (Figure 1.14).114, 120 
 
 




1.5. Thiosemicarbazide-based complexes in hypoxia targeting 
Interest in the past decades has grown in the study of thiosemicarbazides (Figure 1.15), the 
simple hydrazine derivatives of thiocarbamic acid, and the compounds that they can 
produce.121, 122 Thiosemicarbazones are Schiff base ligands that have S and N as donor atoms. 
These compounds have found applications in many fields and their coordination chemistry is 
also being investigated. Their applications are mainly in the field of pharmacology due to their 
biological activity, and include: (i) anti-bacterial activity, (ii) anti-fungal activity, (iii) anti-malarial 
activity, and (iv) anti-tumour activity.123 
 
The ability of thiosemicarbazones to chelate metal ions plays a key role in their biological 
activity and many of their applications. The biological activity of this class of compounds is 
usually enhanced on complexation of the metal, showing evidence of inhibitory behaviour 
against cancer.124, 125 Thanks to their thione-thiol equilibrium, they are highly versatile reagents 
and can act as monodentate or bidentate ligands when coordinated to a metal.126 Coordination 
to metal ions gives these compounds different geometries, enabling the synthesis and 
characterisation of compounds with unique stereochemistry when compared to pure organic 
ligands. One of their main disadvantages is the poor solubility of thiosemicarbazones and their 
metal complexes in aqueous solutions, making them less promising for in vivo applications. 
However, more studies are needed.124 
 
One of the most promising areas in which thiosemicarbazone derivatives are being 
investigated is their use against cancer.127  
 
Figure 1.15. (A) General structure of a Schiff base, (B) thiosemicarbazide, and (C) general structure of 
thiosemicarbazones.  
 
1.5.1. 64Cu(ATSM): copper(II)-diacetyl-bis(N-4-methylthiosemicarbazone) 
For successful imaging and therapy, the choice of radioisotope and bifunctional chelator is of 
great importance: chelators need to be easily attached to a biomolecule and radiolabelling 
conditions need to be biocompatible. There are previous reports of the use of some 64Cu-
labelled macrocyclic chelators for the labelling of biomolecules. However, most of them require 
the use of high temperatures over long periods of time for efficient labelling, which is not 
compatible with sensitive biological systems, since these cannot usually stand elevated 




temperatures and extreme pH ranges. Therefore, what researchers aim to find is a chelating 
system with relatively fast labelling kinetics at room temperature, at near neutral pH and giving 
high yields.128 
 
One such system, of great interest at the moment in the PET imaging field, is the complex 
64copper(II)-diacetyl-bis(N-4-methylthiosemicarbazone), 64Cu(ATSM). The N2S2-type 
bis(thiosemicarbazone) ligands form stable neutral and planar complexes with Cu(II) ions. 
When using Cu(ATSM), radiolabelling takes places easily at room temperature and near 
physiological pH.128-130 Figure 1.16 shows a radioactive 64Cu(ATSM) complex, linked to a 
biologically active molecule. 
 
Figure 1.16. Schematic diagram of a functionalised bis(thiosemicarbazone) complex based on a 
Cu(ATSM/A) core, conjugated to a biologically active molecule (BAM) for receptor targeted imaging, via 
an organic linker. Adapted from reference 128. 
 
It is known that dithiosemicarbazones possess anti-tumour properties, and when complexed 
with Cu(II), their anti-tumour activity is enhanced even more. This, together with other factors 
already mentioned such as the simplicity of the chemistry and the availability of copper 
radioisotopes, turned this class of ligands into promising radiopharmaceuticals.131-133 
 
Using copper radionuclides presents many advantages. In the first place, copper has mainly 
only two oxidation states (I and II) and has a relatively simple coordination and redox chemistry. 
In an aqueous environment, only Cu(II) is stable enough. In the second place, the high natural 
abundance of copper makes it easy to understand its biochemistry and metabolism in humans. 
Moreover, copper has several positron-emitting isotopes, which are quite versatile thanks to 
their broad range of decay schemes [60Cu (t1/2 = 0.40 h, β+ = 93%, EC = 7%); 61Cu (t1/2 = 3.32 
h, β+ = 62%, EC = 38%); 62Cu (t1/2 = 0.16 h, β+ = 98%, EC = 2%); and 64Cu (t1/2 = 12.7 h, β+ = 
17%, EC = 43%)].131, 134, 135 All these features make positron-emitting isotopes of copper very 
attractive options on which to base new positron-emitting radiopharmaceuticals. Among all 
these radioisotopes, copper-64 is the most commonly used due to its half-life of 12.7 h, which 




is ideally suited for PET studies conducted over a 48 hour period. Another advantage of 
copper-64 is that, apart from decaying by positron emission (17%), it also decays by β- 
emission (43%), allowing it to be used as both a diagnostic (imaging) and therapeutic 
(radiotherapy) radionuclide.128, 131, 134 Thanks to having a β+ maximum energy of 0.66 MeV, 
PET images taken by using 64Cu are of very high quality.131 
 
Radioactive 64Cu isotope can decay by three processes: positron emission, electron capture, 
and beta decay. This property makes it an unusual isotope and allows it to be produced by 
using either a cyclotron or a generator. The most common production method for 64Cu uses 
the 64Ni(p,n)64Cu reaction on a cyclotron. The target to produce 64Cu is enriched 64Ni (99.6%), 
which is bombarded on the cyclotron. After the bombardment, 64Cu is separated from the target 
nickel via a one-step procedure using an ion exchange column. Once they are separated, the 
enriched 64Ni can be recovered to 85 - 95%, and reused for future bombardments. This makes 
this radiosynthesis of 64Cu highly cost-efficient.136, 137 
 
In order to obtain the copper-64 complex to be used in PET imaging, a transmetallation 
reaction takes place starting from the corresponding Zn(ATSM) complex. Due to the fact that 
the structures of the zinc complex and those of the copper analogue are very similar, the 
characterisation and the uptake mechanisms of the complexes may be quite similar and can 
be studied with the Zn complexes. This allows two advantages: firstly, zinc (II) is diamagnetic, 
which facilitates the characterisation of new ligand systems and complexes by using NMR. 
Secondly, the zinc(II) complexes are weakly fluorescent, which allows fluorescence 
microscopy to be used to track the uptake and intracellular distribution of the zinc(II) 
bis(thiosemicarbazonato) complexes in cancer cells.133 
 
When labelled with a positron-emitting isotope of copper, Cu(ATSM) has been shown, in vivo 
and in vitro, to be selective for hypoxic tissue. Moreover, clinical studies with this complex have 
produced non-invasive imaging data that is predictive of cancer patients’ response to 
conventional therapy.131 As seen in the schematic representation in Figure 1.17, the redox 
activity of Cu(II) allows the trapping of 64Cu in hypoxic cells via a bioreductive mechanism. 
However, this mechanism is not totally well understood and it is not clear if it is just the action 
of copper that makes the complex hypoxia selective.131 





Figure 1.17. Diagram showing schematically that, whilst 64Cu is trapped in hypoxic cells via a 
bioreductive mechanism due to the lack of O2, it is not trapped in normal (healthy) cells, where there is a 
normal level of O2. Adapted from reference 131. 
 
In this context, the ability of some radiolabelled molecules such as Cu(ATSM) to undergo 
chemical changes in the presence or absence of oxygen, in conjunction with the use of PET, 








1.6. Nanomaterials for medicinal applications: nanomedicines 
design 
Nanomedicine is based on the application of nanotechnology to the area of medicine. Materials 
that have at least one of their dimensions within the nano scale are known as nanomaterials. 
Their use has led to the development of novel devices to detect malignant tumours at an early 
stage, in diagnostic applications, and also to important improvements in efficient drug delivery 
systems for therapy.138 Nanobiotechnology has helped to develop a personalised medicine 
adapted to a specific patient.139  
 
When applied to therapy, nanoparticles can be used as platforms or carriers for insoluble or 
poorly soluble drugs. Moreover, hydrophilic molecules or polymers can be added to a 
nanoparticle surface to improve its solubility and biocompatibility.140 
 
As it has been already mentioned in this chapter, cancer causes a large number of deaths and 
an early diagnosis of this is extremely important for a patient’s survival. For this reason, there 
is a need to invest in research towards the discovery of new tools to allow detection of a tumour 
at a very initial stage.6, 141 For imaging applications, nanomaterials can be used to target tumour 
biomarkers such as cell membrane proteins. It is also possible to target intracellular proteins, 
although the relatively large size of nanoparticles makes it difficult for them to cross the cell’s 
membrane barrier.139, 142  
 
1.6.1. Iron oxide nanoparticles as synthetic scaffolds for MRI contrast agents 
Different types of iron oxides are known, among which there is hematite (α-Fe2O3), maghemite 
(γ-Fe2O3) and magnetite (Fe3O4). In this section, attention is focused on magnetite due to its 
magnetic properties that allow it to be used as an MRI contrast agent.143, 144  
 
As shown in Figure 1.18, Fe3O4 has the structure of a face-centered spinel, that is based on 
32 O2- ions and close-packed along the (111) direction. This type of iron oxide contains divalent 
and trivalent iron. The arrangement is a cubic spinel structure consisting of a cubic close-
packed array of oxide ions, in which all the Fe2+ ions occupy half of the octahedral places and 
the Fe3+ are split evenly across the remaining octahedral and tetrahedral sites. In 
stoichiometric magnetite where FeII/FeIII = 1/2, the divalent iron ions can be partly or totally 
replaced by other divalent ions (e.g., Co, Zn…), and for this reason Fe3O4 can be considered 
both an n- and p-type semiconductor. Due to it having a very small bandgap (0.1 eV), Fe3O4 
is the iron oxide with the lowest resistivity.143, 145 





Figure 1.18. Crystal structure and crystallographic data of magnetite. The black ball is Fe2+, the green 
ball is Fe3+, and the red ball is O2-. Adapted from reference 143. 
 
Magnetite iron oxide nanoparticles with the appropriate properties can be used for several 
biomedical applications, such as MRI contrast agents.146, 147 The requirement is that the 
particles have high magnetisation values, a narrow particle size distribution and sizes of less 
than 100 nm.148, 149 The surface coating needs to be non-toxic and biocompatible and it is 
desirable to allow for a targetable delivery in a specific area.150 Accordingly, 
superparamagnetic iron oxide nanoparticles are used as contrast agents for MRI, one of the 
main applications being for early detection of cancer.151, 152 These nanoparticles enhance the 
signal-to-noise ratio thanks to their unique nanoscale superparamagnetism; that is, high 
magnetism in an external magnetic field, but no residual magnetism when the external 
magnetic field is removed.153, 154  
 
Currently, many of the MRI contrast agents available on the market are gadolinium chelate-
based positive contrast agents. One advantage of the iron oxide nanoparticles when compared 
to the gadolinium chelates is that they have better biocompatibility.155  
 
MRI contrast agents can be positive contrast agents (T1-weighted contrast agents) and 
negative contrast agents (T2-weighted contrast agents), depending on whether they shorten 
the T1 or the T2 relaxation times of water protons inside organs, and both types lead to contrast 
in the magnetic resonance images.156, 157 For magnetic iron oxide nanoparticles, it is their size 
that determines if they can be used as negative or positive contrast agents. Consequently, 
nanoparticles larger than 10 nm are negative contrast agents, while when they are smaller 
than 5 nm as the recently discovered extremely small iron oxide nanoparticles, they can be 
potential positive contrast agents.158, 159  




1.6.2. Quantum dots for optical imaging 
Quantum dots (QDs) are a type of nanoparticles composed of semiconductor materials that 
emit light. Their size is within the nanoscale range and, thanks to this property, they have 
discrete electronic energy states and this gives them some unique optical and electrical 
properties which are different from discrete molecules or bulk materials.139, 160 These unique 
properties of QDs make them very promising and versatile luminophores, and when compared 
to traditional fluorescent probes, QDs have advantages such as size-tuneable light emission, 
narrow and symmetric emission spectra, and broad absorption spectra.146, 161 Moreover, when 
they are coupled to biomolecular affinity ligands (e.g., antibodies, peptides or small molecules), 
QDs can be used for highly sensitive and specific detection of molecular biomarkers or tumour 
cells.162, 163 
 
The size of a quantum dot determines the wavelength of its emission. Usually, the smaller the 
size of a quantum dot, the closer its emission light is to the blue end of the spectrum; and the 
larger its size, the closer the emission light is to the red end. Quantum dots are usually within 
the visible light spectrum, but they can also be tuned beyond that, into the infrared or 
ultraviolet.139 Figure 1.19 shows different vials containing QDs of increasing size and the 
change in their colours when this happens. Probes with emissions that cover the whole visible 
to near infrared wavelength range can be synthesised thanks to the size-dependent properties 
of this type of nanomaterials.161 
 
Figure 1.19. Vials containing QDs of increasing size from left to right and their fluorescence emission. 
Reproduced from reference 161. 
 
Usually, quantum dots are made of hundreds to thousands of atoms of elements from group II 
and VI; III and V; I, III and VI2 or IV. One of the main problems of QDs when they are used for 
biomedical applications is their toxicity, which is a major concern for in vivo imaging. However, 
their toxicity is not a concern when analyses of cells and tissues are carried out on in vitro or 
ex vivo clinical patient samples, and such uses of this kind of fluorophore are the most 
important and clinically relevant applications of them, as they are ultrasensitive probes for in 




vitro biodiagnostics.164-167 For this purpose, a new range of novel heavy metal-free quantum 
dots are being investigated from different semiconductor materials.160 Another problem of QDs 
that emerges when used for biomedical applications is the size of the bioconjugated 
nanocrystals, as this produces steric hindrance and nonspecific protein adsorption.161 
 
A very common type of quantum dot nanocrystals are those with a core made of CdSe, and 
they allow the wavelength of fluorescence emission to be tuned between approximately 500 
and 650 nm by modifying the core size.161, 168, 169 The formation of ternary alloys using CdSe 
has also been investigated, leading to nanocrystals made of three elements such as            
CdSexS1-x, CdTexSe1-x, or HgxCd1-xTe, to name some examples. In these nanocrystals, the 
core size remains constant, whilst the fluorescence wavelength changes due to the 
modifications in the chemical composition.161, 170, 171 Figure 1.20 shows how CdTe QDs can be 
doped with Hg2+ in exchange of the Cd2+ cation, leading to HgxCd1-xTe alloyed nanocrystals.172 
 
Figure 1.20. (A) CdTe QDs where Cd2+ is replaced by Hg2+, forming HgxCd1-xTe QDs, and (B) potential 
energy wells (black lines), quantum-confined kinetic energy levels (blue lines), and wave functions (red 
lines) of electrons and holes in CdTe (left) and HgxCd1-xTe (right) QDs, calculated using the effective 
mass approximation. Reproduced from reference 172. 
  




1.7. Functionalised peptides as targeting molecules 
Peptides are molecules containing different amino acids that are linked together by peptide 
bonds, -C(=O)NH-. The number of amino acids in peptides can differ, going from two to 
approximately 50. The main difference between proteins and peptides is that the latter do not 
have a properly defined 3D structure as proteins do (tertiary structure).173  
 
When some types of tumours are developed, certain peptide receptors may be overexpressed. 
Based on this concept, receptors can be targeted so that peptides can be used as targeting 
molecules for molecular imaging.173 Monoclonal antibodies started to be widely used as 
potential targeting molecules about 30 years ago. However, when trying to use this principle 
in reality, the main issue was the very high molecular mass of antibodies (around 150 kDa).174, 
175 It is only recently that some drugs based on antibodies or fragments of these have become 
commercially available for diagnosis or therapy of cancer. Around 25 years ago, an alternative 
to radiolabelled antibodies was discovered: a radiolabelled peptide, of much smaller molecular 
mass (around 1.5 kDa), which was a somatostatin analogue.173, 176 It was found that most 
human endocrine tumours express a high density of somatostatin receptors, and thanks to this 
a method could be developed in order to localise these tumours and their metastases in vivo 
after injecting a radiolabelled somatostatin analogue.177 Using γ-cameras, the tumours could 
be identified after the radioligand bound to their receptors and these were internalised.173, 178 
This approach has been studied with different peptides and radioligands and due to its 
success, the targeting of overexpressed peptide receptors in tumours using small peptides has 
gained great interest in nuclear medicine.175  
 
The basic principle of in vivo peptide receptor targeting of cancer is schematically shown in 
Figure 1.21. The radiolabelled peptide (P) is injected into the patient and distributed in the 
whole body. If the patient has a tumour with cancer cells expressing the corresponding peptide 
receptor (P-R), the radiopeptide will bind to it and internalise with the receptor into the cell, as 
expressed with arrows, where the radioactivity will accumulate. γ-Cameras can scan the whole 
body and detect the radioactivity accumulated in the tumour. The remaining radioactivity in the 
body will rapidly be cleared through the kidneys.173 





Figure 1.21. Scheme of the in vivo peptide receptor targeting of cancer. Adapted from reference 173. 
 
1.7.1. Bombesin and its derivatives 
The family of bombesin (BBN) peptides owes its name from the original terminology that V. 
Erspamer and his co-workers used to name the first natural ligand described, bombesin, a 
peptide of 14 amino acids that was isolated from the skin of the European frog Bombina 
bombina.179-181  
 
Bombesin has a C-terminal region and ends in Gly-His-Leu-Met-NH2. This makes this peptide 
similar to two bombesin-related peptides present in mammals: gastrin-releasing peptide (GRP) 
and neuromedin B (NMB). The first one, GRP, contains 27 amino acids and was first isolated 
from porcine stomach. The same C-terminal amino acids are shared with bombesin, giving 
them similar biological activities. NMB is a peptide containing 10 amino acids that was originally 
isolated from porcine spinal cord, and has a COOH terminus ending in Gly-His-Phe-Met-NH2. 
The genes encoding for these peptides in humans are on chromosome 18q21 for GRP, and 
15q11 for NMB, and they encode for 148 and 117 amino acid precursors, respectively.182 
 
The structure of bombesin is shown in Figure 1.22, showing the L- configuration as it is made 
of naturally occurring L-amino acids. 




Figure 1.22. Structure of natural L-bombesin: 
Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2. 
 
The mammalian bombesin family of receptors contains three classes of similar receptors: (i) 
BB1-receptor or NMBR: a 390 amino acid NMB-selective receptor, (ii) BB2-receptor or GRPR: 
a 348 amino acid GRP-selective receptor, and (iii) BB3-receptor: a 399 amino acid receptor 
that does not have a preference for either peptide.182 These receptors are all G protein-coupled 
receptors, and they signal primarily through phospholipase C-mediated cascades. They also 
stimulate tyrosine phosphorylation of a number of signalling proteins, but in most tissues they 
do not activate adenylate cyclase.182  
 
All these receptors are overexpressed in a broad range of tumours, including breast, pancreatic 
and prostate cancers. The overexpression of these receptors by various tumours plays a 
crucial role in many aspects of their treatment and management, such as providing targets to 
deliver cytotoxic treatment or image the tumours. Accordingly, some bombesin-receptor 
ligands have been used to couple to other compounds for tumour imaging. Examples of these 
are: coupling to fluorescent probes to be used for optical imaging,183-185 conjugation to 
superparamagnetic iron oxide nanoparticles to enhance detection by MRI,186, 187 and coupling 
to gold nanorods coated with PEG that can be used for photoacoustical imaging, especially in 
breast cancer identification, among many others.188, 189 
 
 
   




1.8. Aim and objectives 
This project involves the design, synthesis and characterisation of novel multimodal systems 
suitable for optical imaging as well as PET/SPECT and MRI. Such systems are of relevance 
to early diagnosis and progression monitoring of degenerative diseases including tumour 
targeting, using optical imaging and positron emission tomography. By following a rational 
design process, we aim to construct highly kinetically stable systems, which may be anchored 
onto targeting biomolecules such as peptides, to be further functionalised. These systems will 
improve the efficacy of binding to cells and the effectiveness of bioimaging techniques. 
 
To sum up, this project aims to build multimodal imaging systems following two approaches, 
one based on a tripodal organic core that can be trifunctionalised using the right conditions 
with three different labels, including a fluorescent molecule (Figure 1.23(A)). The second 
approach is based on magnetic iron oxide nanoparticles suitable for magnetic resonance 
imaging, a fluorescent probe and a coordinated radioisotope that will allow PET or SPECT 
imaging (Figure 1.23(B)). These systems will need to be biocompatible and suitable for a 
cellular environment in order to be used as radiolabelling agents. 
 
Figure 1.23. (A) Scheme of a tripodal organic core trifunctionalised with three different labels, and (B) 
scheme of silica-coated nanoparticles functionalised with fluorescent quantum dots and a chelator. 
 
 




The specific objectives are: 
- The design and synthesis of a new scaffold based on the trifunctionalisation with three 
different labels of a symmetric tripodal organic core. Such labels include a fluorophore, 
and BODIPY derivatives will be especially considered due to their low cytotoxicity and 
high fluorescent properties.  
- The synthesis of a fragment of a bombesin peptide and the coupling of this to one of 
the arms of the tripodal ligand to act as a targeting molecule for prostate cancer cells. 
- The synthesis of tripodal ligands based on different thiosemicarbazides which can 
coordinate to metals, due to their multimodal properties and potential hypoxia 
selectivity. 
- The synthesis of iron oxide nanoparticles and functionalisation of these with quantum 
dots and metal-ligand complexes. 
- The in vitro evaluation of the most promising compounds in different cell lines, focusing 
strongly on prostate cancer cells, and cytotoxicity studies. 
- The radiolabelling of the most promising bifunctional chelators and scaffolds with 
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Chapter 2. Synthesis and characterisation of systems based 
on a symmetric tripodal organic core 
2.1. Overview of Chapter 2 
This Chapter describes the synthesis and characterisation of new symmetric tripodal 
derivatives having a fully-substituted benzene core (compound 1) and featuring a range of 
functionalities. In order to substitute this molecule with three different labels several reactions 
have been carried out, and are described hereby (Figure 2.1). A pathway to multifunctional 
structures involves the careful design and synthesis, often multi-stage, of an organic ligand 
with precisely spaced functional groups. As seen in natural systems, there is a close 
relationship between the structure of a compound and its functionality.1 In this chapter, the 
construction of a multi-membered, complex chemical entity using self-assembly driven 
processes where building blocks are held together by dynamic covalent bonds has been 
investigated and is reported.2  
 
Figure 2.1. Aimed tripodal ligand with three different labels attached. 
 
After exploring a variety of conditions, the reaction between a tripodal core precursor and 
several carboxylic acid derivatives was achieved, and this yielded a mixture of products that 
were purified by silica gel column chromatography (Scheme 2.1). Several new mono- and 
disubstituted products were isolated and characterised spectroscopically after purification of 
the crude mixture.  
 
The optimum reaction conditions were found using simple starting materials such as benzoic 
acid, and a 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) derivative was synthesised 
and attached to the tripodal core, obtaining the mono- and disubstituted BODIPY derivatives. 
Furthermore, two different linkers were incorporated into the system and one of these will be 
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used to couple to a peptide (the [7-13] bombesin fragment). An alternative other linker, which 
contains an azido functional group, was incorporated with the aim of carrying out “click” 
chemistry with an alkyne derivative via a strain-promoted alkyne-azide cycloaddition (SPAAC) 
(copper-free) reaction using a dibenzocyclooctyne acid derivative.3 Moreover, a screening of 
the reaction conditions including temperature, stoichiometry of the starting materials and time 
was carried out in order to make the reaction more accessible for biomolecules. This was 
necessary as it has been shown that peptide-based building blocks usually need to be treated 
at lower temperatures and for shorter periods of time as they are sensitive to heat due to 
supramolecular arrangements. 
 
Scheme 2.1. General scheme for the reaction of bromide derivatives and carboxylic acid groups to 
form an ester derivative.  
 
The cytotoxicity of the most promising compounds emerging hereby, which incorporated a 
BODIPY derivative, was tested for their activity in prostate cancer cells (PC-3 cell line) using 
MTT assays. Colocalisation studies by confocal fluorescence imaging using LysoTracker Red 
and ER-Tracker Red co-staining assays, which localise within the lysosomes and the 
endoplasmic reticulum, respectively, were carried out. The living cells were imaged with a laser 
scanning confocal microscope and using associated techniques, mainly at the Rutherford 
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2.2. Synthesis and characterisation of the tripodal organic core 
The precursor 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene was chosen as the starting 
material in order to attach up to three different labels and create a potential multimodal system.  
 
The tripodal core derivative (compound 1) was synthesised following a previously described 
procedure.4 In order to obtain this compound, zinc powder was first dissolved in acetic acid 
and mixed with HBr, triethylbenzene and paraformaldehyde. The mixture was heated to 90 oC 
under reflux and stirred for 48 hours (Scheme 2.2). The precipitate was then isolated, and the 
filtrate (a red-brown liquid) was heated up again and stirred for 24 more hours to increase the 
yield of the reaction (see experimental details). Finally, a substantial amount of a white powder 
was obtained, and TLC was performed in order to check its purity, using a 1:9 ratio of 
acetone:hexane. The TLC showed a single spot, indicating that the compound isolated was 
pure. After this, the product was characterised and used without further purification. 
 
Scheme 2.2. Reaction to obtain compound 1. 
 
HPLC analysis was performed to check more accurately the purity of this product as it is 
important for it to be completely pure in order to be used in the next steps that will be described 
in this chapter. The HPLC chromatogram in the 280 nm channel shows a single peak at 12.4 
minutes (Appendix A), indicating that the compound was pure and there were no traces of 
starting materials or by-products. 
 
This product was then characterised via NMR spectroscopy. Resonances in the 1H NMR 
spectrum matched with the resonances expected for this structure (Figure 2.2). The singlet 
with an integral related to 6 H atoms at 4.57 ppm is due to the protons from the bromomethyl 
groups, H1. The quartet at 2.92 ppm integrates for 6 H and corresponds to the three CH2 groups 
of the ethyl arms, H2; while the triplet at 1.33 ppm refers to the three CH3 resonances from the 
same ethyl groups, H3. The peak at approximately 2.20 ppm is due to acetic acid traces still 
present in the sample.  
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In order to confirm the molecular structure, mass spectrometry was performed. The spectrum 
obtained using nanoelectrospray ionisation in the positive mode shows a highly intense peak 
at m/z = 457.9507, which corresponds to the [M+NH4]+ ion (Appendix A), as it can be seen 
from the amplification of the obtained and expected isotopic patterns. The effect of the two 
bromine isotopes, 79Br and 81Br, can be observed in this mass spectrum. These two isotopes 
exist in an approximately 1:1 ratio (50.5:49.5, exactly). This means that a compound containing 
one bromine atom will have two peaks similar in height in the molecular ion region, depending 
on which bromine isotope the molecular ion contains. In the spectrum for compound 1, peaks 
of similar intensity with a gap of two m/z units can be observed, evidencing the presence of 
bromine atoms in the molecule. 
 
Figure 2.2. 1H NMR (300 MHz, CDCl3, 298 K) spectrum of compound 1. 
 
Finally, the compound was analysed by FT-IR spectroscopy. The obtained spectrum confirmed 
that the expected functional groups can be found in the product (Appendix A). 
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2.3. Synthesis and characterisation of a BODIPY (boron-
dipyrromethene) derivative 
Compounds incorporating BODIPY are a class of fluorescent dyes based on a dipyrromethene 
system complexed with a tetrasubstituted boron atom, commonly a BF2 unit. BODIPY 
derivatives have become widely popular as imaging dyes due to the numerous advantages 
that they present: BODIPY probes are highly stable, have large extinction coefficients, intense 
absorption, high quantum yields and are stable in physiological environments.5-7 For this 
reason, BODIPY-based dyes have been used as scaffolds for the construction of  
multifunctional fluorescent probes.8  
 
In this chapter, a BODIPY derivative with a carboxylic acid substituent was synthesised and 
characterised to be used as a fluorophore in the aimed tripodal multimodal system. The 
synthesis consisted of the reaction between 2,4-dimethylpyrrole and 4-formylbenzoic acid in 
dichloromethane at room temperature with a couple of drops of trifluoroacetic acid, adding 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), triethylamine and boron trifluoride diethyl 
etherate (Scheme 2.3). A purple slurry crude was obtained, which was purified by silica gel 
column chromatography, and the fraction of interest was further purified by recrystallisation 
from THF/hexane, to finally yield a red solid (compound 2). This synthesis was challenging due 
to the fact that many by-products are obtained from the polymerisation of pyrrole, which are 
difficult to separate from the desired compound. Moreover, as previously reported, the yield 
for this reaction was rather low (20-30%), but consistent with literature data, and much higher 
than those of porphyrins, which are typically less than 20%.9-11  
 
Scheme 2.3. Reaction to obtain compound 2. 
 
The purity of the BODIPY derivative (compound 2) was tested by HPLC (Appendix A). A high 
intensity peak at 9.2 minutes was shown using the 500 nm channel, corresponding to the 
compound of interest. Other minor peaks can be seen, which can be assigned to impurities 
but due to their much lower intensity they can be ignored.  
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NMR spectroscopy was carried out to confirm the structure of this molecule. The 1H NMR 
spectrum shows two doublets that integrate for 2 H each, at 8.11 and 7.52 ppm, and these are 
the protons in the benzene core H1 and H2, respectively (Figure 2.3). A singlet at 6.19 ppm 
integrating for two protons corresponds to the 2 H from the substituted pyrrole rings, H4. In the 
upfield region of the spectrum, two singlets can be found at 2.45 and 1.32 ppm and correspond 
to the methyl groups attached to the pyrrole rings, H5 and H3, respectively, and integrate for 6 
H resonances each.  
 
Figure 2.3. 1H NMR (500 MHz, DMSO-d6, 298 K) spectrum of compound 2. 
 
Further characterisation of this compound includes mass spectrometry, which was carried out 
using electrospray ionisation in negative mode, and the spectrum revealed a peak at m/z = 
367.1455, which corresponds to the [M-H]- ion (Appendix A). 
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2.4. Monofunctionalisation strategies of the tripodal core 
After several different functionalisation attempts aiming to derivatise the tripodal core 
(compound 1) and attach different moieties, it was found that the reaction between this product 
and different carboxylic acids was successful. The mechanism for this reaction is a nucleophilic 
substitution catalysed by a base, in which the carboxylic group attacks the carbon adjacent to 
the bromide that acts as the leaving group.12  
 
In this context, a first reaction was carried out using benzoic acid as a test as this is an 
inexpensive and common reagent. 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 
1) and benzoic acid were mixed in acetonitrile in a 1:1 ratio, together with 1.5 equivalents of 
potassium carbonate as the base, and the mixture was stirred under reflux overnight (Scheme 
2.4). The reaction was followed by TLC at different times and three spots could be clearly 
identified, one due to the starting material (compound 1) and two additional ones. After this 
time, the solvent was evaporated and the crude solid dissolved in chloroform and extracted 
three times with an aqueous solution of sodium hydroxide to remove any possible remaining 
traces of acid. The organic layers were concentrated under vacuum and the obtained solid 
was purified by silica gel column chromatography to yield three different compounds: the 
mono- and disubstituted tripodal molecules (compounds 3 and 4, respectively), and some 
unreacted starting material (compound 1). The proportions found in the final mixture were 51% 
(monosubstituted, 3), 31% (disubstituted, 4) and 18% (starting material, 1).   
Scheme 2.4. Reaction between compound 1 and benzoic acid yielding two new products (compounds 
3 and 4) and excess of the starting material. 
Chapter 2. Synthesis and characterisation of systems  




The two new products were characterised by NMR spectroscopy. The 1H NMR spectra for the 
new synthesised compounds 3 and 4 have resonances with coupling patterns and associated 
coupling constants that match with the expected ones for these molecules (Figure 2.4), thus 
confirming the molecular structures in solution proposed.  
 
Figure 2.4. 1H NMR (500 MHz, CDCl3, 298 K) spectra of compounds 3 (A), and 4 (B). 
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The two spectra have nine different peaks each, corresponding to the nine different groups of 
equivalent protons in each molecule. The resonances occurred at same or similar chemical 
shift in both cases, but integrate for different number of protons depending on the substitution 
of each molecule, and they also show different multiplicity. In this context, there are peaks at 
8.05, 7.55 and 7.42 ppm that in the case of compound 3 are multiplets and for compound 4 
are a doublet and two triplets, and they correspond to H4, H6 and H5, respectively. For 
compound 3, they integrate for 2 H, 1 H and 2 H, respectively, and for compound 4 they 
integrate double, due to the double substitution of this molecule, which contains two units of 
the benzoic acid derivative. The different multiplicity for these peaks is mainly due to the fact 
that the rotation of compound 4 is hindered due to the existence of two bulky groups, while 
compound 3 has only one. In the upfield region of the spectra there are two singlets, the more 
deshielded one corresponds to H3, and integrates for 2 H in the case of compound 3 (5.44 
ppm) and for 4 H in the case of compound 4 (5.48 ppm). The less deshielded singlet (4.64 
ppm for compound 3 and 4.68 ppm for compound 4) corresponds to the protons in the CH2Br 
groups, and integrates for 4 H and 2 H for the mono- and disubstituted products, respectively. 
The ethyl groups attached to the benzene core appear as two different groups of resonances, 
as there are two ethyl groups equivalent between them and another one inequivalent. 
Accordingly, quartets at 3.00 and 2.93 ppm in the spectrum of compound 3 correspond to H7 
(J = 7.6 Hz) and H2 (J = 7.6 Hz), and they are two quartets integrating for 2 and 4 H, 
respectively. For this same molecule, the two triplets at 1.39 and 1.29 ppm correspond to H8 
(J = 7.6 Hz) and H1 (J = 7.6 Hz) and integrate for 3 and 6 H, respectively. In the case of 
compound 4, the two quartets at 2.97 and 2.89 ppm correspond to H7 (J = 7.6 Hz) and H2 (J = 
7.5 Hz) and integrate for 4 and 2 H, respectively. Finally, the two quartets at 1.32 and 1.24 
ppm for this compound correspond to H8 (J = 7.6 Hz) and H1 (J = 7.5 Hz) and integrate for 6 
and 3 H, respectively. 
 
The 1H resonances of all the products were assigned with the help of a two dimensional 1H-1H 
COSY spectrum. The COSY NMR spectrum of compound 4 shows the coupling resonances 
between protons in the ethyl groups H1-H2, H7-H8, and the aromatic protons, H4-H5 and H5-H6 
(Figure 2.5). 
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Figure 2.5. 1H-1H COSY NMR (500 MHz, CDCl3, 298 K) spectrum of compound 4. 
 
After the successful synthesis of compounds 3 and 4, the same conditions were adapted and 
applied to attach the previously synthesised BODIPY derivative (compound 2) to the tripodal 
precursor unit (compound 1). This time, the mono- and disubstituted products (compounds 5 
and 6, respectively) were obtained in proportions of 34% and 32% in the final mixture, 
respectively, and the remaining 34% of the mixture corresponded to unreacted tripodal ligand 
used as starting material (compound 1) (Scheme 2.5). This is almost a 1:1:1 ratio of starting 
material, mono- and disubstituted products, which differs from the ratio obtained in the previous 
reaction, which was of almost 1:3:2, with a much bigger proportion of monosubstituted product 
formed in the mixture.  
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Scheme 2.5. Reaction between compound 1 and compound 2 yielding two new products (compounds 
5 and 6) and excess of the starting material. 
 
The two new BODIPY derivatives reported hereby are promising as cellular imaging probes 
due to their high fluorescence and contain one and two free bromomethyl arms that can be 
further functionalised with different labels.13 These two new products were characterised by 
NMR spectroscopy and mass spectrometry using nanoelectrospray ionisation in the positive 
mode. From the spectrum for the monosubstituted BODIPY derivative (compound 5), a peak 
at m/z = 729.1490 can be seen, which corresponds to the protonated [M+H]+ ion (Figure 2.6). 
For the disubstituted derivative (compound 6), the peak at m/z = 1016.3777 can be assigned 
to the [M+H]+ ion (Appendix A).  
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Figure 2.6. Mass spectrum of compound 5 using nESI+, and amplification of the isotopic pattern. 
 
1H NMR spectroscopy was used to compare the spectra of the new products with those of the 
two starting materials (compounds 1 and 2). For the monosubstituted product (compound 5) 
(Figure 2.7), two doublets at 8.16 and 7.38 ppm that integrate for 2 H each correspond to the 
four protons of the benzene ring in the BODIPY molecule, H5 and H6, respectively. The singlets 
at 5.98 and 5.48 ppm, which integrate for 2 H each, correspond to H8 and H4, respectively, and 
the next singlet at 4.63 ppm that integrates for 4 H is due to H1. In the upfield region of the 
spectrum, two quartets at 2.99 and 2.94 ppm that slightly overlap correspond to H10 (J = 7.6 
Hz) and H2 (J = 7.7 Hz), respectively, which are the CH2 groups of protons from the ethyl 
substituents of the tripodal ligand. The six methyl groups from the BODIPY molecule that are 
attached to the two pyrrole rings appear as two singlets that integrate for 6 H each at 2.54 and 
1.35 ppm, for H9 and H7, respectively. Finally, the two CH3 groups from the ethyl substituents 
appear as two triplets at 1.38 and 1.30 ppm, again in a slightly overlapped region, and 
correspond to H11 (J = 7.6 Hz) and H3 (J = 7.5 Hz), respectively. 
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Figure 2.7. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 5. 
 
Comparing the spectrum of compound 5 to the one of compound 6 (Figure 2.8), a similar 
distribution of peaks can be observed. The main difference is that in the 1H NMR spectrum of 
compound 6, all the resonances corresponding to the BODIPY substituent integrate for two 
times the number of protons, due to the disubstitution of this molecule. Moreover, the 
resonances due to the ethyl groups that are attached to the benzene core of the tripodal ligand 
and the CH2 groups next to the ester and the bromo units keep their multiplicity but their 
integration changes. 
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Figure 2.8. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 6. 
 
19F NMR spectrum was recorded on all the BODIPY derivatives, as it can be seen for 
compound 5 (Figure 2.9). A quartet at -146.2 ppm was observed, due to the coupling between 
the two fluorine nuclei (which are equivalent) with the boron nucleus. 11B has a spin quantum 
number of 3/2, which is the reason why a quartet is seen from the coupling with only one atom. 
Due to 10B, that exists in an abundance of almost 20% and has a spin quantum number of 3, 
yielding broader peaks than 11B, the quartet is not symmetrical. The coupling constant for this 
resonance was found to be 32.1 Hz. 
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Figure 2.9. 19F NMR (470 MHz, CDCl3, 298 K) spectrum of compound 5. 
 
11B NMR experiments were also carried out, as shown for compound 5 (Figure 2.10). In this 
case, a triplet at 0.7 ppm with a coupling constant of 32.8 Hz can be seen, due to the coupling 
between the boron nucleus and the two fluorine nuclei, which are equivalent.  
 
Figure 2.10. 11B NMR (160 MHz, CDCl3, 298 K) spectrum of compound 5. 
 
Next, a linker with a terminal carboxylic acid group and a tert-butoxide group was attached to 
the tripodal ligand (compound 1) using the reaction conditions already described and purified 
by silica gel column chromatography (Scheme 2.6). The carboxylic acid group protected with 
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a tert-butoxide group can be later used to attach a peptide with previous deprotection. 
Compound 9 was obtained. 
 
Scheme 2.6. Reaction between compound 1 and 4-(tert-butoxy)-4-oxobutanoic acid to produce the 
monosubstituted derivative (compound 9). 
 
The purity of this product after column chromatography was tested by HPLC, and a peak at 
12.3 minutes was observed in the chromatogram in the 280 nm channel (Figure 2.11). 
 
Figure 2.11. HPLC chromatogram of compound 9 in the 280 nm channel. 
 
The new monosubstituted product was also characterised by mass spectrometry. The mass 
spectrum recorded using nanoelectrospray ionisation in positive mode revealed a peak at m/z 
= 552.1132, corresponding to the [M+NH4]+ ion (Appendix A). 
 
NMR spectroscopy was used to characterise this new molecule (Figure 2.12). The 1H NMR 
spectrum shows two singlets at 5.20 and 4.59 ppm, due to H3 and H7, respectively, and 
corresponding to 2 and 4 H. In the upfield region of the spectrum, there are two quartets that 
integrate for 2 and 4 H at 2.95 and 2.84 ppm, and correspond to H8 (J = 7.7 Hz) and H2 (J = 
7.6 Hz) respectively. Between 2.63 and 2.53 ppm there is a multiplet corresponding to the 
protons of the two CH2 groups of the succinate linker attached to the molecule, H4 and H5. The 
9 protons from the tert-butoxide group, H6, appear as a singlet at 1.42 ppm. Finally, at 1.35 
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and 1.25 ppm there are two triplets that integrate for 3 and 6 H, respectively, and correspond 
to H9 (J = 7.6 Hz) and H1 (J = 7.6 Hz). In this spectrum, a second order pattern can be observed 
in the case of the resonances corresponding to H4 and H5. These protons are chemically 
equivalent but magnetically inequivalent. Therefore, instead of seeing two triplets, a second 
order coupling system is observed. The magnetical inequivalence is due to the orientation of 
the ethyl and bromomethyl arms with respect to the plane of the phenyl ring.  
 
Figure 2.12. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 9. 
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Figure 2.13. 1H-13C HSQC NMR (500 MHz, CDCl3, 298 K) spectrum of compound 9. 
 
1H-13C HSQC and 1H-13C HMBC NMR experiments were carried out to assign the different 
resonances in the 13C{1H} spectrum to each different carbon atom in the molecule. Accordingly, 
1H-13C HSQC was recorded in deuterated chloroform and the carbon atoms directly bound to 
one or more protons could be identified (Figure 2.13). To assign the carbon resonances due 
to C atoms that are not directly linked to protons, such as the carbons that form the phenyl ring 
or the two carbonyl groups, the 1H-13C HMBC spectrum was used (Figure 2.14). This way, the 
aromatic carbons and the carbons from the two carbonyl groups could be assigned to 
resonances between 130 and 150 ppm, and at approximately 175 ppm, respectively. 
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Figure 2.14. 1H-13C HMBC NMR (500 MHz, CDCl3, 298 K) spectrum of compound 9. 
 
Finally, all the carbon atoms in compound 9 could be assigned to their resonances in the 
13C{1H} NMR spectrum (Figure 2.15). 
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Figure 2.15.  13C{1H} NMR (126 MHz, CDCl3, 298 K) spectrum of compound 9. 
 
Another linker containing a carboxylic acid group at one end and an azido functional group at 
the other was synthesised in order to attach it to the tripodal ligand (compound 1) and use it to 
perform click chemistry with a compound containing an alkyl group. In this context, 6-
azidohexanoic acid (compound 7) was synthesised from bromohexanoic acid using sodium 
azide by performing a reaction at room temperature for 16 hours. The new compound could 
be isolated as a yellow oil and was fully characterised. The 1H NMR spectrum confirmed that 
the desired product was obtained (Appendix A). The acidic proton can be observed as a broad 
singlet at 10.62 ppm. The rest of protons of this molecule appear in the upfield region of the 
spectrum as two triplets that integrate for 2 H each and correspond to H1 (3.24 ppm) and H5 
(2.33 ppm), respectively. An overlapped doublet of quintuplets appears between 1.65 and 1.54 
ppm corresponding to 4 H, H2 and H4. Finally, H3 appears as a multiplet at 1.40 ppm and 
integrates for two protons.  
 
Next, 6-azidohexanoic acid (compound 7) was incorporated into the tripodal ligand (compound 
1) following the same reaction conditions previously described with potassium carbonate and 
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acetonitrile as a solvent (Scheme 2.7). Compound 8 was isolated after silica gel column 
chromatography, and was characterised spectroscopically.  
Scheme 2.7. Reaction between compound 1 and 6-azidohexanoic acid (compound 7) to produce the 
monosubstituted derivative (compound 8). 
 
The new monosubstituted product was characterised by MS and NMR spectroscopy. The 1H 
NMR spectrum of compound 8 shows the same peaks as for compound 7, plus the peaks due 
to the ethyl groups from the tripodal core (H1, H2, H11 and H10 at 1.25, 2.84, 1.35 and 2.96 ppm, 
respectively), the methyl groups next to the bromide atoms (H9 at 4.60 ppm) and the protons 
next to the new ester bond (H3 at 5.18 ppm) (Figure 2.16). The coupling constants for the two 
triplets that are due to H8 and H4 are 6.9 and 7.5 Hz, respectively; and those for the two quartets 
that correspond to H10 and H2 are 7.6 and 7.6 Hz, respectively. 
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Figure 2.16. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 8. 
 
Compound 8 was synthesised aiming towards its future use in performing “click” chemistry, 
and subsequently attaching a radiochelator, such as deferoxamine (DFO), for potential 
applications in PET and SPECT imaging.14 Following this approach, a cyclooctyne derivative 
functionalised with a carboxylic acid group was used to couple to DFO. This cyclooctyne 
derivative was chosen because it can be used in strain-promoted copper-free azide-alkyne 
“click” chemistry reactions, and it can react with compounds containing an azido group without 
the need of a Cu(I) catalyst to form a stable triazole linkage. The reaction between 
dibenzocyclooctyne (DBCO) acid and DFO takes place in three steps. Firstly, the activation of 
the carboxylic acid group in order for it to react with an amine is necessary, and this was carried 
out using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as 
activating reagent. Then, the deferoxamine mesylate salt was deprotonated using 
triethylamine to obtain a neutral terminal amino group. The final step involves the addition of 
this neutral DFO compound to the activated carboxylic acid to force the coupling of these two 
products (Scheme 2.8). 
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Scheme 2.8. Reaction between dibenzocyclooctyne (DBCO) acid and deferoxamine (DFO). This 
coupling reaction takes place in three steps: (A) activation of the carboxylic acid group of DBCO with 
PyBOP (1), followed by (B) deprotonation of the terminal amine of DFO which is initially a salt (2), and 
coupling of the activated DBCO acid with the neutral DFO (3). 
 
The above reaction was followed by HPLC at different stages, taking aliquots from the reaction 
flask at different times (Figure 2.17). After 48 hours, the solvent was removed under reduced 
pressure and the yellow solid that emerged was purified by silica gel column chromatography 
using a solvent system of methanol in dichloromethane. One fraction was isolated and dried 
under vacuum, and mass spectrometry was performed to identify significant fragments of the 
product. This was not possible and conclusive results could not be deducted. Due to time 
restrains and cost of the dibenzocyclooctyne acid derivative this reaction could not be 
repeated.  
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Figure 2.17. HPLC chromatograms in the 280 nm channel of the reaction described in Scheme 2.8 at 
different times. DFO (2) (blue line) refers to deferoxamine after it has been free-based; 24 h (3) (red line) 
refers to the step 3 of the reaction after 24 hours, and 48 h (3) (green line) refers to the same step of the 
reaction after 48 hours. 
Chapter 2. Synthesis and characterisation of systems  




2.5. Difunctionalisation strategies of the tripodal core 
Orthogonal coupling of several different functionalities has been a very important area of 
research in drug discovery and molecular imaging design.15 
 
In order to include two different substituents in the tripodal molecule, compound 9 was reacted 
with 6-azidohexanoic acid (compound 7) using the same conditions previously described for 
this type of reactions (Scheme 2.9). From this reaction, the disubstituted (compound 14) and 
trisubstituted (compound 15) products could be isolated and fully characterised, together with 
some remaining monosubstituted starting material (compound 9). The final mixture contained 
three different products in percentages of 40% (di-, 14), 52% (trisubstituted, 15) and 8% 
(unreacted starting material, 9). These were separated by silica gel column chromatography 
using a solvent system of ethyl acetate in hexane. 
Scheme 2.9. Reaction between compound 9 and compound 7 yielding two new products (compounds 
14 and 15) and excess of unreacted starting material. 
 
The new products were characterised by HPLC (Figure 2.18), and they all showed to be pure 
with a peak around 12.3 minutes. The very similar retention times of these two new compounds 
and the monosubstituted starting material is due to the similarity of their structures, which differ 
in the number of linkers that they are functionalised with, but at the same time these two types 
of linkers have similar structures and functional groups. 
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Figure 2.18. HPLC chromatogram in the 280 nm channel of compounds 9 (yellow line), 14 (blue line), 
and 15 (orange line), and amplification of the area with the maximum intensity peaks.  
  
The new molecules were also characterised by mass spectrometry and NMR spectroscopy. 
The mass spectrum of compound 14 using nanoelectrospray ionisation in positive mode shows 
a peak at m/z = 627.2740, which corresponds to the [M+NH4]+ ion. The mass spectrum of 
compound 15 using atmospheric pressure chemical ionisation in positive mode, shows peaks 
at m/z = 704.4345 and 709.3901, which correspond to the [M+NH4]+ and [M+Na]+ ions, 
respectively (Appendix A).  
 
The 1H NMR spectrum of compound 14 (Figure 2.19) showed a multiplet at around 5.19 ppm 
which corresponds to H3 and H12, and integrates for 4 H in total. Next, a singlet at 4.61 ppm 
that corresponds to the sole CH2Br group integrates for 2 protons, H9. In the upfield region of 
the spectrum, the two protons next to the azido functional group, H17, appear as a triplet at 
3.25 ppm with a coupling constant of 6.9 Hz. A multiplet between approximately 2.85 and 2.73 
ppm that integrates for 6 H corresponds to the protons in the three ethyl groups, H2, H7 and 
H10. The two adjacent CH2 groups of the succinate linker (H4 and H5) can be found as multiplets 
at 2.58 and 2.54 ppm, and these peaks integrate for 4 H in total. A triplet at 2.34 ppm with a 
coupling constant of 7.5 Hz is due to H13, the two proton resonances next to the carbonyl group 
of one of the two ester linkages. The 4 H corresponding to H14 and H16 appear as two 
quintuplets at 1.67 and 1.59 ppm (J = 7.5 and 7.1 Hz, respectively). Next, the 9 H from the tert-
butoxide group appear as a singlet at 1.41 ppm, and this is overlapped with a multiplet 
corresponding to 2 H from one of the linkers, H15. A multiplet with a shape similar to a triplet 
integrating for 6 H at 1.25 ppm corresponds to H8 and H11, which appear together due to the 
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similarity between the two linkers that makes the molecule almost symmetric. Finally, the 
remaining proton resonances from the CH3 group, H1, appear as a triplet at 1.16 ppm (J = 7.5 
Hz).  
 
Figure 2.19. 1H NMR (500 MHz, CDCl3, 298 K) spectra of compounds 14 (A), and 15 (B). 
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Compound 15 consists of a trisubstituted tripodal core with two azido terminal linkers and a 
succinate derivative, which make the molecule completely symmetric. In this context, the two 
CH2 groups next to the two different ester bonds appear as two singlets at 5.22 and 5.20 ppm 
for H3 and H7, respectively, which correspond to 2 and 4 H. A triplet at 3.24 ppm corresponds 
to H12 and integrates for 4 H, with a coupling constant of 6.9 Hz. At 2.74 ppm there is a 
quadruplet integrating for 6 H and corresponds to the CH2 protons from the ethyl groups, H2 
and H13 (J = 7.5 Hz). There is a multiplet between 2.59 and 2.51 ppm that corresponds to the 
protons of the two CH2 groups from the succinate linker, H4 and H5. Next, a triplet at 2.33 ppm 
with a coupling constant of 7.5 Hz that integrates for 4 H corresponds to H8. Two quintuplets 
at 1.66 and 1.59 ppm are due to H9 and H11 (J = 7.6 and 7.6 Hz, respectively), some of the 
methylene groups from the azido terminal linker. The 9 H from the tert-butoxide group appear 
at 1.40 ppm as a singlet, overlapped with the H10 protons. Finally, there is a triplet at 1.17 ppm 
that corresponds to 9 H, which was assigned to H1 and H14 (J = 7.5 Hz). 
 
FT-IR spectroscopy was carried out to characterise the newly synthesised compounds, 14 and 
15, and compare them to the starting materials (compounds 7 and 9) (Figure 2.20). In the four 
spectra, a band at approximately 1700 cm-1 due to the carbonyl functional group stretching can 
be identified. Moreover, in compounds 7, 14, and 15, the stretching due to the azido functional 
group can be seen as a band at around 2000 cm-1. For compounds 14 and 15, a band at 
around 1150 cm-1 corresponding to the ester C-O-C stretching can be observed (Table 2.1). 
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Table 2.1. Band assignment for the FT-IR spectra of compounds 7, 9, 14 and 15 (Figure 2.20). 
Compound Wavenumber / cm-1 Vibrational mode 
7 






2963 C-H st 
1726 C=O st 
14 
2970 C-H st 
2101 N3 st 
1728 C=O st 
1140 C-O-C st 
15 
2946 C-H st 
2091 -N3 st 
1728 C=O st 
1141 C-O-C st 
 
Another difunctionalisation reaction that was carried out was that between the monosubstituted 
BODIPY derivative (compound 5) and 4-(tert-butoxy)-4-oxobutanoic acid, a succinate 
derivative linker, to produce the disubstituted product (compound 13) (Scheme 2.10). The 
reaction mechanism, as previously, is a nucleophilic substitution where a new ester linkage is 
formed, with the bromide atom acting as the leaving group. 
 
Scheme 2.10. Reaction between compound 5 and 4-(tert-butoxy)-4-oxobutanoic acid yielding the 
disubstituted product (compound 13). 
 
Compound 13 was analysed by mass spectrometry using electron (impact) ionisation in 
positive mode, and from the spectrum a peak can be seen at m/z = 822.4, corresponding to 
the molecular ion, [M]+· (Appendix A). In this case, no other side-products could be isolated. 
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The 1H NMR spectrum of compound 13 shows different peaks corresponding to the different 
groups of equivalent protons present in the molecule (Figure 2.21). In this context, there is a 
doublet at 8.16 ppm that corresponds to the two protons named as H14. There is another 
doublet at 7.39 ppm that corresponds to the other group of two protons from the benzene core 
of the BODIPY molecule, H13. Two singlets at 5.98 and 5.49 ppm correspond to H16 and H12, 
the two protons attached to the pyrrole ring and the two protons next to one of the ester 
linkages, respectively. A singlet at 4.64 ppm corresponds to H3. Slightly more upfield, there is 
a multiplet between 2.97 and 2.81 ppm that integrates for 6 H and corresponds to H2, H7 and 
H10, the CH2 protons from the ethyl groups attached to the tripodal core. Another multiplet 
between 2.61 and 2.56 ppm that is slightly overlapped with a singlet at 2.55 ppm corresponds 
to H4 and H5, the 4 H from the succinate linker. The above mentioned singlet integrates for 6 
H and corresponds to H17, assigned to the two methyl groups from the BODIPY molecule. 
Another singlet at 2.04 ppm corresponds to H9, the two protons from the CH2Br group. Between 
1.5 and 1.0 ppm there are peaks that are due to the remaining protons: a singlet at 1.42 ppm 
corresponds to the 9 H from the tert-butoxide group of the molecule, H6; another singlet at 1.34 
ppm corresponds to H15, the other two CH3 groups from the BODIPY molecule. Finally, there 
is a multiplet between 1.24 and 1.18 ppm that corresponds to H1, H8 and H11, the CH3 protons 
from the three ethyl groups of the tripodal core. 
 
Figure 2.21. 1H NMR (500 MHz, CDCl3, 298 K) spectrum of compound 13.  
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2.6. Trifunctionalisation strategies of the tripodal core 
The disubstituted product containing two different linkers (compound 14) was used to attach 
the synthesised BODIPY derivative (compound 2) to the third arm, in order to make it 
fluorescent and obtain compound 16 (Scheme 2.11).  
 
Scheme 2.11. Reaction between the disubstituted tripodal derivative (compound 14) and compound 2 
yielding a trisubstituted molecule (compound 16). 
 
In order to achieve the desired trifunctionalisation of the core, the conditions used involved a 
1:1 ratio of reagents and 1.5 equivalents of potassium carbonate in acetonitrile stirring 
overnight under reflux. The same work-up described in Section 2.4 was followed. The final 
desired product was purified by silica gel column chromatography with a solvent system of 
ethyl acetate in hexane, and an orange solid was obtained. The purity of this product was 
tested by HPLC, and the chromatogram showed a single peak at 14.6 minutes in the 500 nm 
channel, confirming the purity of this compound (Figure 2.22). 
 
Figure 2.22. HPLC chromatogram of compound 16 in the 500 nm channel. 
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Compound 6 was used as starting material to create a new trisubstituted molecule with two 
BODIPY derivatives and one 4-methyl-3-thiosemicarbazide arm. In this context, compound 6 
was dissolved in acetonitrile together with 4-methyl-3-thiosemicarbazide in a 1:1 ratio and they 
were stirred overnight under reflux (Scheme 2.12). The brown solid obtained from this reaction 
(compound 17) was analysed by mass spectrometry using electrospray ionisation in positive 
mode, and it showed a peak at m/z = 1040.4874, which corresponds to the [M+H]+ ion 
(Appendix A). 
 
Scheme 2.12. Reaction between the disubstituted tripodal derivative (compound 6) and 4-methyl-3-
thuiosemicarbazide yielding a trisubstituted molecule (compound 17). 
 
Compound 17 was synthesised with the idea of using it to coordinate to a metal, potentially on 
the arm substituted with a thiosemicarbazide derivative (Figure 2.23). In this context, zinc(II) 
acetate was used since it was anticipated that a diamagnetic complex would be obtained, 
meaning that the NMR spectrum of the resulting complex can be easily interpreted. The 
reaction was carried out using one equivalent of the substituted product (compound 17) and 
one equivalent of the metal salt (zinc acetate); they were mixed in methanol and stirred under 
reflux for 16 hours. The resulting orange-brown solution was dried under vacuum, and the 
resulting solid was dissolved in dichloromethane and washed with water several times. The 
two different phases were treated independently but only a brown solid was obtained from the 
organic phase, which was analysed. NMR spectroscopy was carried out and the resulting 
spectrum was different from the starting material (compound 17). However, mass spectrometry 
using both positive mode nanoelectrospray ionisation and matrix-assisted laser 
desorption/ionisation (MALDI) did not show the expected ions, though highly complex and 
multiply charged ions were observed at higher m/z showing no incorporation of zinc. The 
possible formation of complex polymeric structures, or supramolecular units connected by 
hydrogen bonds, would hinder the characterisation of the final product.16 
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Figure 2.23. Proposed structures of the synthesised compound 17 coordinated to zinc(II); (A) with one 
molecule of the ligand and two remaining water molecules coordinated to the metal ion, and (B) with 
two molecules of the ligand. 
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2.7. Optimisation of the reaction conditions for the functionalisation 
of the tripodal core 
In order to make the substitution reaction of compound 1 more accessible for the conjugation 
of biomolecules or peptides, an optimisation of the reaction conditions was carried out studying 
the reaction crude at different times, and also using different temperatures and various 
equivalents of the tripodal ligand (starting material). For this purpose, two slightly different 
tripodal molecules and benzoic acid were used for all the optimisation studies. Other 
parameters, such as the base (K2CO3) or the solvent (acetonitrile), were not modified as these 
do not play a key role in the stoichiometry of the reaction. 
 
In the case of the reaction time study, benzoic acid and compound 1 were used as starting 
materials at a 1:1 ratio together with 1.5 equivalents of potassium carbonate. The reaction 
mixture was dissolved in acetonitrile and stirred under reflux at 100 oC. Aliquots of this 
suspension were taken at different times, starting at time = 0 when the temperature reached 
100 oC. Each aliquot was filtered through cotton wool to remove the potassium carbonate and 
dried under a nitrogen flow. The resulting white solid was dissolved in deuterated chloroform 
and analysed by 1H NMR spectroscopy (Figure 2.24). Resonances at 4.58, 4.62 and 4.67 ppm 
corresponding to the starting material (compound 1), the mono- (compound 3), and the 
disubstituted (compound 4) products, respectively, were used to determine the proportion of 
each compound present. This procedure was repeated several times, at the beginning every 
hour until 4 hours had passed from the start of the reaction, and then every 2 hours until 8 
hours had passed. The next aliquot was collected 24 hours after the start, and finally the last 
one was taken 2 hours after that, after 26 hours in total from the start of the reaction. 
Chapter 2. Synthesis and characterisation of systems  





Figure 2.24. 1H NMR (500 MHz, CDCl3, 298 K) spectra of the crude mixture at different times, specified 
in every spectrum. Percentages over the peaks indicate the proportion of each compound (1, 3 and 4) 
present at the mixture at each time. 
 
It can be seen that at the start of the process, when t = 0 hours (at 100 oC), the percentage of 
starting material (compound 1) is the highest (49%), and a very small amount of disubstituted 
product has been formed (11%). However, after one hour has passed, the amounts do not 
vary significantly, and after 24 hours the distribution of the products in the mixture does not 
change anymore, obtaining a 46% of the monosubstituted compound, a 14% of the 
disubstituted derivative, and still containing a 40% of unreacted starting material (compound 
1). 
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The temperature and stoichiometry studies were carried out with benzoic acid and a variety of 
compound 1, a tripodal core substituted with methyl instead of ethyl groups (Scheme 2.13), 
and modifying the chosen factor in each case.  
Scheme 2.13. Reaction between 1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene and benzoic acid to 
form a mixture of unreacted tripodal ligand and mono- and disubstituted products (compounds 10 and 
11, respectively). 
 
Upon completion of the temperature screening, 1,3,5-tris(bromomethyl)-2,4,6-
trimethylbenzene was deemed suitable to be used as a tripodal starting material and the same 
conditions described above were used. Three parallel reactions were set up at three different 
temperatures: 25 oC (room temperature), 40 oC and 60 oC. All the reactions took place 
overnight and, after this time, the solvent was removed under reduced pressure, and the white 
solid was dissolved in dichloromethane and washed with an aqueous solution of sodium 
hydroxide. The organic layers were collected and the solvent was removed under reduced 
pressure. The crude product was purified by silica gel column chromatography using a solvent 
system of ethyl acetate in hexane. When a lower temperature is used there is a lower 
percentage of unreacted starting material in the final mixture, and a higher percentage of 
monosubstituted product is formed. The amount of disubstituted product formed does not 
change significantly using the three different temperatures. However, there is a change in the 
amount of the monosubstituted product formed (increases) and the unreacted starting material 
(decreases) when the temperature is lower (Table 2.2). This is likely due to the fact that at a 
higher temperature the nucleophilic substitution occurs faster and the disubstituted product is 
formed more quickly than at lower temperatures, exhausting all the available acid derivative 
earlier and leaving more unreacted starting material.17 
 
Table 2.2. Different temperatures used for the functionalisation reaction of the tripodal core and 
percentages of each compound found in the final mixture. 





RT (25) 12 60 28 
40 27 42 31 
60 42 26 32 
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The same general procedure for the reaction and purification of the final mixture was used 
when the stoichiometry of the reaction was the parameter studied. In this case, it was the 
number of equivalents of the tripodal ligand used as starting material, 1,3,5-tris(bromomethyl)-
2,4,6-trimethylbenzene, that were modified. It was thought that if there were more molecules 
of the tripodal compound, there would be less chances to obtain the disubstituted product, as 
this would push the reaction towards the formation of the monosubstituted derivative. With this 
approach in mind, two and five equivalents of 1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene 
were used against one equivalent of benzoic acid. The number of equivalents of base 
(potassium carbonate) used remained unchanged in both cases (i. e., 1.5 eq). It was noticed 
that, when the number of equivalents of the tripodal starting material was increased, a higher 
percentage of monosubstituted product was formed, and a lower amount of the disubstituted 
product was produced. When five equivalents of tripodal starting material were used, no 
disubstituted product could be isolated, although the purification of the final reaction mixture 
became more difficult due to the close retention factors of the two compounds seen in the TLC 
plate (Table 2.3). 
 
Table 2.3. Different number of equivalents of tripodal ligand used for the functionalisation reaction of the 
tripodal core and percentages of each compound found in the final mixture. 
Starting material 
equivalents 





2 9 77 14 
5 34 66 - 
 
In summary, it was seen from this study of the reaction conditions using benzoic acid that a 
lower temperature and the use of a higher number of equivalents of the tripodal ligand (used 
as starting material) favour the formation of the monosubstituted product, which can be 
obtained in a somewhat higher percentage from the final mixture. This finding is important for 
the investigation into the step-wise synthetic functionalisation of the tripodal ligand, and it can 
help towards the trifunctionalisation of the molecule.18   
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2.8. Attempted functionalisation reactions of the tripodal core 
The functionalisation of the tripodal organic core (compound 1) with 1, 2, and 3 deferoxamine 
(DFO) units, respectively, was attempted, applying the previously reported method where 
amines have been shown to act as nucleophiles.19 Accordingly, a commercial deferoxamine 
mesylate salt was used together with the tripodal ligand and a base to react under different 
conditions and achieve the desired products (Scheme 2.14). 
Scheme 2.14. General reaction between compound 1 and deferoxamine mesylate salt to produce 
compound 19. 
 
In order to obtain this desired product (compound 19), different reaction conditions were first 
attempted (Table 2.4). All of these reactions were carried out under nitrogen atmosphere and 
using dry solvents. They all involved as work-up the removal of the solvent under reduced 
pressure and, in some cases, extractions with water and organic solvents to remove the base 
and obtain the desired product in the organic phase, which was dried under vacuum. Yellowish 
oils were obtained in most cases, which were characterised by mass spectrometry and other 
techniques such as NMR spectroscopy. No conclusive results regarding the identity of the final 
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Table 2.4. Different conditions used to carry out the reaction between compound 1 and deferoxamine 
(DFO) mesylate salt. 
Comp. 1 / eq DFO salt / eq Base / eq Solvent T / oC Time / h 
1 1 K2CO3 / excess DMF 60 24  
1 2 K2CO3 / excess DMF 60 24  
1 4 K2CO3 / excess DMF 60 24  
3 1 K2CO3 / excess DMF 60 24 
1 1 DIPEA / 2 DMF 90  1  
1 1.4 K2CO3 / 1.03 DMF 80 48  
1 1 NaOH / 1 MeOH 55 4  
2 1 NaOH / 1 MeOH 55 4  
1 1 NEt3 / 3 H2O/AcCN 20 1.5  
1 1 K2CO3 / 1.5 DMF 150 (reflux) 24  
1.2 1 NEt3 / 1 DMF 25 48  
 
When this reaction was carried out following the last set of conditions specified in Table 2.4, 
an oil could be isolated that, when was characterised by HPLC (Appendix A) and mass 
spectrometry, showed to contain the desired product (compound 19). Taken together, these 
two analyses support the hypothesis that a desired compound of an acceptable purity for 
further investigations was achieved. The mass spectrum recorded using electrospray 
ionisation in negative mode shows a peak at m/z = 919.3429, that corresponds to the [M-H]- 
ion, as well as a good isotopic pattern match (Figure 2.25). 
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Figure 2.25. Mass spectrum of compound 19 using ESI-, and amplification of the isotopic pattern. 
 
Regarding the HPLC chromatogram, a major peak can be seen at 7.4 minutes in the 280 nm 
channel, and peaks of lower intensity can be observed before and after this main one 
(Appendix A). The compound obtained via this synthesis was later used for radiolabelling 
experiments with the positron-emitting isotope zirconium-89 (Section 2.9). 
 
Since it was found that the optimisation of the previously described reaction does not lead to 
promising results, the coupling of deferoxamine to a succinic anhydride tail tag was pursued 
instead, in order to change the terminal free amino group of the molecule for a carboxylic acid 
group, with different reactivity and potentially more readily functionalisable (Scheme 2.15). 
Chapter 2. Synthesis and characterisation of systems  





Scheme 2.15. Reaction between deferoxamine mesylate salt and succinic anhydride to achieve the 
coupling of these two reagents using triethylamine as a base, and form compound 18. 
 
In order to achieve a terminal carboxylic acid group, different conditions were tried varying the 
number of equivalents of deferoxamine mesylate salt and succinic anhydride, all of them using 
N,N’-dimethylformamide as a solvent, and at different temperatures and reaction times (Table 
2.5).20 However, it was not until a base was added that the desired product could be identified. 
In this context, the optimal conditions found for this reaction were DFO salt:succinic 
anhydride:triethylamine in a 1:1.2:1 ratio, stirring at room temperature for 72 hours. The work-
up in all the cases involved the removal of the solvent under reduced pressure to yield a yellow 
oil.  
 
Table 2.5. Different conditions used to carry out the reaction between deferoxamine (DFO) mesylate 
salt and succinic anhydride. 
Succinic / eq DFO salt / eq Base / eq Solvent T / oC  Time / h 
1.2 1 - DMF 0, then RT 17  
1.2 1 - DMF 30 24  
1 1 - DMF RT 24  
2 1 - DMF RT 24  
1.2 1 NEt3 / 2 DMF RT 72  
 
When the reaction was carried out following the last conditions specified in the above table 
with a base, an oil could be isolated and characterised by mass spectrometry using 
electrospray ionisation in negative mode. The spectrum showed a peak at m/z = 659.3631, 
which corresponds to the [M-H]- ion for the expected molecule (compound 18) (Figure 2.26), 
and a good isotopic pattern match. The use of triethylamine facilitated the completion of the 
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reaction by deprotonating the ammonium group of the DFO salt, and making it more readily 
available to attack the succinic anhydride group.  
 
Figure 2.26. Mass spectrum of compound 18 using ESI-, and amplification of the isotopic pattern. 
 
The purity of this compound was checked by HPLC using a solvent system of water and 
acetonitrile both containing 0.1% of trifluoroacetic acid. The chromatogram showed a peak at 
approximately 6.9 minutes in the 280 nm channel (Figure 2.27). Protonation on the column is 
likely to account for broadening of this trace (0.1% TFA).21 
 
Figure 2.27. HPLC chromatogram of compound 18 in the 280 nm channel.  
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Since the reaction between the tripodal ligand (compound 1) and carboxylic acid derivatives 
was previously successfully employed to form ester products, compound 1 was reacted with 
compound 18 to produce the corresponding ester (Figure 2.28). The reaction was performed 
under two different conditions: (i) using the DFO derivative:tripodal ligand in a 1:1.2 ratio and 
adding 1 equivalent of triethylamine, using DMF as a solvent and mixing the reagents at 25 oC 
for 48 hours, and (ii) using the reagents in a 1:1 ratio with 2 equivalents of K2CO3, using DMF 
as a solvent and mixing the reagents under reflux at 150 oC for 24 hours. In both cases the 
solvent was removed under reduced pressure when the reaction time was finished. When 
using the conditions specified in (ii), extractions were carried out with dichloromethane and 
water, and finally the organic layers were removed under vacuum. Using the procedure (ii), a 
dark brown solid was obtained, which was characterised by 1H NMR spectroscopy. 
Figure 2.28. Desired product obtained from the reaction between compounds 1 and 18. 
 
The 1H NMR spectrum of compound 19 was compared to that of DFO (Figure 2.29) and at the 
same time also to the one of compound 18 (Figure 2.30). 
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Figure 2.29. 1H NMR (500 MHz, DMSO-d6, 298 K) spectrum of deferoxamine (DFO). 
 
In the 1H NMR spectrum of deferoxamine, a singlet at 2.53 ppm that corresponds to 3 H is 
assignable to the protons of the terminal methyl group, H1. The two protons of the terminal 
primary amine group appear as another singlet at 1.94 ppm. The rest of aliphatic protons 
resonances can be found between approximately 3.60 and 1.00 ppm. The resonances for the 
protons from the secondary amines appear as a broad singlet at 7.86 ppm, and the ones for 
the protons from the OH groups appear as another broad singlet at 7.62 ppm. 
 
Due to the complexity of the molecule most of the peaks could not be assigned fully, however 
it can be seen that the spectra of compounds 18 and 19 are different to the one of the pure 
DFO, with different peaks and multiplicity.  
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Figure 2.30. 1H NMR (500 MHz, 298 K) spectra of DFO (DMSO-d6), and compounds 18 (CD3OD) and 
19 (CDCl3). 
 
Taking advantage of the fact that an amine is a nucleophile and it can undergo substitution 
reactions by displacing the bromide group of the arms of the tripodal ligand, the reaction 
between compound 1 and Zn(ATSM/A) (compound 35c) was attempted (Scheme 2.16). 
 
Scheme 2.16. Attempted reaction between compound 1 and Zn(ATSM/A) (compound 35c). 
 
This reaction was carried out under the same conditions that proved to be successful for the 
functionalisation of the tripodal core (compound 1), using a 1:1 ratio of reagents with 1.5 
equivalents of K2CO3, acetonitrile as a solvent, and stirring the mixture under reflux overnight. 
An orange suspension was obtained, which was analysed by TLC at different times but the 
Chapter 2. Synthesis and characterisation of systems  




reaction mixture did not reveal any clear spots. Acetonitrile was removed under reduced 
pressure and the crude solid was dissolved in dichloromethane to carry out aqueous 
extractions. The organic phase was dried under vacuum and an orange solid was obtained, 
which was analysed by mass spectrometry and NMR spectroscopy but this did not yield 
conclusive results. The obtained product appeared to be rather insoluble and this hindered its 
characterisation.  
 
In order to introduce a fluorescent tag, fluorescein-5-thiosemicarbazide was used. This 
molecule is a derivative of fluorescein, a non-toxic, commercial, organic fluorescent dye 
typically used for imaging applications, very common in confocal laser scanning microscopy 
due to its ability to produce good contrast and quality images, and also due to being excited 
by the ordinarily used 488 nm wavelength of an Ar+ laser.1, 22 Moreover, fluorescein tags have 
advantages such as low toxicity to cells, high quantum yields (0.85 – 0.97), water solubility, 
large extinction coefficients (90000 M-1cm-1), high photostability and being biologically 
tolerable.23, 24 On the down side, fluorescein derivatives present many different isomers and 
tautomers, their equilibria in solution are pH dependent, and this makes it difficult for them to 
be characterised (Scheme 2.17).25, 26   
 
Scheme 2.17. Tautomerism of fluorescein-5-thiosemicarbazide.25 
 
Accordingly, the coupling of fluorescein-5-thiosemicarbazide to the tripodal ligand (compound 
1) was attempted in order to create a fluorescent molecule able to be further functionalised. 
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Several conditions were used with the aim of optimising this reaction (Scheme 2.18). The 
solvent used in all the cases was acetonitrile as this can easily dissolve the two products, and 
all the reactions took place overnight and at different temperatures, since these conditions 
have been proven to work with compounds of similar reactivity (Table 2.6). 
 
Table 2.6. Conditions used for the reaction between fluorescein-5-thiosemicarbazide (F-5-TSC) and 
compound 1. 
Entry Comp. 1 / eq F-5-TSC / eq Base / eq Solvent T / oC Time / h 
1 1 1 - AcCN/DMF 66 16 
2 1 1 - AcCN 80, reflux 16 
3 1 1 - AcCN 90, reflux 16 
4 1 1 K2CO3 / 
1.5 
AcCN 100, reflux 16  
 
In all the cases, filtrations or extractions were carried out once the reaction time was finished 
and in some the crude was purified by silica gel column chromatography, yielding a mixture of 
products difficult to characterise. When conditions shown in the entries 2 and 3 of the above 
table were used, a solid precipitated. It was filtered, and the filtrate was dried under vacuum to 
yield another solid.  
 
Scheme 2.18. Reaction between compound 1 and fluorescein-5-thiosemicarbazide to obtain the 
conjugate as an HBr salt. 
 
The solid materials were analysed by mass spectrometry using electrospray ionisation in 
negative mode, and in the case of the solid coming from the filtrate, a peak corresponding to 
the expected molecule could be observed at m/z = 780.0656, with other peaks in the isotopic 
pattern due to minor impurities (Figure 2.31). The overall structure of the obtained molecule is 
unclear based on information from solution spectroscopies alone, as the tripodal core and the 
fluorescein unit can be attached either by a sulphur atom or by an ester linkage (as described 
in Chapter 4 for thiosemicarbazide derivatives). 
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Figure 2.31. Mass spectrum of the product resulting from the reaction between compound 1 and 
fluorescein-5-thiosemicarbazide using ESI-, and amplification of the isotopic pattern.  
 
Next, the most promising product formed between fluorescein-5-thiosemicarbazide and the 
tripodal ligand was reacted with Zn(ATSM/A) to try to couple this molecule to the system. The 
resulting product would be a potential bimodal molecule, incorporating a fluorophore and a 
radiochelator with potential selectivity for hypoxic tissue. The reaction was carried out with one 
equivalent of each compound dissolved in methanol and stirring at 80 oC under reflux for 16 
hours. After this time, the formed solid was filtered and the filtrate was dried under vacuum. 
Two different fractions, both as orange-yellow solids, emerged, and they were characterised 
by the common techniques but yielded no conclusive results: HPLC chromatograms showed 
multiple peaks, and NMR spectra were unclear, with peaks that could not be assigned to any 
of the proposed obtained molecules (Figure 2.32). This is not surprising given the solution 
equilibria likely to occur in wet solvents, and the possibility of protonation occurring during 
HPLC analysis (when using a mobile phase of acetonitrile and water both containing 0.1% 
TFA). 
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Figure 2.32. Desired product containing a fluorescent unit and a radiochelator.  
 
Another attempted reaction was that between the fluorescein-tripodal derivative and a 
thiosemicarbazide compound, 4-methyl-3-thiosemicarbazide, as this type of products have 
potential anti-tumour activity (Figure 2.33).27 For this purpose, one equivalent of the fluorescent 
tripodal derivative (shown in Scheme 2.18) and 2.2 equivalents of the thiosemicarbazide 
compound were dissolved in acetonitrile and stirred under reflux for 24 hours. The solvent was 
removed under reduced pressure and an orange solid was obtained, which was characterised 
by the common characterisation techniques but no clear conclusions could be deducted as it 
probably did not correspond to the expected product. By mass spectrometry, a peak due to 
the starting material, the fluorescein derivative, could be observed. 
 
Figure 2.33. Proposed structure of the product from the reaction between the tripodal compound 
containing fluorescein-5-thiosemicarbazide and 4-methyl-3-thiosemicarbazide. 
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2.9. Radiolabelling experiments with zirconium-89 
2.9.1. Cyclotron production of zirconium-89 
In these experiments, the positron-emitting radiotracer zirconium-89 was prepared at the 
Wales Research and Diagnostic Positron Emission Tomography Imaging Centre (PETIC) via 
the 89Y(p,n)89Zr reaction using the cyclotron CYCLONE 18/9. The zirconium-89 radiolabelling 
experiments at PETIC were carried out under the supervision of Dr. Stephen Paisey. 
 
2.9.2. Method development 
The radioisotope zirconium-89 was obtained from the cyclotron in a 1 M oxalic acid solution 
and the pH was adjusted to 6.8 – 7.5 by addition of a few drops of a 1 M solution of sodium 
carbonate, in order to be suitable for radiolabelling the two DFO-based products (compounds 
18 and 19). The pH-adjusted 89Zr4+ solution was then added to the product of interest in 
dimethylsulfoxide, and the reaction was stirred at room temperature for 1 hour. After this time, 
the two samples were analysed by radio-HPLC using a C18 column, with a solvent system of 
acetonitrile and water containing 0.1% of trifluoroacetic acid, but conclusive results were not 
obtained. Subsequently, the radiolabelling efficiency was determined by radio-TLC using an 
eluent of 50 mM diethylenetriaminepentaacetic acid (DTPA) (pH 5.5), in which the 89Zr4+ bound 
to the compound appears at the origin of the plate (Rf < 0.1), and the free 89Zr4+ cations are 
chelated by DTPA and elute with the solvent front (Rf > 0.9) (Figure 2.34). This procedure is 
based on a previously reported protocol.28 
 
Figure 2.34. Radio-TLC chromatogram of free 89Zr4+ ions. TLC was eluted using 50 mM DTPA as the 
mobile phase. 
 
As the two used compounds (18 and 19) are based in deferoxamine, a well-known zirconium 
chelator, the coordination of the radioisotope to the ligands can be expected to be comparable 
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to that of DFO, on the hydroxamate groups of the ligand and with two water molecules in order 
to be octa-coordinated (Scheme 2.19).29  
Scheme 2.19. Reaction between deferoxamine derivatives (compounds 18 and 19) and zirconium-89 
with proposed coordination. 
 
The radiolabelling efficiency for compounds 18 and 19 showed to be of ≥ 99.9% (Figure 2.35).  
 
Figure 2.35. Radio-TLC chromatograms of compounds 18 (A) and 19 (B) with 89Zr suggesting a RCY 
≥ 99.9%. TLC was eluted using 50 mM DTPA as the mobile phase. 
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2.9.3. “Cold” chemistry reactions  
The same method used to radiolabel the two DFO-based ligands was tried in “cold” chemistry, 
using ZrCl4. The ligand and the zirconium salt were mixed in a 1.2:1 ratio under nitrogen in a 
Schlenk flask and stirred at room temperature overnight. Acetonitrile was used as a solvent, 
and a 1 M aqueous solution of K2CO3 was used to adjust the pH of the stock zirconium solution 
to approximately 7. Oils were obtained in both cases, which were analysed by mass 
spectrometry. The coordination of the ligands with the zirconium cation was expected (Figure 
2.36), however in the mass spectra no evidence could be found for the formation of these 
complexes or for the incorporation of zirconium. 
 
Figure 2.36. Expected products formed between Zr4+ and compounds 18 (A), and 19 (B). 
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2.10. Probing the functionality of new fluorophores: estimation of 
quantum yields 
The quantum yield (QY) is an important physical property of a substance that gives an idea of 
the efficiency of a fluorescence process. The fluorescence quantum yield (Φ) expresses the 
ratio of the number of emitted photons to the number of absorbed photons per unit of time.30 
Accordingly, the Φ could be expressed as:  
Φ = No. of emitted photons / No. of absorbed photons 
 
The quantum yield is referred to as “relative” when it is measured according to a well-known 
standard and related to this by the following equation: 













Equation 2.1. Formula employed to calculate the quantum yield of the newly synthesised fluorescent 
compounds. 
 
In this equation, the subscript r refers to the reference or standard (Ru(bpy)32+ in this case), 
while s refers to the new compounds. Φr and Φs are the fluorescence QY of Ru(bpy)32+ (0.042) 
and of the unknown sample, respectively. A is the absorbance of the solution, E is the corrected 
emission intensity, I is the relative intensity of the exciting light and n is the average refractive 
index of the solutions.31, 32 
 
UV/visible and fluorescence spectra of solutions of known concentrations of the new 
fluorescent dyes in chloroform were acquired and the QY was measured at room temperature 
according to Equation 2.1 (Table 2.7). A solution of Ru(bpy)32+ in water with a concentration of 
0.03 mg/mL was used as standard. 
 
Table 2.7. Quantum yield calculations for the new BODIPY derivatives.  
Compound λ maxabs (nm) λ maxem (nm) ∆λ (nm) QY 
2 504 511 7 0.12 
5 504 515 11 0.11 
6 504 515 11 0.13 
13 505 515 10 0.07 
16 504 509 5 0.57 
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By comparing the obtained results with different studies of BODIPY derivatives in chloroform 
as solvent, it can be seen that the values fall within the common range (0.01-0.82).33 The 
synthesised BODIPY carboxylic acid derivative (compound 2) and the mono- and disubstituted 
tripodal derivatives containing BODIPY (compounds 5 and 6, respectively) present very similar 
quantum yield values, slightly higher than the one for the tripodal derivative containing a 
BODIPY molecule and a linker (compound 13). Finally, the trisubstituted derivative containing 
one molecule of BODIPY and two different linkers (compound 16) has a surprisingly higher 
quantum yield. 
 
Normalised UV/visible spectra of compounds 2, 5, 6, 13 and 16 in chloroform all showed the 
same absorption peak at around 504 nm (Figure 2.37). 
 
Figure 2.37. Normalised UV/visible spectra of compounds 2, 5, 6, 13 and 16 in chloroform. 
 
Fluorescence spectroscopy was also carried out to acquire the excitation and emission spectra 
of all the mentioned molecules and they all showed similar fluorescence profiles, with an 
excitation peak at 505 nm and an emission peak at 517 nm (Figure 2.38). The similarity in all 
the compounds fluorescent properties is due to the fact that they are all BODIPY derivatives 
based on compound 1. Accordingly, the Stokes shift of these compounds is small, of around 
12 nm (Table 2.8). 
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Figure 2.38. Normalised fluorescence spectrum of compound 5 in chloroform, showing excitation 
(black) and emission (red). 
 
Table 2.8. Excitation and emission wavelengths for the UV/visible and fluorescence spectra of 
compound 5, and its corresponding Stokes shift.   
Compound λ maxex (nm) λ maxem (nm) ∆λ (nm) 
5 505 517 12 
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2.11. Epi-fluorescence and confocal fluorescence imaging 
investigations 
PC-3 cells were incubated with a DMSO : serum-free medium (1:99) suspension of 100 µM 
concentration of some of the newly synthesised compounds containing a fluorophore. In order 
to study the uptake and distribution of these compounds in cells, single-photon laser scanning 
confocal microscopy was carried out. For this purpose, the prostate cancer (PC-3) cells were 
incubated for 15 minutes with each of the products at 37 oC and imaged. PC-3 cells were grown 
according to standard serial passage protocols, placed onto glass bottom dishes and allowed 
to grow to a suitable confluence.  
 
The obtained images confirm the uptake by cells of compounds 2, 5, 6, 13 and 17, with the 
majority of their emission lying within the green and red channels. Furthermore, they do not 
seem to damage the cell morphology. The images show that for compounds 2, 5 and 6 there 
is strong emission in the green and red channels of the spectra when the probe is excited at 
488 nm, while only green emissions can be seen using 405 nm lasers (Figure 2.39-2.40 and 
Appendix A).  
 
Figure 2.39. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 15 minutes 
at 37 oC with compound 2. Final concentration: 100 μM in serum-free medium (1% DMSO). a-e) λex = 
405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-green-red channels; b, g, l) blue 
channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel (λem = 570-
750 nm); e, j, o) DIC channel. Scale bar: 50 μm. 
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Figure 2.40. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 15 minutes 
at 37 oC with compound 6. Final concentration: 100 μM in serum-free medium (1% DMSO). a-e) λex = 
405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-green-red channels; b, g, l) blue 
channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel (λem = 570-
750 nm); e, j, o) DIC channel. Scale bar: 50 μm. 
 
Colocalisation studies with known, commercial dyes (Invitrogen) were carried out in order to 
understand how some of these compounds localise throughout the cell cytoplasm and 
organelles. For this purpose, trackers were used, in particular LysoTracker Red and 
Endoplasmic Reticulum (ER)-Tracker Red (Figure 2.41). In order to carry out these studies, 
prostate cancer cells were incubated for 30 minutes with the corresponding tracker at 37 oC, 
after which they were washed and control images were taken of the cells with the tracker only. 
Following this, the compound of interest was added to the cells and these were incubated 
again for 20 minutes at 37 oC. More images were acquired of the cells containing both the new 
product and the tracker (Appendix A). 
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Figure 2.41. Structures of LysoTracker Red (left) and ER-Tracker Red (right) (Invitrogen). 
 
When the LysoTracker Red (λex = 577 nm, λem = 590 nm) was used, small emission in the blue 
channel could be observed when the probe was excited with a laser of 405 nm wavelength, 
apart from the emission in the green and red channels at 405 and 488 nm (Figure 2.42). When 
the ER-Tracker Red (λex = 587 nm, λem = 615 nm) was used, emission in the red channel could 
be observed when the probe was excited with lasers of 405, 488 and 561 nm wavelength, 
apart from the normal emission due to the fluorophore in the green and red channels for lasers 
of 405 and 488 nm (Figure 2.43). From these studies, it can be concluded that the compounds 
2, 5 and 6 exhibit very strong fluorescence, they all enter the cells and distribute mainly in the 
cytoplasm, especially in the endoplasmic reticulum. There is no emission from the nuclei of the 
cells, and compounds 5 and 6 showed some precipitation during the incubation period, as can 
be seen from the confocal microscopy images. 
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Figure 2.42. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 30 minutes 
at 37 oC with LysoTracker Red, and 20 minutes with compound 5. Final concentration: 100 μM in 
serum-free medium (1% DMSO) solution of compound 5, with a 100 nM solution of LysoTracker Red. 
λex = 488 nm. a) Blue channel (λem = 417-477 nm); b) green channel (500-550 nm); c) red channel (λem 
= 570-750 nm); d) overlay of DIC-blue-green-red channels. Scale bar: 50 μm. 
 
 
Figure 2.43. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 30 minutes 
at 37 oC with ER-Tracker Red, and 20 minutes with compound 6. Final concentration: 100 μM in serum-
free medium (1% DMSO) solution of compound 6, with a 1 μM solution of ER-Tracker Red. λex = 488 
nm. a) Red channel (λem = 570-750 nm); b) green channel (500-550 nm); c) overlay of DIC-blue-green-
red channels. Scale bar: 50 μm. 
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Moreover, compounds 13 and 17 were also tested in prostate cancer cells by laser scanning 
confocal microscopy studies. The same incubation and imaging protocols previously described 
were followed. In the case of compound 13, strong emission can be observed in the green 
channel when the probe is excited with lasers of 405 and 488 nm. There is some minor 
emission in the red channel for the three lasers used – 405, 488 and 561 nm wavelengths. 
This is probably due to precipitation of the compound, which was not completely soluble in the 
serum-free medium used for the microscopy studies (Figure 2.44). 
 
Figure 2.44. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 15 minutes 
at 37 oC with compound 13. Final concentration: 100 μM in serum-free medium (1% DMSO). a-e) λex = 
405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-green-red channels; b, g, l) blue 
channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel (λem = 570-
750 nm); e, j, o) DIC channel. Scale bar: 50 μm. 
 
Compound 17 showed to have strong emission in the green channel for lasers of 405 and 488 
nm excitation wavelength, and some less strong emission for 561 nm (Figure 2.45). Weak 
emission in the blue channel when the probe is excited at 405 nm can also be observed. For 
this compound there is also some emission in the red channel, but this is probably due, as in 
the previous case, to precipitation of the compound in the cells, which is not completely soluble 
in the serum-free medium used for the analysis, and required extra phosphate buffered saline 
(PBS) washing to remove the excess of product. 
Chapter 2. Synthesis and characterisation of systems  





Figure 2.45. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 15 minutes 
at 37 oC with compound 17. Final concentration: 100 μM in serum-free medium (1% DMSO). a-e) λex = 
405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-green-red channels; b, g, l) blue 
channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel (λem = 570-
750 nm); e, j, o) DIC channel. Scale bar: 50 μm. 
 
The confocal microscopy studies showed that the compounds enter the cells and they do not 
modify the cell morphology. These findings constitute a promising result for using BODIPY-
based derivatives as synthetic scaffolds for multimodality imaging applications, with the 
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2.12. Investigations using two-photon fluorescence lifetime imaging 
microscopy 
Fluorescence lifetime imaging microscopy (FLIM) was carried out with the most promising new 
fluorescent compounds to study their lifetime characteristics in both solution and in prostate 
cancer cells. The first experiments carried out were the testing of the lifetime of the new 
fluorophores in solution using DMSO as solvent. Time-correlated single-photon counting 
(TCSPC) was used for this purpose, followed by a FLIM study in vitro using PC-3 cells. All 
these experiments were carried out at the Rutherford Appleton Laboratory in the Central Laser 
Facilities (CLF) by Dr. Vincenzo Mirabello and Dr. Haobo Ge.  
 
The products were tested by TCSPC (Table 2.9). Each photon detected and collected in 
TCSPC was plotted to calculate the fluorescence lifetime. The results obtained from TCSPC 
(Figure 2.46) consist of three components: 
2, ԏn (ps) that is the lifetime, and ԏn (%) which is 
the lifetime percentage (n can be more than one if there is more than one component 
modelled). These last two components represent the duration within which the corresponding 
molecule exists in an excited state. Finally, ԏm is the overall lifetime. It can be observed that 
each compound can be detected in the solution and has a relatively high number of counts, 
especially compounds 2, 13 and 17. 
 
Figure 2.46. TCSPC decay and fitting curves for compounds 2 (A), 5 (B), 6 (C), 13 (D), and 17 (E), 
tested using (A), (D), (E) 10 mM and (B), (C) 100 μM solutions in DMSO excited at 810 nm with a laser 
power between 0.5 and 1.27 mW. Black dots are the measured counts at different times and the red 
lines are the fitting curves. 
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Table 2.9. Two-photon TCSPC data for compounds 2, 5, 6, 13 and 17. 10 mM solutions in DMSO 
were used for compounds 2, 13 and 17, and 100 μM solutions in DMSO for compounds 5 and 6. They 
were excited at λex = 810 nm with a laser power between 0.5 and 1.27 mW. 
Compound 
2
 ԏ1 (ps) a1 (%) ԏ2 (ps) a2 (%) ԏ3 (ps) a3 (%) ԏm (ps) 
2 1.21 51 77.8 2238 15.0 4911 7.2 730 
5 1.02 2655 100.0 - - - - 2655 
6 1.16 1133 43.2 3326 56.8 - - 2379 
13 1.50 155 39.4 2217 35.4 3834 25.3 1814 
17 1.19 214 57.2 639 34.8 1930 7.9 1364 
 
From all the compounds tested in solution, compound 5 has only one component for the 
fluorescence lifetime. Compound 6 has two components, and compounds 2, 13 and 17 have 
three components in major or minor contribution. The ԏ2 and ԏ3 can be due to interactions of 
the compounds with the solvent (dimethylsulfoxide), or to the existence of isomers or pH-
dependent protonated and non-protonated species. 
 
There are three different ranges of values for 
2
: when it is 1.0, the fitting is optimal; values 
between 1.0 and 1.3 indicate incomplete single exponential fit; while if it is higher than 1.5, it 
suggests that there was significant noise within the TCSPC set-up or more than on the decay 
profile of the compound and the data cannot be considered completely reliable. According to 
this, all the results obtained for the tested molecules are reliable except for compound 13, 
which has a χ2 of 1.50. Data collected for compound 5 has the best fit, with a χ2 of 1.02. 
 
The two-photon excitation fluorescence spectra of solutions of the compounds in DMSO were 
collected in order to study the emission properties of these products when excited in a two-
photon excitation regime. The curves for the five compounds tested (2, 5, 6, 7 and 13) exhibited 
a sharp absorption peak at approximately 550 nm wavelength (Figure 2.47).  
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Figure 2.47. Two-photon excitation fluorescence spectra of solutions of 2 (A), and 13 (B), tested using 
10 mM solutions in DMSO and excited at 810 nm with laser power between 0.5 and 1.27 mW.  
 
The two-photon fluorescence spectra of these compounds in PC-3 cells were recorded at one 
or two different sites of the cells and at the background, which were imaged using single-
photon laser scanning confocal microscopy (Figure 2.48). Compounds 2 and 13 were 
incubated in cells with LysoTracker Red and this can be seen in the curves, with a second 
peak emerging between 600 and 650 nm. Since all the tested products are BODIPY derivatives 
based on compound 1 they all have emission at the same region of the spectrum, between 
500 and 550 nm. 
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Figure 2.48. Single-photon laser scanning confocal fluorescence microscopy, and two-photon 
excitation fluorescence spectra of PC-3 cells treated with 10 mM solutions of each compound in 1% 
DMSO. λex = 810 nm. Cells were incubated at 37 oC for 20 minutes with 2 (A), 2 + LysoTracker Red 
(B), 5 (C), 6 (D), 13 + LysoTracker Red (E), and 17 (F). 
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The two-photon FLIM mapping and intensities in PC-3 cells were measured for compounds 2, 
5, 6, 13, 17 and also 2 and 3 containing LysoTracker Red (Figure 2.49). It can be observed 
that these compounds enter the cells and accumulate mainly in the cytoplasm while emitting 
fluorescence. Fluorescence lifetime distribution curves are the overall fluorescence lifetime 
decays summarised from the fluorescence lifetime mapping in PC-3 cells. From these plots, it 
can be seen that the fluorescence lifetime distribution for compound 2 is between 2.5 and 3.5 
ns, approximately. When it was added to the cells with a LysoTracker Red, which localises 
within the lysosomes, the fluorescence lifetime distribution of the same compound showed to 
be between approximately 1.5 and 2.5 ns. The maximum number of counts is at 2.0 ns, and 
the peak has a tail which is due to the tracker. Control studies of the commercial LysoTracker 
Red alone showed that it has a fluorescence lifetime distribution between 2.0 and 4.5 ns, with 
a maximum number of counts at 3.0 ns. For compound 5, the fluorescence lifetime distribution 
is between 0.5 and 1.5 ns, approximately, with a tail that goes up to 3.0 ns but with a much 
lower number of counts. Compound 6 has a lifetime distribution between 1.6 and 2.8 ns, with 
a maximum number of counts at approximately 2.0 ns. Compound 13 alone and with a 
LysoTracker Red has a fluorescence lifetime distribution between approximately 0 and 2.0 ns, 
with a maximum number of counts at 0.5 ns. Finally, compound 17 has a fluorescence lifetime 
distribution between 2.0 and 3.5 ns, with a maximum number of counts around 2.5 ns. The 
number of counts is high for all the studied products, in particular for compounds 2, 5 and 17. 
All the compounds have two different components for the lifetime distribution in cells (Table 
2.10), which can be seen in major or minor proportion in the fluorescence lifetime distribution 
curves. These are due to different interactions of the molecules with the solvent. In all the 
cases, ԏ1 is the major component of the fluorescence lifetime, but for compound 6, ԏ1 and ԏ2 
exist in an almost 1:1 ratio. Moreover, the data collected are reliable, since all the values for 

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Table 2.10. Two-photon TCSPC data for compounds 2, 2 + LysoTracker Red, 5, 6, 13, 13 + 
LysoTracker Red and 17, tested using 10 mM solutions in DMSO in PC-3 cells excited at λex = 810 nm 
with a laser power between 0.5 and 4.5 mW. 
Compound 
2
 ԏ1 (ps) a1 (%) ԏ2 (ps) a2 (%) ԏm (ps) 
2 1.06 1384 71.4 6905 28.6 2963 
2 + LysoTracker  1.02 1631 67.2 5693 32.8 2963 
5 1.07 257 86.8 5077 13.2 895 
6 1.05 384 50.9 2802 49.1 1570 
13 1.13 116 90.2 1531 9.8 255 
13 + LysoTracker  1.25 162 83.2 1662 16.8 414 
17 1.10 1955 73.1 5340 26.9 2866 
 
 
Figure 2.49. Fluorescence lifetime distribution curves, fluorescence lifetime mapping of ԏm, and two-
photon fluorescence intensity diagram of PC-3 cells treated with 10 mM solutions of each compound in 
1% DMSO. λex = 810 nm. Cells were incubated at 37 oC for 20 minutes with 2 (A), 2 + LysoTracker 
Red (B), 5 (C), 6 (D), 13 (E), 13 + LysoTracker Red (F), and 17 (G). 
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2.13. Cell viability by MTT assays 
The use of tetrazolium salts is a commonly applied technique in cell biology to measure 
metabolic activity and cell viability and estimate the IC50 values of the drug candidates. The 
mechanism of action of MTT consists in the cellular uptake of the MTT dye, that is reduced by 
nicotinamide species (such as NAD(P)H) present in the mitochondria of the cells to form the 
formazan species, which are insoluble in the serum-free medium, and dimethylsulfoxide needs 
to be added in order to solubilise them and measure the absorbance (Scheme 2.20). The 
concentration can then be calculated from the absorbance, and the number of viable cells in 
the presence of a compound of interest can be calculated.34-36 
 
Scheme 2.20. Formation of the formazan dye detected in MTT assays by biological reduction of this 
molecule. 
 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were carried out in 
order to estimate the IC50 value of the tripodal organic core used as starting material 
(compound 1), the BODIPY carboxylic acid derivative (compound 2), and the tripodal ligand 
with one and two of the bromomethyl arms substituted for a BODIPY derivative (compounds 5 
and 6, respectively) (Figure 2.50). The IC50 value corresponds to the half maximal inhibitory 
concentration, and it is a measure that indicates how effective a substance is to inhibit a 
specific biological process. In this case it refers to what concentration of compound is needed 
to kill half of the population of cells. MTT assays were carried out with the assistance of Dr. 
Haobo Ge. 
 
In order to carry out these assays, PC-3 cells in 96 well plates were treated with each of the 
compounds in serum medium (1% DMSO) at different concentrations for 48 hours at 37 oC. 
Then, MTT was added to the cells and incubated for 2 hours. The insoluble formazan species 
was solubilised with 100 μL of DMSO. A spectrophotometer was used to quantify the 
absorbance of the solution by the cells (with an absorption wavelength of 570 nm) and a dose 
response curve was plotted to calculate the IC50 of each of the products (Table 2.11).  
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Figure 2.50. IC50 in PC-3 cells after 48 hours of treatment at 37 oC with compounds 1, 2, 5 and 6. 
(The data were collected from six repeated measurements on the same day; N = 1). 
 
It can be seen that the tripodal ligand with the three bromomethyl arms (compound 1) is the 
one with the lowest IC50, meaning that it is the most toxic compound for the cells out of the four 
products tested here. The less cytotoxic product is the BODIPY derivative (compound 2). When 
the bromomethyl arms of the starting tripodal ligand are substituted by one and two BODIPY 
derivatives, respectively (compounds 5 and 6), the toxicity of the products decreases. It can 
be concluded that the three bromomethyl arms of compound 1 make it more toxic, and when 
these are substituted by the synthesised BODIPY derivative (compound 2), which has very low 
cytotoxicity, the toxicity of the tripodal derivatives is also decreased.37 Also, smaller molecules 
are usually more cytotoxic than larger molecules because they can be more easily up taken 
by cells.38 
 
Table 2.11. Summary of compounds tested in MTT assays using PC-3 cells and IC50 values found for 
each of them. 
Compound IC50 / M 
1 (2.2 ± 0.6)·10-6 
2 (3.1 ± 0.2)·10-4 
5 (1.0 ± 0.3)·10-4 
6 (1.2 ± 0.2)·10-4 
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2.14. Summary of Chapter 2 
Chapter 2 describes an investigation into the functionalisation of a symmetric tripodal organic 
core (compound 1). After investigating several different reaction conditions and several types 
of precursor molecules, it was seen that the reaction between compound 1 and many 
carboxylic acid derivatives was successful. The mono-, di- and trisubstituted products were 
isolated in different yields and some of the unreacted tripodal starting material could be 
recovered. Reactions generally consisted in a nucleophilic substitution where the bromide 
group leaves the molecule. Moreover, the reaction conditions were optimised in order to make 
this reaction more compatible for the use of biomolecules, which can usually not stand high 
temperatures for prolonged periods of time. It was seen that using lower temperatures and a 
higher number of equivalents of compound 1, the formation of the monosubstituted product 
was favoured. However, the step-wise functionalisation cannot be completely achieved and a 
mixture of products is obtained in all the cases. 
 
A BODIPY derivative containing a carboxylic acid group was synthesised, characterised and 
incorporated as a tag. This was the fluorophore of choice due to its high fluorescence quantum 
yield and biocompatibility. The tripodal starting material containing three “arms” was 
successfully trisubstituted, forming three new ester bonds, with a succinate linker, an azido 
terminal linker and a BODIPY derivative. The azido terminal linker was attached with the idea 
of performing “click” chemistry using a DBCO-substituted deferoxamine derivative, but this was 
not successfully achieved. The succinate linker was attached with the idea of using it to include 
a peptide to the system, as will be described in Chapter 3. All the newly synthesised 
compounds were characterised by NMR spectroscopy, MS, FT-IR, HPLC, and UV/visible and 
fluorescence spectroscopy, when necessary. 
 
Several other functionalisation reactions were attempted, including the functionalisation of the 
tripodal core with the fluorophore fluorescein-5-thiosemicarbazide. This reaction was tried 
using different conditions and in some cases a peak corresponding to the expected molecule 
could be observed in the mass spectrum, however in most cases the isolated solid could not 
be fully characterised.  
 
The functionalisation of DFO probed to be feasible, and two deferoxamine derivatives were 
synthesised. Radiolabelling with zirconium-89 was carried out, yielding a radio-incorporation 
factor of ≥ 99.9% in both cases, which is promising in terms of new radiotracers design. 
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Imaging in PC-3 cell line was carried out using laser scanning confocal microscopy and FLIM, 
with single-photon and two-photon excitation regimes. The confocal microscopy results 
showed that the synthesised molecules are up taken by the living cells investigated, with good 
penetrability through the cell membrane, although they do not enter the nuclei. All of these 
compounds are retained in the cytoplasm and do not damage or alter the cell morphology. 
Colocalisation studies were performed using LysoTracker Red and ER-Tracker Red in PC-3 
cells, and these showed how the tested molecules localise mainly in the endoplasmic 
reticulum. 
 
FLIM experiments were carried out to determine the fluorescence lifetime, and the lifetime 
components distributions were measured for solutions of the fluorescent molecules in DMSO. 
In TCSPC, the fluorescence lifetime was observed, in all the cases with two or more 
components exponential fitting functions using standard protocols, consistent with previous 
investigations carried out by Prof. Stanley Botchway and his team at the Research Complex 
at Harwell.39  
 
Toxicity assays were carried out on the tripodal starting material (compound 1) and this 
substituted with one and two BODIPY derivatives (compounds 5 and 6, respectively). They 
showed that by substituting the bromomethyl arms of the starting molecule with the 
fluorophore, the toxicity decreases significantly, making the materials more biocompatible and 
less toxic to the cancer cells investigated. 
 
In summary, this new type of fluorophores show promising properties to be used as synthetic 
scaffolds for molecular imaging probes for in vitro studies, with relatively low toxicity levels and 
comparable with recently reported probes,11 and opening up the possibility of further 
functionalisation.  
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Chapter 3. Synthesis of imaging agents incorporating a 
bombesin derivative 
3.1. Overview of Chapter 3 
This Chapter describes the synthesis and spectroscopic characterisation of a rarely-explored 
peptide as a gastrin-releasing peptide (GRP) targeting analogue, the [7-13] fragment of 
bombesin, and its attempted incorporation into a fluorescent tripodal system with two BODIPY 
units described in the previous chapter (Figure 3.1). This fragment was chosen instead of the 
full length peptide due to the fact that it can be more easily synthesised and characterised, and 
it conserves the properties of the full length sequence. Moreover, a deferoxamine conjugate 
containing this shorter bombesin-based amino acid sequence has also been synthesised and 
characterised spectroscopically.  
 
Bombesin is a peptide formed by 14 amino acids, and it is an amphibian homolog to the 
mammalian gastrin-releasing peptide, which has been studied as a targeting ligand for 
diagnosis and therapy of GRP positive tumours.1 
 
Figure 3.1. Schematic representation of a tripodal system incorporating the [7-13] bombesin fragment 
peptide and how this would get into a cell expressing the gastrin-releasing peptide (GRP) receptor.  




Regulatory peptides are a type of peptide that take part in the information transfer process 
between cells in several different organs and tissues in the body, and can act locally or at a 
distance.2 In general, regulatory peptides, such as the bombesin fragment used here, present 
many advantages: they are structurally small biomolecules, readily diffusible and they show a 
rapid clearance from the blood. For this reason, radiolabelled regulatory peptides are 
interesting potential agents for PET and SPECT imaging using radioisotopes for early 
diagnosis or treatment of human disease.3, 4 Furthermore, high affinity receptors for these 
peptides are over-expressed in many cancer cells, and they can be used as new molecular 
targets for cancer diagnosis and therapy.5 Peptides are efficient targeting elements suitable 
for the delivery of drugs to the tumour vessels, and many areas of research now focus on using 
the tumour-targeting potential of peptides to develop imaging agents and to direct drugs.6, 7 
Molecules containing fluorescent dyes and chelators for radioisotopes can be used to tag 
biomolecules such as peptides or antibodies using standard bioconjugation techniques, and 
the resulting new conjugates will constitute promising trimodal units for cell imaging and 
applications in PET and/or SPECT.8 
 
Molecules containing targeting peptides can localise within the tumour receptors existing in 
cancer cells. In this context, peptide conjugates containing a bombesin fragment bind with 
strong affinity and selectivity to the gastrin-releasing peptide receptor (GRPr) and have been 
developed to target tumour cells overexpressing such receptors (e. g., prostate, breast, ovarian 
and small cell lung cancer) using non-invasive imaging technologies.9, 10 GRP receptors are 
located on the cellular membrane. Molecules incorporating targeting peptides represent 
relevant non-viral vectors for tumour targeting, imaging and therapy.11 However, when a 
molecule contains two targeting units, the choice of targeting mode remains under debate.12 
In this case, the desired molecule would contain a BODIPY derivative, which is known to target 
the endoplasmic reticulum found in the cytoplasm of cells, and a bombesin sequence that 
binds to the GRPr positioned on the cellular membrane. It was unclear which targeting 
molecule would lead the distribution of the complex and whether the coexistence of both 
moieties could compromise the biological targeting capabilities of one of them.13-15 
 
  




3.2. Synthesis and characterisation of the [7-13] bombesin fragment 
The [7-13] bombesin fragment is a heptapeptide with affinity for a binding site on the 
bombesin/gastrin-releasing peptide receptor. It is the minimum sequence of the bombesin 
peptide that stimulates receptor activity.16 It is formed by glutamine, tryptophan, alanine, valine, 
glycine, histidine and leucine (Figure 3.2).  
 
Figure 3.2. Structure of the [7-13] L-bombesin fragment synthesised hereby, showing the different 
amino acids that form the peptide: Gln-Trp-Ala-Val-Gly-His-Leu-NH2. 
 
The [7-13] bombesin sequence (compound 22) was synthesised using solid-phase peptide 
synthesis (SPPS), with an automated peptide synthesiser (Scheme 3.1). The basic concept in 
solid-phase peptide synthesis is the step-wise construction of a peptide chain attached to an 
insoluble polymeric support (e. g., a resin).17 The amino acids used are protected by an Fmoc 
(9-fluorenylmethoxycarbonyl) group, which is attached to the N-terminal amino function of the 
molecule. Side-chain protection of other functional groups is provided by other protecting 
groups which are typically sensitive to acidic conditions. The Fmoc protecting group is base-
labile, and it is usually removed with a base, in this case piperidine. The side-chain protecting 
groups are removed at the end by treatment of the peptide with trifluoroacetic acid (TFA), which 
also cleaves the bond that anchors the peptide to the resin support. The synthesis of this 
bombesin fragment has previously been carried out in the group and optimised throughout the 
years.18 
 





Scheme 3.1. Steps involved in the synthesis of the [7-13] bombesin fragment using solid-phase peptide 
synthesis.  
 
To synthesise the [7-13] bombesin fragment, a Rink amide resin was used, with a loading 
capacity of 0.59 mmol/g. The resin was first swollen with dichloromethane and N,N’-
dimethylformamide, followed by removal of the Fmoc group with a solution of 20% piperidine 
in N,N’-dimethylformamide. After deprotection, the coupling with the first amino acid was 
carried out. Three equivalents of each amino acid were used, all of them Fmoc protected. To 
carry out the coupling, solutions of N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 




hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine 
(DIPEA) in N,N’-dimethylformamide were used. All the coupling reactions took place at 75 oC, 
except the one for the second amino acid, Fmoc-His(Trt)-OH, which took place at room 
temperature and for a longer period of time. The different conditions for the coupling of Fmoc-
His(Trt)-OH were chosen in order to avoid racemisation of this amino acid during the coupling 
step, which occurs at elevated temperatures.19, 20 When the seven amino acids were coupled, 
the peptide was deprotected at the N-terminus and, finally, cleavage of the peptide from the 
resin was carried out for 2 hours with a cleavage “cocktail” of trifluoroacetic acid : water : phenol 
: triisopropylsilyl in a 88:5:5:2 (v/v/v/v) ratio. This particular cleavage “cocktail” composition was 
required due to the presence of Trp. Moreover, it has shown to yield good results in terms of 
cleavage yields and purity of the peptide for almost all types of peptides.21, 22 The suspension 
of the resin in the cleavage “cocktail” was filtered and the peptide was precipitated by adding 
cold diethyl ether and collected by centrifugation. It was purified by semi-preparative HPLC 
using a C18 cartridge and water and acetonitrile as the solvent system, to yield a white solid. 
After purification, HPLC chromatography was carried out to test the purity of the product and 
it showed to be of 85%, with a major peak at 7.1 minutes and a much less intense peak at 2.8 
minutes, corresponding to some side product of the reaction, possibly a truncated bombesin 
fragment.23 
 
The compound obtained was characterised by NMR spectroscopy. The 1H NMR spectrum of 
the bombesin fragment was acquired in deuterated methanol and the resonances were 
assigned with help of the two-dimensional 1H-1H COSY NMR spectrum. The chemical shifts of 
the resonances were in accordance with the values found in the literature.24 The 1H resonances 
for amino acid residues that contain aromatic groups (tryptophan and histidine) can be found 
between approximately 8.50 and 7.00 ppm (Figure 3.3). In this region, protons due to impurities 
occur and this makes it difficult for the resonances corresponding to the protons in the aromatic 
residues of Trp and His to be fully assigned. The region that goes from around 4.90 to 3.00 
ppm contains the resonances due to the protons adjacent to the NH groups in the peptide 
backbone (αCH). Finally, the resonances of the protons in the side groups of the amino acids 
are observed in the region between approximately 3.20 to 0.85 ppm. 





Figure 3.3. 1H NMR (500 MHz, CD3OD, 298 K) spectrum of the [7-13] bombesin fragment (compound 
22). (A) Whole spectrum, and (B) expansion of the different regions of the spectrum.  
 




Furthermore, the solid was analysed by mass spectrometry using nanoelectrospray ionisation 
in positive mode, and from the spectrum, peaks due to the [M+H]+ and [M+Na]+ ions were 
observed at m/z = 809.4417 and 831.4227, respectively, as expected (Figure 3.4). 
 
Figure 3.4. (A) Mass spectrum of compound 22 using nESI+, (B) isotopic pattern for [M+H]+, and (C) 
isotopic pattern for [M+Na]+.  




Circular dichroism (CD) is a characterisation technique that uses the ability of chromophores 
to absorp differently left and right circularly polarised radiation. Such compounds either present 
chiral structures or are placed in chiral environments. Peptides can contain a number of 
chromophores that can generate CD signals: the peptide bond absorption is located in the far 
UV region (240 – 180 nm), and this area can provide information about the secondary structure 
of such molecules (α-helix and β-sheet). The UV region that goes from 320 to 260 nm is due 
to the aromatic amino acid side chains and can provide information about the tertiary structure 
of the peptide or protein.25 Circular dichroism of the full length bombesin peptide has been 
reported in the literature for the investigation of the secondary structure of this peptide both in 
solid state and in solution. The results showed that the peptide can adopt different 
conformations depending on the concentration, consisting mainly in disordered structure and 
intermolecular β-sheet species.26 
 
In this work, CD was used on the [7-13] L-bombesin fragment to study its chiral properties 
(Figure 3.5). 200 μM solutions of the compound in dimethylsulfoxide, water and acetonitrile 
were used. Maximum absorption peaks were obtained at 286 nm for the solution in 
dimethylsulfoxide, and 281 nm for the solutions in water and acetonitrile, as it can be seen 
from the UV/visible spectra. As expected, this peptide sequence does not show a defined 
secondary structure in solution. This is due to the fact that it is formed from only seven amino 
acids, and in order to have a secondary structure, peptides need to have at least ten amino 
acids. Accordingly, the structure of a disordered peptide can be expected for the [7-13] 
bombesin fragment synthesised hereby, with a random coil conformation. In all the cases, for 
the maximum absorption peak in the UV/visible spectrum, the CD spectra have a negative 
peak at around 285 nm (in the case of water, it looks like it is positive but this is due to the 
background noise). Therefore, it can be concluded that the molecule under study is chiral. This 
was expected as this compound is formed by chiral amino acid residues existing in the L- form. 
 
 





Figure 3.5. Circular dichroism spectra of the [7-13] L-bombesin fragment in (A) dimethylsulfoxide, (B) 
water, and (C) acetonitrile, together with their absorption spectra. 




3.3. Synthetic strategies to incorporate the [7-13] bombesin fragment 
into a tripodal linker system 
In order to attach the synthesised peptide fragment to the tripodal unit described in Chapter 2, 
a strategy using a succinate derivative linker was adapted from the literature and applied 
hereby.27 The use of a molecule containing a BODIPY derivative to incorporate a peptide would 
allow a fluorescent system able to localise specifically within cancer cells with the 
corresponding receptor. 
 
The first approach was the deprotection of the tripodal ligand containing a tert-butoxide 
protected acid linker using trifluoroacetic acid (TFA) and dichloromethane as solvent in a 1:1 
ratio. This way, a free COOH group would be obtained for attachment to the peptide fragment 
(Scheme 3.2). 
 
Scheme 3.2. Attempted deprotection reaction of compound 9 explored towards achieving a free 
carboxylic acid group. 
 
This reaction was carried out overnight at room temperature and the solvent was removed 
under reduced pressure. The obtained solid was characterised by MS (using electrospray 
ionisation) and NMR spectroscopy, but the desired product of the reaction shown in the 
scheme above could not be isolated. 1H NMR spectroscopy of the resulting mixture showed 
that the singlet peak due to the nine protons of the tert-butoxide group disappeared, but new 
resonances emerged. It can be concluded from the spectrum that the ester linkage existing 




between the tripodal ligand and the linker breaks under the used conditions, and two products 
coexist in the final mixture: succinic anhydride and a tripodal molecule with a hydroxyl-methyl 
arm. This is consistent with the behaviour of various succinate prodrugs, where the ester 
linkage breaks under acidic conditions and the succinate derivative cycles to form succinic 
anhydride.28, 29  
 
In order to test the suitability of the conditions applied for the removal of the tert-butoxide group 
and achieving the desired free carboxylic acid, the analogous reaction was carried out by using 
the succinate linker alone, and the product was characterised by NMR spectroscopy and MS 
(Scheme 3.3).  
 
Scheme 3.3. Deprotection reaction of the succinate derivative linker to yield succinic acid. 
 
The 1H NMR spectrum of this product was consistent with that expected for this new molecule. 
The 1H NMR spectrum of the starting material, 4-(tert-butoxy)-4-oxobutanoic acid, shows a 
singlet at 1.44 ppm due to the protons of the tert-butoxide group, H1, and a multiplet between 
2.63 and 2.52 ppm due to the four protons in the two CH2 groups of the molecule, H2 and H3 
(Figure 3.6). The spectrum of the new molecule, succinic acid, shows a singlet at 2.56 ppm 
that is due to the four protons in the two CH2 groups of the product, H2, which are now 
equivalent due to the symmetry of the molecule, and a broad singlet at around 5.10 ppm can 
be seen due to H1, the acidic protons.  





Figure 3.6. 1H NMR (500 MHz, 298 K) spectra of (A) the starting material, 4-(tert-butoxy)-4-oxobutanoic 
acid (CDCl3), and (B) succinic acid (CD3OD). 
 




Since the deprotection of the linker alone took place successfully under the conditions 
described above, the coupling between the [7-13] bombesin fragment and the protected 
succinate linker was carried out to try to identify the ideal reaction conditions (Scheme 3.4). 
 
Scheme 3.4. Coupling of the [7-13] bombesin fragment to a succinate linker via a carboxylic acid-amine 
coupling reaction. 
 
This coupling reaction between compound 22 and the succinate derivative was carried out 
mixing DIPEA and HBTU in a 2:1 ratio with the bombesin fragment and the linker containing a 
carboxylic acid group at room temperature under a flow of nitrogen. The reaction mixture was 
stirred overnight, and a pale white solid could be isolated, which corresponded to the expected 
product (compound 24). It was analysed by mass spectrometry using positive mode 
electrospray ionisation, and from the spectrum peaks could be seen at m/z = 965.5235 and 
987.5059, which correspond to the [M+H]+ and [M+Na]+ ions, respectively (Figure 3.7). 





Figure 3.7. (A) Mass spectrum of compound 24 using ESI+, (B) isotopic pattern for [M+H]+, and (C) 
isotopic pattern for [M+Na]+. 
 
The next step carried out was the deprotection of the conjugate formed between the bombesin 
fragment and the succinate linker, protected with a tert-butoxide group (compound 24). This 
was achieved using the same conditions applied to 4-(tert-butoxy)-4-oxobutanoic acid, with 
dichloromethane and trifluoroacetic acid in a 1:1 ratio and stirring the contents overnight at 
room temperature (Scheme 3.4).  
 
The desired product, the deprotected molecule (compound 25), was isolated by removing the 
solvent under reduced pressure, and characterised by mass spectrometry using electrospray 
ionisation in positive mode (Figure 3.8). 





Figure 3.8. (A) Mass spectrum of compound 25 using ESI+, (B) isotopic pattern for [M+H]+, and (C) 
isotopic pattern for [M+Na]+. 
 
The purity of compound 25 was analysed by HPLC using a solvent system of water and 
acetonitrile with 0.1% of TFA (Figure 3.9). A peak at 7.0 minutes in the 280 nm channel 
indicated that the product was obtained with a purity of approximately 93%, with an impurity 
corresponding to the 7% of the mixture that can be seen in the HPLC chromatogram at around 
10.0 minutes, and could be due to some traces of the protected starting material remaining in 
the product.  





Figure 3.9. HPLC chromatogram of compound 25 in the 280 nm channel. 
 
Once the coupling between the [7-13] bombesin fragment and the succinate linker was 
achieved, and the deprotection of the carboxylic acid group of the conjugate was successfully 
performed, the reaction between the bombesin-linker complex (compound 25) and the tripodal 
ligand (compound 1) was carried out.  
 
The molecule resulting from this reaction was explored further, as a potential synthetic scaffold 
for a bimodal system with differing functionalities held together by the tripodal core, and 
containing a peptide fragment and two fluorescent moieties. In order to facilitate this reaction, 
the tripodal derivative chosen was compound 6, which contains two BODIPY molecules and 
only a free bromomethyl arm (Scheme 3.5). This route was chosen as it would avoid the 
formation of di- and trisubstituted derivatives, given that only one arm would be available to 
undergo a nucleophilic substitution reaction. This would also likely make the isolation and 
characterisation of the final product simpler.  
 
In order to carry out this reaction, the same conditions that proved successful as described in 
Section 2.4 in Chapter 2 for reactions involving these functional groups were used. The two 
reagents were dissolved with potassium carbonate in acetonitrile in a 1:1:1.5 ratio. These were 
stirred at room temperature overnight under a flow of nitrogen. After this time, the solvent was 
removed under reduced pressure and the orange oil that was obtained was isolated and 
analysed by NMR spectroscopy and MS. HPLC analysis was used to check the purity of the 
product. However, spectroscopic investigations did not yield conclusive results regarding the 
identity of the final product. 
 




Scheme 3.5. Attempted reaction between compounds 25 and 6 to form a desired trisubstituted 
molecule, with fluorescent properties and a targeting peptide. 
 
Mass spectrometry was carried out using a high definition electrospray ionisation method in 
positive (Figure 3.10) and negative modes coupled to an HPLC unit. The different peaks in the 
spectra were subtracted to calculate the m/z loss between each of them, and try to associate 
it to the loss of an amino acid, since using this method the fragmentation of the molecule into 
the individual amino acids or fragments could occur.30 However, conclusive results could not 
be deducted, and it was not possible to find any peak at any charge that could be assigned to 
the desired molecule from the reaction or fragments of this.  





Figure 3.10. Mass spectrum of the product resulting from the reaction between compounds 25 and 6 
using ESI+. Peaks corresponding to the expected molecule or fragments of this could not be identified. 
  
The same reaction was carried out using the same reagents but at 80 oC and for a shorter 
period of time (three hours) to test its success at a higher temperature. From the mass 
spectrum of the product obtained by electrospray ionisation using both positive and negative 
modes, peaks corresponding to the molecular formula of the expected compound could not be 
observed. The reason why this reaction did not work as expected could be due to the large 
size of the two molecules and the steric hindrance for the two functional groups to react. 
Related chemistry has been used to link a variety of complex carboxylic acid derivatives to a 
similar scaffold. However, there are no examples of reactions with unprotected peptides.27 
 
Due to time restrictions, it was not possible to repeat this reaction to find the right conditions 
to achieve the desired peptide-targeted final product. With more time and further 
investigations, this reaction should be achievable and this would constitute an interesting 
finding, as a peptide with these functionalities could be attached to the tripodal systems fully 
discussed in Chapter 2, and a potential multimodal molecule could be built. Potential further 
experiments would include carrying out the same reaction with simpler precursors, i. e., using 
compound 1 and the peptide fragment, instead of the already disubstituted tripodal molecule. 
This would facilitate the reaction between the two functional groups of interest. If successful, 
the BODIPY tag could be incorporated to the system at a later stage. 




3.4. Synthesis of a deferoxamine derivative targeted with the [7-13] 
bombesin fragment 
Considering the challenges involved at incorporating fluorophores onto the bombesin 
fragment, a parallel approach was adopted. Compound 18 was used to attach the synthesised 
peptide fragment in order to create a molecule consisting of a potential radiochelator labelled 
with the [7-13] bombesin fragment (compound 23) (Scheme 3.6). Radiolabelled bombesin-
based peptides exhibit great potential as targeting vectors for imaging and radionuclide therapy 
of tumours expressing the GRPr.31, 32 Maecke et al. reported a series of copper(II) radio-
chelators targeted with bombesin.33 
 
Scheme 3.6. Reaction between compounds 18 and 22 to yield compound 23. 
 
Several reaction conditions were investigated, and attempts to optimise these were made, as 
follows (Table 3.1). All the reactions were carried out at room temperature and using N,N’-
dimethylformamide as solvent. The best conditions were found to be an overnight room 
temperature reaction, under nitrogen atmosphere and using all the reagents in a 1:1 ratio; the 
bombesin fragment, compound 18, DIPEA and HBTU or 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (reactions 2 and 3, 
respectively). HBTU and HATU were used as activators of the carboxylic acid group, which 
was attacked by the N-terminal primary amino group of the [7-13] bombesin fragment to yield 
the new molecule as an orangish solid. The solvent of the reaction was removed under reduced 
pressure, and the crude reaction mixture was characterised by mass spectrometry using 
electrospray ionisation in positive mode (Figure 3.11). The peak at m/z = 1451.8096 
corresponds to the molecular ion, [M]+·, and a peak of lower m/z ratio, at 809.4528, corresponds 




to the free [7-13] bombesin fragment used as starting material, indicating that some unreacted  
compound still exists in the system, or fragmentation led to the appearance of this peak in 
mass spectrometry.  
Figure 3.11. Mass spectrum of compound 23 using ESI+, and isotopic pattern for [M]+·. 
 
Table 3.1. Reaction conditions used for the coupling between compounds 18 and 23. 
Entry 18 / eq 23 / eq Activating reagent / eq Base / eq Time / h Coupling 
1 1 1 EDC, NHS / 1, 1 - 24 No 
2 1 1 HBTU / 1 DIPEA / 1 16 Yes 
3 1 1 HATU / 1 DIPEA / 1 16 Yes 
 
Due to the broad diversity of peptides species available, there is not a general coupling reagent 
ideal for all the peptidyl bond formation reactions, and the most efficient coupling reagent for 
each type of reaction needs to be identified, which poses a challenge.34 In general, HBTU and 
HATU are considered superior to carbodiimide-based reagents (e. g. EDC). HBTU and HATU 
are phosphonium and aminium salts, and these are considered the new generation of coupling 
reagents, which have become very popular in the last few years thanks to the advantages that 
they present: faster and more efficient couplings achievable with less epimerisation.35 
Moreover, it has been reported that HATU, a variant form of HBTU, is very efficient in difficult 
sterically hindered couplings and it usually produces a minimal level of racemisation. This is 
usually the reagent of choice when rapid and mild coupling reactions are required.36 





Conditions using carbodiimide-based coupling reagents, specifically 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) were also applied, but the formation of the conjugate 
was not observed (Scheme 3.7). Carbodiimide reagents present some drawbacks, such as the 
rearrangement of the activated carboxylic acid into an unreactive urea derivative. For this 
reason, N-hydroxysuccinimide (NHS) was added as an additive with the aim of improving the 
efficiency of the reaction.37 Furthermore, due to carbodiimides being condensing reagents, 
side reactions of unprotected amino acids side chains have been reported (such as the 
conversion of amides to nitriles). This creates the need for appropriate side-chain protecting 
groups to prevent such side reactions when these reagents are used.38 
Scheme 3.7. Attempted reaction between compounds 18 and 22 to yield compound 23 using EDC 
and NHS. 
 
The mechanism of the coupling reaction using HATU or HBTU, respectively, consists in the 
activation of the carboxylic acid group using such activating reagents.39 The activated acid 
derivative, which is an ester, is then attacked by the amino function of the peptide. The reaction 
led to completion with the formation of the corresponding amide bond (Scheme 3.8). 
 
In conclusion, a compromise of speed, purity and by-products produced needs to be achieved 
in order to choose the ideal coupling reagent for an amide bond formation reaction. In this 
case, it was found that HBTU and HATU, which constitute a new generation of coupling 
reagents, were useful to carry out a successful coupling reaction to achieve the desired product 
effectively.  





Scheme 3.8. Coupling reaction and mechanism between a carboxylic acid (DFO derivative) and a 
peptide ([7-13] bombesin fragment) using HATU. 
  




3.5. Summary of Chapter 3 
The [7-13] bombesin fragment was successfully synthesised via a solid-phase peptide 
synthesis strategy, and characterised using HPLC and MS, and also 1H NMR spectroscopy 
was used to assign some of the proton resonances. A succinate linker derivative was attached 
to the peptide fragment via a carboxylic acid-amine coupling reaction, and the tert-butoxide 
group of the linker was later removed to provide a free N-terminal carboxylic acid group. This 
functional group was used to try to attach the peptide-linker fragment to the (already 
disubstituted) tripodal ligand precursor containing two BODIPY molecules (compound 6). The 
same reaction conditions that proved to be successful in Chapter 2 were used hereby, but at 
room temperature due to concerns regarding the stability of the peptide derivative. This 
reaction did not lead to the desired final product (consisting of the trisubstituted tripodal ligand) 
and the obtained mixture was explored by MS and NMR spectroscopy. Further studies need 
to be carried out in order to identify the correct reaction conditions to achieve the desired 
compound containing the bombesin fragment. Once this molecule was obtained, it would be 
interesting to perform cellular imaging investigations to observe the distribution of the 
compound in cells, given the importance of BODIPY derivatives in optical imaging applications.  
 
Additionally, the as-synthesised [7-13] bombesin fragment was coupled to compound 18, a 
deferoxamine derivative containing a carboxylic acid terminal group instead of an amino 
function. DFO is an important chelator recently used to bind radiometals (such as 68Ga and 
89Zr) for PET and SPECT molecular imaging applications. This reaction was carried out using 
both HATU and HBTU as activating reagents. The deferoxamine-bombesin fragment 
conjugate was successfully characterised by MS, thus supporting the hypothesis that the new 
product (compound 23) was isolated. This constitutes a promising scaffold for radiolabelling 
with the PET radioisotope zirconium-89, as it contains a DFO derivative, known to bind Zr(IV) 
in water, and it can potentially be used for PET imaging. Moreover, the incorporation of the [7-
13] bombesin fragment facilitates the targeting of the molecule to cancer cells containing the 
gastrin-releasing peptide receptor.  
 
Coordination reaction attempts to incorporate metal ions such as Ga(III) or Zr(IV) would prove 
the potential of this molecule to bind to radiometals, and further investigations into the 
radioimaging applications would be an important aspect of tracer development.  
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Chapter 4. Synthesis and structural studies of tripodal 
thiosemicarbazide systems 
4.1. Overview of Chapter 4 
Self-assembly is a potent tool to assemble molecules and nanocomposites into ordered 
macroscopic structures. New functional materials can be obtained by self-assembly, such as 
photonic crystals and ordered DNA structures.1 A variety of organic molecular building blocks 
for self-assembly in supramolecular chemistry are available (Figure 4.1).2 Their intermolecular 
structures go from simply linear to bent or star-like, and contain different functional groups. 
Among them, tripod-shaped units have been commonly used to construct supramolecular 
structures. Some advantages for the use of these tripodal molecules are that they allow the 
formation of open networks with pores, which can be used for selective adsorption and 
immobilisation of guest molecular species.3, 4 Intermolecular interactions (including hydrogen 
bonding, metal-ligand interactions or van der Waals interactions) between the different 
molecules or counter ions present in the structure can help to stabilise the porous networks.5, 
6 Such tripodal molecules usually consist of a flat core and peripheral arms including terminal 
functional groups of one type, and helping this way to create intermolecular interactions of the 
same strength and directionality.7, 8 
 
Figure 4.1. Schematic representation of the self-assembly of monomers to form oligomers and 
encapsulate guest species. Adapted from reference 9. 
 
Tripodal ligands are tridentate molecules, and they constitute a type of versatile scaffolds to 
build mono- and polynuclear coordination compounds. They have the ability to potentially 
chelate metal ions and form stable complexes.10 In many occasions, such tripodal organic 
compounds are built by coupling three binding strands with chelating moieties to an anchor 
unit X (e.g., a single atom or a polyatomic platform, in this case a substituted benzene ring) 
with three functional groups for coupling with binding strands. 




As it has already been described in Chapter 1, thiosemicarbazide derivatives and some of their 
transition metal ion complexes have several potential biological applications, including anti-
fungal, anti-viral, anti-bacterial and anti-tumour activities.11-13 Moreover, thiosemicarbazides 
are good scaffolds for self-assembly in supramolecular chemistry, due to the presence of 
multiple functional groups.14 
 
This Chapter describes the synthesis of four tripodal ligands based on a benzene core 
substituted with three thiosemicarbazide arms. The difference between the ligands lies in the 
terminal group of the thiosemicarbazide arms (methyl, ethyl, phenyl and allyl groups). These 
ligands can also potentially be used to encapsulate metals, forming a cage-type structure. 
Initially, it was proposed that the reaction for the formation of the ligands went through an N-
alkylation pathway on the terminal NH2 group of the thiosemicarbazides. However, thanks to 
obtaining crystal structures for three of these four ligands, it was possible to see that what 
actually occurred was an S-alkylation. The structure and self-assembling properties of the 
ligands were studied by NMR spectroscopy, using conventional 1H NMR and 2D NOESY, 
ROESY and DOSY NMR experiments. These types of compounds seem to self-assemble in 
solution at the concentrations used for the NMR experiments, as it can be seen from the 
obtained spectra, and has been previously reported for similar species.15-18 The toxicity of the 
compounds was tested using crystal violet assays in prostate cancer (PC-3), mice breast 
cancer (EMT6) and epithelial fibroblast (FEK-4) cell lines. 
 
Recently, there has been great interest in the investigation into the design and synthesis of 
molecules that are able to organise themselves into specific supramolecular arrangements that 
are stable in the solid state form. This is due to the fact that the incorporation of specific 
components into a crystal lattice can lead to the development of new materials with 
characteristic chemical and physical properties.19, 20 
  




4.2. Synthesis of tripodal thiosemicarbazide derivatives 
Ligands with a fully substituted benzene core containing three thiosemicarbazide arms were 
synthesised with the idea of using them as chelates for different metals. In order to achieve 
these compounds, the reagents 4-methyl-3-thiosemicarbazide, 4-ethyl-3-thiosemicarbazide, 
4-phenyl-3-thiosemicarbazide and 4-allyl-3-thiosemicarbazide were used as starting materials, 
accordingly, together with compound 1, which was described in Chapter 2 (Scheme 4.1). 
Scheme 4.1. Reaction to obtain compounds 26 (R = methyl), 27 (R = ethyl), 28 (R = phenyl) and 29   
(R = allyl), as tri-HBr salts. 
 
The starting materials were dissolved in acetonitrile in a 1:4 ratio for compound 1 and the 
corresponding thiosemicarbazide derivative, respectively, and the reaction mixture was heated 
under reflux for 48 hours. After this time, a solid could be isolated, characterised and used 
without further purification. Using four different thiosemicarbazide derivatives four compounds 
were obtained, which differed in the substituent of the trisubstituted arms (compounds 26, 27, 
28 and 29) (Figure 4.2). 





Figure 4.2. Compounds obtained from the reaction between compound 1 and four different 
thiosemicarbazide derivatives (Scheme 4.1). 
 
The four compounds shown above were successfully characterised by mass spectrometry. 
The spectra showed peaks for the expected molecular formulae, as it can be seen for 
compound 29; the spectrum obtained by positive mode nanoelectrospray ionisation shows a 
peak at m/z = 592.3010 that corresponds to the [M+H]+ ion, and a peak at m/z = 296.6546 that 
corresponds to the doubly protonated species, [M+2H]2+ (Figure 4.3). 





Figure 4.3. Mass spectrum of compound 29 using nESI+, and amplification of the isotopic patterns. 
 
Compounds 26, 27, 28 and 29 were also characterised by infrared spectroscopy in the solid 
state. The FT-IR spectrum of compound 26 shows bands that can be assigned to stretching 
vibrations within the compound (Figure 4.4 and Table 4.1). Accordingly, N-H stretching bands 
can be observed at 3161 cm-1, and C-H stretching bands at around 2965 cm-1. At 1650 cm-1 
there are bands corresponding to C=N stretchings. Finally, at lower frequencies of 
approximately 739 and 664 cm-1, there are bands that can be assigned to the stretching of C-
S and C-Br groups, respectively. This type of vibrations in the FT-IR spectrum are 
characteristic for the four ligands synthesised hereby. 





Figure 4.4. FT-IR spectrum of compound 26. 
 
Table 4.1. Band assignment for the FT-IR spectrum of compound 26 (Figure 4.4). 












4.2.1. Synthesis of ligands under acidic and basic conditions 
The efficiency of the previous synthesis under acidic and basic conditions was tested to see if 
the same product could still be obtained. Molecules that are pH-sensitive and change their 
structure and properties according to this parameter have been reported in the literature, and 
are known as molecular switches.21-23 For the purpose of investigating if the synthesised 
thiosemicarbazide ligands can act as such, two reactions were performed using the same 
conditions as previously described (compound 1 and 4-ethyl-3-thiosemicarbazide in a 1:4 ratio, 
respectively), using acetonitrile as solvent and heating the reaction mixture under reflux for 48 
hours. The initial pH of the mixture at room temperature was approximately 4. This is due to 
the slight acidity of the thiosemicarbazide derivatives.  
 
In the case of the reaction carried out under acidic conditions, three drops of concentrated HCl 
were added to the reaction flask, and the pH of the mixture descended to 2. From the solution, 




a white solid precipitated. After heating for 48 hours, the reaction mixture was yellow and 
contained a solid. The mixture was filtered and dried, and a light brown solid obtained. The 
filtrate was dried under reduced pressure and this yielded a purple oil. The two products were 
independently analysed by mass spectrometry, FT-IR and NMR spectroscopy. The 1H NMR 
spectrum of the solid that was obtained by filtration from the final mixture showed the 
resonances for the expected molecule (compound 27). The 1H NMR spectrum of the solid that 
was obtained by drying the filtrate did not match with this structure, and instead it showed 
resonances corresponding to a mixture of the ligand and the starting material (compound 1) 
(Figure 4.5). 
 
Figure 4.5. 1H NMR (500 MHz, CD3OD, 298 K) spectra of compound 27 (· 3 HBr), and of the filtered 
and dried solids from the reaction carried out using acidic conditions. 
 
In the case of the reaction carried out under basic conditions, triethylamine was added to the 
starting mixture (initial pH = 4) at room temperature to adjust the pH to a value around 8-9. In 
this case, the formation of a white solid was also observed upon the addition of the base. After 
heating for 48 hours, the aspect of the mixture was an orange solution with a solid, which was 




filtered and dried. A pink solid was isolated. The filtrate was dried under reduced pressure and 
yielded an orange solid. As for the previously described reaction, the two products were 
analysed by mass spectrometry, FT-IR and NMR spectroscopy. In this case, the 1H NMR 
spectra of the solid obtained by filtration or by drying the filtrate did not show the resonances 
assignable to the expected product. Instead, they both showed similar resonances that are 
very close to the ones for the starting material (compound 1) (Figure 4.6). 
 
Figure 4.6. 1H NMR (500 MHz, 298 K) spectra of compound 1 (CDCl3), and of the filtered and dried 
solids from the reaction carried out using basic conditions (CD3OD). 
 
These results suggest that under acidic conditions the ligand of interest is formed, however 
this does not occur under basic conditions. This may be explained by the preferred formation 
of the –SH form of the thiosemicarbazide under acidic conditions. This favours the reaction 
between the –SH group and the CH2Br arms of compound 1 to form the corresponding tripodal 
thiosemicarbazide compound. 
  




4.3. Characterisation of the ligands and NMR study 
Compounds 26, 27, 28 and 29, isolated as their 3 HBr salts, were characterised by NMR 
spectroscopy. The proton resonances of such molecules are complex, since the structure of 
the compounds is not symmetric due to the different orientations of the arms with respect to 
the plane of the benzene ring. The 1H NMR spectrum of compound 27 (recorded at 298 K) 
(Figure 4.7) shows a singlet at 4.55 ppm that integrates for 4 H and corresponds to the protons 
of the two methyl groups linked to the thiosemicarbazides, H3. Another singlet at 4.36 ppm 
corresponds to the remaining methyl group of this kind, H6. At around 3.47 ppm there is a peak 
with a multiplicity close to a quartet that integrates for 6 H and corresponds to the protons of 
the CH2 groups in the three thiosemicarbazide arms, H4. A multiplet at around 2.91 ppm 
integrating for 6 H corresponds to the protons of the CH2 groups in the three ethyl arms of the 
complex, H1. In the upfield region of the spectrum, there is a peak between 1.36 and 1.31 ppm 
that resembles a triplet and integrates for 9 H, which is due to H2, the protons in the three CH3 
groups of the ethyl arms of the molecule. Finally, a multiplet between 1.27 and 1.17 ppm 
corresponds to 9 H and is due to H5. It can be observed that the equivalent protons in the 
molecule appear as a multiplet instead of the multiplicity that would be expected. This is due 
to the chemical equivalence but magnetical inequivalence of these protons due to the different 
arms in the complex adopting different positions with respect to the plane of the benzene ring, 
which generates different surroundings for the protons. In summary, for compound 27 the 
equivalent protons of the three thiosemicarbazide arms appear at the same regions of the 
spectrum, except for H3 and H6, which are seen as two differentiated singlets. 
 
Figure 4.7. 1H NMR (300 MHz, CD3OD, 298 K) spectrum of compound 27 (· 3 HBr). 




The 1H NMR spectrum of compound 29 (recorded at 298 K) (Figure 4.8) shows a similar 
tendency to that observed in the spectrum of compound 27. However, the main difference lies 
in the fact that for compound 29 all the protons in the three thiosemicarbazide arms appear 
divided in two: as if two of the arms were equivalent among them, and a third one was 
inequivalent and for this reason appears separately. Accordingly, the CH allyl protons appear 
as two multiplets between 6.02 – 5.92 ppm and 5.92 – 5.81 ppm and these integrate for 1 H 
(H9) and 2 H (H5), respectively. Other two multiplets between 5.41 – 5.31 ppm and 5.31 – 5.21 
ppm that integrate for 2 H and 4 H, respectively, correspond to the CH2 allyl protons, H10 and 
H6. Two singlets at 4.54 ppm and 4.38 ppm correspond to H3 and H7, respectively, the CH2 
groups that connect the thiosemicarbazide arms to the benzene ring. Between 4.10 and 4.06 
ppm there is a multiplet with the shape of two peaks that correspond to 2 H and 4 H, 
respectively, and are due to H8 and H4. In the upfield region of the spectrum there are two sets 
of peaks due to the protons from the CH2CH3 arms of the molecule. The 6 protons named as 
H1 appear as a multiplet between 2.90 and 2.86 ppm, and the 9 protons named as H2 are seen 
as a multiplet between 1.33 and 1.30 ppm. 
 
Figure 4.8. 1H NMR (500 MHz, CD3OD, 298 K) spectrum of compound 29 (· 3 HBr). 
 
1H-1H nuclear Overhauser enhancement spectroscopy (NOESY) is an NMR experiment that 
can be useful to investigate the spatial relationships among proximal protons and study 




structural details of their interaction. In this context, NOESY cross peaks indicate proximity 
between protons. NOESY uses the dipolar interaction between protons that are closer in space 
than around 5 Å. Such dipolar interactions depend also on how quickly the molecule tumbles 
in solution and on the molecular mass: a molecule of low molecular mass tumbles fast in 
solution, and a molecule of high molecular mass tumbles slowly compared to the previous, and 
for this reason it will have positive NOESY cross peaks.24  
 
In this work, NOESY NMR was recorded using compounds 26, 27, 28 and 29 at 298 K. From 
the NOESY NMR spectrum of compound 26, it can be observed that there are six correlations 
among the protons of this molecule (Figure 4.9). Correlations between the protons of the ethyl 
arms of the compound, H1 and H2, with the methyl groups of the thiosemicarbazide arms, H3 
and H5, are observed. Also correlations between H1 and H2, and between H3 and H5. All these 
correlations are seen as positive peaks, which a priori would indicate that they are due to 
exchange. However, it is not possible to have exchange between these groups of protons 
(such as a CH2 and a CH3 of an ethyl group). Thus, it could be concluded that the molecule 
that is being studied has a higher molecular mass than expected, which would explain the 
existence of positive exchange peaks in the NOESY spectrum.25 This would imply that this 
type of compounds self-assemble to form aggregates in the methanol solutions of the 
concentration used for these NMR experiments. It was found that methanol improved the 
formation of hydrogen bonding in the molecule, and this favoured self-aggregation into a 
polymeric network. 





Figure 4.9. 1H-1H NOESY NMR (500 MHz, CD3OD, 298 K) spectrum of compound 26 (· 3 HBr). 
  
1H-1H rotating frame Overhauser enhancement spectroscopy (ROESY) is a 2D NMR technique 
useful to study possible intramolecular interactions within the different protons of a molecule. 
ROESY is seen as an alternative to NOESY in the study of molecules of intermediate or large 
size.26, 27 NOESY experiments work for molecules of very low and very high molecular weight. 
However, for molecules of molecular weight between approximately 1000 and 2000 Da, 
NOESY does not work. In the case of molecules with a molecular mass within this interval, a 
ROESY experiment can help to obtain NOE information. Consequently, for high molecular 
weight molecules, NOESY and ROESY experiments will produce similar results, but the cross 
peaks will be in phase with the diagonal for a NOESY spectrum, and in the opposite phase for 
a ROESY. 
 
The ROESY spectrum of compound 26 shows negative cross peaks that indicate spatial 
proximity between the protons in the ethyl arms of the molecule (H1 and H2) and the protons 




from the thiosemicarbazide arms (H3 and H5), and between H1-H3, H1-H5, H2-H3 and H2-H5, 
respectively (Figure 4.10). 
 
Figure 4.10. 1H-1H ROESY NMR (500 MHz, CD3OD, 298 K) spectrum of compound 26 (· 3 HBr). 
 
1H diffusion-ordered spectroscopy (DOSY) is an NMR method discovered by Morris and 
Johnson,28 that aims to identify the molecular components of a mixture sample and obtain 
information about their size. DOSY builds a two-dimensional spectrum: the first dimension (x 
axis) is a conventional 1H NMR spectrum of the sample, and the second dimension (y axis) 
constitutes the diffusion coefficients of the different components present in it. It is possible to 
measure diffusion coefficients of different components of a mixture using DOSY NMR. These 
coefficients are important because they are sensitive to molecular size and shape, and can 
provide information about the molecular weight and molecule aggregation status.29 
 
In this context, 1H DOSY NMR was carried out on the four ligands (compounds 26, 27, 28 and 
29). All the 2D spectra showed the presence of only one compound in the sample and a signal 
for water (with a resonance at approximately 4.87 ppm), as it can be seen for compound 26 
(Figure 4.11). 





Figure 4.11. 1H DOSY NMR (500 MHz, CD3OD, 298 K) spectrum of compound 26 (· 3 HBr). 
 
Moreover, the experimental diffusion coefficients (Dexp) for the four different compounds were 
calculated from the DOSY spectra in deuterated methanol using MestRenova (Table 4.2). The 
values for the Dexp of the four compounds tested were found to be between approximately  
3.4·10-10 m2/s and 4.8·10-10 m2/s. These values are smaller than those expected for the 
corresponding single molecules, which presumably consist of just a substituted tripodal core.30 
Consequently, it can be concluded that these molecules self-aggregate in solution at the 
concentration needed to obtain an NMR spectrum using methanol as solvent, forming a larger 
product.17, 31 Furthermore, the existence of hydrogen bonding making the molecules to self-
assemble is also a possibility due to the elevate number of functional groups able to achieve 
such interactions.32, 33 This matches with the information extracted from the NOESY 
experiments, which also suggested some degree of aggregation and the existence of bigger 
size structures in solution. 




Table 4.2. Diffusion coefficient values found for compounds 26, 27, 28 and 29, and for H2O, calculated 
from the 1H DOSY spectra using MestReNova.  











*The diffusion coefficient values were obtained in cm2·s-1 using MestRenova and converted to m2·s-1. 
 
By using 1H NMR spectroscopy on the ligands at room temperature (298 K), it was not possible 
to elucidate the resonances due to the protons in the different arms of the compounds with a 
well-defined multiplicity. For this purpose, NMR experiments at variable temperature were 
carried out, with the idea that at lower temperatures the molecule should decrease its motion 
and the different arms should stop rotating freely around the benzene ring plane. For 
compound 26, 1H NMR spectroscopy was performed at 213 K (-60 oC), 233 K (-40 oC), 253 K 
(-20 oC), 273 K (0 oC), 298 K (25 oC), 313 K (40 oC), and 323 K (50 oC) (Figure 4.12). It was 
observed that at lower temperatures the multiplicity of the resonances appear less defined, as 
it can be seen for the peak due to H2 at around 1.30 ppm. This resonance appears as a well-
defined triplet when the temperature is 40 oC or higher. Something similar occurs with the 
multiplet at around 2.85 ppm due to H1: it has the shape of a multiplet at lower temperatures, 
and becomes more well-defined as the temperature increases, although it is not a clear quartet. 
The protons from the terminal methyl groups in the thiosemicarbazide arms (H4 and H6) appear 
at low temperatures as two independent peaks with the shape of multiplets between 3.15 and 
2.95 ppm. When the temperature of the experiment reaches up to 50 oC, the two peaks initially 
separated merge in one multiplet. The resonances for H3 and H5 are two singlets at around 
4.50 and 4.25 ppm, and their shape and position do not change considerably. However, due 
to the peak corresponding to water (present in the deuterated solvent) shifting from around 
5.53 to 4.56 ppm as the temperature increases, when it reaches up to 50 oC the peak for H3 
cannot be observed as this is overlapped with the peak for water. This remarkable shift of the 
resonance due to H2O presence may well be due to the hydrogen bonding interactions present 
in this molecule that change with the temperature. 





Figure 4.12. Variable temperature 1H NMR (500 MHz, CD3OD) spectra of compound 26 (· 3 HBr) at 
213 K (-60 oC), 233 K (-40 oC), 253 K (-20 oC), 273 K (0 oC), 298 K (25 oC), 313 K (40 oC), and 323 K 
(50 oC). 




Variable temperature 1H NMR spectroscopy was also performed using compound 27, at 233 
K (-40 oC), 298 K (25 oC), and 313 K (40 oC) (Figure 4.13). In this case, the same tendency is 
observed: the resonance due to H2 becomes a triplet as the temperature increases. The 
resonance for H1 also shows a more defined multiplicity when the temperature increases. 
However, the peaks due to H4 and H5 do not change significantly, and H3 and H6 appear as 
two different singlets at all the temperatures used for the experiments. 
 
Figure 4.13. Variable temperature 1H NMR (500 MHz, CD3OD) spectra of compound 27 (· 3 HBr) at 
233 K (-40 oC), 298 K (25 oC), and 313 K (40 oC).  




4.4. Single crystal X-ray diffraction: structural characterisation 
It was initially thought that the reaction for the formation of the ligands with three 
thiosemicarbazide arms went through a mechanism in which the terminal amino group of the 
thiosemicarbazide acted as a nucleophile and removed the bromide atom from the arms of 
compound 1 (Scheme 4.2). In this case, the expected resulting compound would have been a 
trisubstituted tripodal core with each thiosemicarbazide derivative connected to the benzene 
core through the terminal N atom of the starting material molecule. This type of reactivity has 
been previously reported in the literature in many occasions.34 
Scheme 4.2. Predicted reaction of compound 1 with thiosemicarbazide derivatives. 
  
Therefore, it was not until a crystal suitable for single crystal X-ray diffraction was obtained and 
analysed that it was seen that this reaction actually occurs through the S atom of the 
thiosemicarbazide derivatives, and these are connected to the tripodal core by this atom. It is 
known that thiosemicarbazide derivatives present a tautomerism equilibrium between the keto 
and the enol forms of the molecule (thione/thiol equilibrium) (Scheme 4.3), and this finding 
reveals that, for the reaction treated in this chapter, the predominant reactive tautomer is that 
in the enol form. In some inorganic complexes, the enol form of thiosemicarbazides have been 
observed, rendering the thiosemicarbazide to act as a mono negatively charged ligand.35, 36 
The enol form is found in a number of metal complexes, though in these the SH group is often 
deprotonated. The S-alkylation of thiosemicarbazides was first reported by Yamazaki in 
1975,37 and it has been described on several occasions since then.38-40 
 
Scheme 4.3. Tautomerism equilibrium of a thiosemicarbazide. 
 




In the case of compounds 26, 27 and 29, crystals suitable for single crystal X-ray diffraction 
were obtained by using liquid-liquid diffusion techniques. Each solid was dissolved in the 
minimum amount of methanol, and diethyl ether was the solvent of choice to form a second 
layer over the methanol one. The appearance of crystals was observed some weeks after the 
crystallisation experiment was set up. The single crystal X-ray diffraction data were collected 
and solved by Dr. Gabriele Kociok-Köhn. 
 
The ORTEP representation of compound 29 shows a non-symmetrical structure, with the three 
ethyl arms pointing at the same direction, towards the upwards plane of the benzene ring 
(Figure 4.14). The three thiosemicarbazide arms are oriented in the same direction, 
downwards with respect to the benzene ring plane. The terminal allyl (NH-R) groups of the 
thiosemicarbazide arms are pointing upwards, the same direction as the ethyl arms of the 
molecule. Two of them are oriented on the left and the third one on the right. There are Br- 
atoms that crystallise with the structure of the compound, and a methanol molecule from the 
solvent used to obtain the crystals. 
 
Figure 4.14. ORTEP diagram of the molecular structure of compound 29 (· 3 HBr). 
 
The refinement of the crystal structure of the molecular formula for compound 29 showed that 
each unit cell contains two molecules of the product, each asymmetric unit with a molecular 
formula of C27H48N9S3. This implies that the molecule is triply protonated. Moreover, 6 Br- 
atoms can be found in each unit cell in total, which play the role of counter ions (4 Br- atoms 
can be seen in Figure 4.14 because some of them are only partially occupied). A molecule of 
methanol (the solvent used to obtain the crystals) also localises in the unit cell. Accordingly, 




the structure of compound 29 is a triply protonated molecule with three bromine atoms as 
counter ions and a delocalised double bond (it has been placed between two atoms in the 
representation for clarity) (Figure 4.15). 
 
Figure 4.15. Compound 29 as shown in the crystal structure data, triply protonated and with three 
bromine atoms as counter ions. 
 
The unit cell of compound 29, with the disordered atoms being omitted for clarity, shows two 
molecules of the ligand that have intercalated arms: one of the molecules has the three ethyl 
arms upwards and the three thiosemicarbazide arms downwards, and the other one has them 
in opposite directions, downwards and upwards, respectively (Figure 4.16). Six Br- atoms are 
disordered within the cell, distributing on the edges, faces, and inside the cell. Therefore, the 
two molecules of the same compound form a cage-like structure, and for this reason, these 
compounds have potential applicability as cages to encapsulate and bind ions and metals.41 
 
Figure 4.16. Molecular structure of compound 29 showing the two molecules found inside the unit cell. 
 




The crystal structure of compound 29 showed to exhibit some degree of self-assembly through 
hydrogen bonding, from the N-H atoms of the molecules with the existing Br- ions located in 
different places in the unit cell. The anion-assisted formation of discrete homodimeric and 
heterotetrameric assemblies by benzene-based protonated molecules has previously been 
described in the literature.42 This promotes the creation of a polymer-type structure, with 
different layers of tripodal molecules ordered in the space (Figure 4.17).43 The distance 
between two benzene rings located in two consecutive planes with the thiosemicarbazide arms 
pointing towards each other is about 8 Å, and the distance between two benzene rings in two 
consecutive planes with the ethyl arms pointing towards each other is about 5-6 Å. From this 
information, it cannot be considered that π-π stacking interactions exist among the 
molecules.44, 45 
 
Figure 4.17. Different units of the molecular structure for compound 29 showing hydrogen bonding with 
the Br- ions present in the crystal, and with the molecules being organised in different layers. 
 
The existence of a self-assembled supramolecular structure was first revealed by NOESY 
NMR experiments, and confirmed using 1H DOSY NMR when the calculated diffusion 
coefficients for these molecules were found to be smaller than expected for a single molecule 
of this size, suggesting that a bigger structure exists. This is also observed by single crystal X-
ray diffraction, demonstrating that the self-assembly of this type of molecules also occurs in 
the solid state.  
 
Two types of angles were measured in the molecule (Figure 4.18). On one side, the angle that 
form the ethyl arms with respect to the benzene ring, which is about 112° for the three of them. 
On the other side, the angle that the thiosemicarbazide arms form with respect to the benzene 
ring, calculated from the S atom to the C atom that forms the ring, has a value between 103 
and 106°. 





Figure 4.18. Molecular structure of compound 29 showing: (i) the angle formed between the plane 
benzene ring and the ethyl arms (112°), and (ii) the angle formed between the plane benzene ring and 
the thiosemicarbazide arms (103-106°). 
 
The molecular structure of compound 26 was also elucidated. The unit cell of this molecule 
also showed to contain two units of the compound, with intercalated arms and forming a cage-
like structure (Figure 4.19). Six Br- atoms could also be found distributed within the unit cell, 
but these and the disordered parts were omitted in the representation for clarity. It can be seen 
that two of the terminal methyl substituents of the thiosemicarbazide arms are oriented in the 
same direction (downwards), while the third one is oriented towards the opposite direction 
(upwards). This is consistent with observations from NMR spectroscopy, whereby the 
resonances observed in the 1H NMR spectrum of the molecule showed the three methyl groups 
as two independent singlets integrating for 6 H and 3 H, respectively.  





Figure 4.19. Molecular structure of compound 26 showing the two molecules that can be found inside 
the unit cell. 
 
The last molecular structure that was found by single crystal X-ray diffraction was that of 
compound 27 (Figure 4.20). As for the previous cases, the disordered Br- atoms found within 
the unit cell were omitted in the representation for clarity. In this structure, the three 
thiosemicarbazide arms of the two molecules located inside a unit cell point towards opposite 
directions, far from each other and with the ethyl arms of each compound that point towards 
each other, forming a cage-like structure. Regarding the terminal ethyl substituents in the three 
thiosemicarbazide arms, two of them are oriented in the same side of the plane, and the third 
one is oriented in the opposite side. This matches with the resonances observed in the 1H 
NMR spectrum of this compound, that indicate that some of the groups of the 














Figure 4.20. Molecular structure of compound 27 showing the two molecules found inside the unit cell. 
 
By using the molecular structures obtained, the bond distances in the thiosemicarbazide arms 
were measured and compared to those in one of the starting materials, 4-methyl-3-
thiosemicarbazide (CDCC No. 1205752) (Figure 4.21).46 It can be seen that the bond distances 
do not change significantly with respect to those in the starting material (Table 4.3). The most 
notable change is that the S1-C1 distance seems to increase slightly, so that this bond loses 
some character of double bond. Conversely, the C1-N2 distance decreases, so that this bond 
retains some character of double bond. This can be explained by the existence of a delocalised 
double bond between the S1-C1, C1-N2 and C1-N3 system (Scheme 4.4). Both nitrogen atoms 
(N2 and N3) are bound to a hydrogen atom. Regarding the bond between the 
thiosemicarbazide arms and the benzene ring, this is evidently single. 
 
Scheme 4.4. Equilibrium existing in any thiosemicarbazide derivative, where the double bond is 
delocalised within three bonds. 
 
 





Figure 4.21. Molecular structures of 4-methyl-3-thiosemicarbazide (A), and compound 27 (B), showing 
the labelled atoms used to calculate the bond distances.  
 
Table 4.3. Distances (Å) of selected bonds in 4-methyl-3-thiosemicarbazide (TSC) and compounds 26, 
27 and 29 (these last three as 3 HBr salts) * (Figure 4.21).  
Compound S1-C1 C1-N2 C1-N3 N3-C2 N1-N2 S1-Ph  
TSC 1.702(1) 1.346(2) 1.317(2) 1.445(2) 1.401(2) - 
26 1.751(3) 1.312(4) 1.313(4) 1.443(5) 1.406(4) 1.849(3) 
27 1.757(4) 1.313(5) 1.306(5) 1.460(5) 1.410(4) 1.858(4) 
29 1.742(3) 1.317(4) 1.321(4) 1.469(4) 1.419(4) 1.830(3) 
* To calculate the bond distances of the thiosemicarbazide arms in the synthesised compounds, one 
arm was taken as an example. 
 
  




4.5. Attempted complexation to metals 
Metal-based PET radiotracers have become a centre of attention in the past few years.47-49 
Zirconium, gallium and copper are elements with isotopes that can act as β+-emitters and can 
therefore be used in positron emission tomography, such as zirconium-89, gallium-68 and 
copper-64.50 The synthesis of new metal-based PET imaging agents requires a strong 
attention on the speciation of the metal ions in the presence of aqueous buffers and the 
environment. 
 
Thiosemicarbazide compounds usually react with metallic cations, resulting in complexes 
where the thiosemicarbazides behave as chelating agents.36 In this context, a broad number 
of reactions between the synthesised thiosemicarbazide derivatives (compounds 26, 27, 28 
and 29) and different metal salts were attempted (Table 4.4). 
 
It was envisaged that these ligands could encapsulate a metal centre, similar to the cage 
structures synthesised by Willans et al.,51 who created a rigid NHC cage ligand capable of 
binding metal ions, in particular Ag(I). The ligands used hereby were designed with possible 
anti-cancer functionality by incorporating thiosemicarbazide derivatives into their structure. 
Thiosemicarbazides have been reported to have enhanced anti-cancer properties when bound 
to a metal centre.52 
 
The seventeen reactions carried out have been divided in three groups for discussion, 
according to the metal salt that was used as starting material, and are explained in detail in 
Appendix B.2. However, it was interesting to see the colour changes of every reaction while 
this was taking place and also the colour of the one or more solids that could be isolated at the 






























ZrCl4 / 1 





THF 90 (reflux) 24 
2 27 / 1 - - EtOH 25 24 
3 27 / 1 - - EtOH 60 5 
4 
GaCl3 / 1 





THF 90 (reflux) 24 
5 26 / 1 - 
CH3COONa 
(buffer) 
MeOH 50 (reflux) 7 
6 26 / 1 - - MeOH 50 (reflux) 7 
7 27 / 1 - - EtOH 25 5 
8 
InCl3 / 1 
26 / 1 - 
CH3COONa 
(buffer) 
MeOH 50 (reflux) 7 
9 26 / 1 - - MeOH 50 (reflux) 7 
10 
Cu(OAc)2·
H2O / 1 





THF 90 (reflux) 24 









29 / 1 - - MeOH 50 (reflux) 7 
13 
Ni(OAc)2·4
H2O / 1 





THF 90 (reflux) 24 
14 27 / 1 
K2CO3 / 
3.5 
















29 / 1 - - MeOH 50 (reflux) 6 
 
 




Table 4.5. Colours observed during the reactions carried out between the tripodal thiosemicarbazide 
ligands and the different metal salts, and of the resulting solid(s). 
Entry Metal salt Colour of the reaction 
mixture (initial) 
Colour of the 
reaction mixture 
(end of reaction) 








2 Colourless transparent - Yellow-white 







5 Colourless transparent - White 
6 Yellowish transparent - White 
7 Colourless transparent - White 
8 
InCl3  
Colourless transparent - Pink-white 
9 Colourless transparent - White 
10 
Cu(OAc)2·H2O 
Light brown suspension - Green-brown 














- Light brown 




15 Zn(OAc)2 White suspension - White 
16 
Zn(OAc)2 
Yellowish transparent - 
Yellow 
Yellow 
17 Zn(OAc)2 White suspension - Yellow 
  
  




4.6. Towards the bioconjugation of the tripodal system 
In order to test the scope of reactions that allow the bioconjugation of the tripodal molecule, 
the synthesis of a trisubstituted tripodal molecule with three L-cysteine arms was explored. 
Amino acids are the basic building blocks that when combined can form proteins.53 L-cysteine 
(a common and cheap amino acid) was chosen because, among all the possible amino acids, 
it is of great interest due to the multifunctional groups present in the molecule (-SH, -NH2, -
COOH).54 These multiple functional groups can be used for the conjugation of metallic ions or 
other functional groups.55 Moreover, cysteine is a non-essential amino acid that the body can 
synthesise, and it is responsible for the stabilisation of the secondary structure of proteins.56 
 
This reaction was carried out using 4 equivalents of L-cysteine and 1 equivalent of compound 
1, applying the same conditions described for the thiosemicarbazide derivatives synthesis: 
acetonitrile as a solvent and stirring the contents for 48 hours under reflux (Scheme 4.5). A 
solid crashed out from the reaction (compound 30), and it was filtered and washed with 
acetonitrile. 
 
Scheme 4.5. Reaction between compound 1 and L-cysteine yielding compound 30 (· 3 HBr). 
 
L-cysteine molecules present an isomerism equilibrium between the neutral and the zwitterion 
forms (Scheme 4.6). In this molecule, the nitrogen atoms from the primary amine groups act 
as donors in hydrogen bonds in which the carboxylate oxygen atoms that belong to adjacent 
molecules act as acceptors.57 For this reason, strong hydrogen bonding can be expected in 
the obtained molecule, which contains three units of L-cysteine.   





Scheme 4.6. Isomerism equilibrium between the neutral and zwitterion forms of L-cysteine in 
compound 30. 
 
The solid isolated from the reaction was characterised by NMR spectroscopy. Problems were 
found due to the insolubility of the compound in all the solvents tested, even when adding 
some drops of acid (trifluoroacetic acid) or base (triethylamine). However, the solid was slightly 
soluble in methanol and 1H NMR spectroscopy was carried out (Figure 4.22). Some 
resonances could be identified and assigned to some of the protons of the molecule, such as 
the protons from the three CH2CH3 arms that, as for other derivatives, appeared as two 
multiplets between 3.00 – 2.78 ppm (H1) and 1.32 – 1.12 ppm (H2). Resonances assignable to 
protons from the cysteine arms were found as a triplet at 4.09 ppm (H5) and a doublet at 3.08 
ppm (H4). 
 
Figure 4.22. 1H NMR (500 MHz, CD3OD, 298 K) spectrum of compound 30 (· 3 HBr). 




The solid from this reaction was also analysed by FT-IR spectroscopy and compared to the 
starting material, L-cysteine (Figure 4.23). It was observed from the spectrum of compound 30 
that the characteristic band at around 2555 cm-1 corresponding to the S-H stretching in the 
cysteine molecule disappears when compared to the spectrum of L-cysteine. This suggests 
that the initial –SH group has reacted with the CH2Br arms and it no longer exists in the final 
product.58 Moreover, a band at around 3680 cm-1 that has a higher intensity in compound 30 
than in the starting material indicates the existence of hydrogen bonding within the molecules.  
 
Figure 4.23. FT-IR spectra of compound 30 (· 3 HBr) (orange) and L-cysteine (green). 
 
The mass spectrum of compound 30 when analysed using negative mode nanoelectrospray 
ionisation showed a peak at m/z = 560.1935, which corresponds to [M-H]- (Figure 4.24). This 
confirmed the formation of the desired molecule. This result constitutes a promising finding 
towards the functionalisation of biomolecules. Moreover, the resulting molecule is also a 
potential chelator for metal ions through the S, O and N atoms present in the molecular 
structure. 





Figure 4.24. Mass spectrum of compound 30 using nESI-, and amplification of the isotopic pattern. 
 
Moreover, to study if the toxicity of the thiosemicarbazide derivatives could be modified by 
replacing the Br- counter ions by PF6-, an anion exchange reaction was carried out. For this 
purpose, 3 equivalents of NH4+ PF6- and 1 equivalent of compound 26 were added to a flask 
and dissolved in methanol, then stirred for a few hours at room temperature (Scheme 4.7). 
Finally, the solvent was removed under reduced pressure and a white solid was obtained, that 
was tried to recrystallise by using several different techniques. This reaction was also 
attempted using dichloromethane as a solvent. 
 
Scheme 4.7. Attempted anion exchange reaction to replace the Br- ions by PF6- in compound 26. 
 
Crystals suitable for single crystal X-ray diffraction could not be obtained. Other techniques 
such as NMR spectroscopy and mass spectrometry were carried out but they did not confirm 
the success of this reaction.  




4.7. Crystal violet assays 
Crystal violet assays were carried out on compounds 26, 27, 28 and 29 (each considered as 
3 HBr salts) using three different cell lines (PC-3, EMT6 and FEK-4), and the cell viability was 
measured after 24, 48 and 72 hours incubation times. To perform this type of assays, a crystal 
violet solution was added to the cells in order to stain them (Figure 4.25). The mechanism of 
action is different than that for MTT assays, since in this case the compound is not being 
reduced. When using a crystal violet solution after incubation of the cells with the compounds 
of interest, the cells are stained. Since the cells that are alive remain at the bottom of the plate, 
the well plates are carefully rinsed with water to remove all the dead cells. Subsequently, the 
alive cells are fixed with methanol and their absorbance is read with a plate reader (with an 
absorption wavelength of 570 nm), considering that only the alive cells are present in the plate 
and they will all emit light due to the staining with crystal violet. From the absorbance measure, 
the IC50 can be plotted and calculated (Figure 4.26). These assays were performed by Dr. 
Haobo Ge in the Department of Pharmacy and Pharmacology at the University of Bath. 
 
Figure 4.25. Structure of an organic chloride salt that is the monochloride salt of the crystal violet 
solution used to stain the cells. 
 
In PC-3 cells, the least toxic molecule appears to be compound 26, with a surprisingly high 
IC50 value when compared to the other compounds. However, it is noticeable that after 48 
hours the compound is more toxic than after 72 hours. This was not expected, as it is thought 
that a compound becomes more toxic for cells after more hours have passed of its incubation. 
Compound 27 shows to be quite non-toxic in PC-3 cells as well, with IC50 values similar to the 
ones for compound 29. Compound 28 is the most toxic one for PC-3 cells out of the four. 
Regarding the results obtained when carrying out the assays in an EMT6 cell line, compound 
26 is still the least toxic one, although the same tendency where the molecule appears to be 
more toxic after 48 hours than after 72 hours is observed. The same anomaly happens with 
compound 28, with a toxicity relatively higher than the one of compound 26. Compounds 27, 
28 and 29 have IC50 values close to each other for the EMT6 cells type. The IC50 value for 
compound 27 decreases significantly from the 24 hours to the 48 hours measure, while the 
value for compound 29 decreases more gradually after each 24 hours interval. Finally, when 




looking at the data obtained for the FEK-4 cell line, compound 26 still appears to be not very 
toxic in the micromolar range, however, the toxicity increases significantly after the 72 hours 
incubation period. Compound 27 is also quite non-toxic for this cell type, with IC50 values similar 
to the ones for compound 26 after the 24 and 72 hours period, but an increase in the IC50 value 
is observed after 48 hours of incubation, implying that this molecule is less toxic after 48 hours 
than after 24 or 72 hours. Compounds 28 and 29 are, therefore, the most toxic compounds out 
of the four in FEK-4 cells. For compound 28 there is a dramatic decrease of the IC50 value from 
the 24 hours to the 48 hours period. For compound 29, the toxicity levels remain mostly 
unchanged during the three intervals of incubation periods, with the greater toxicity being after 
the 48 hours incubation time. In general, it can be concluded that compounds 28 and 29 are 
the most toxic out of the four in all the cell lines tested hereby (PC-3, EMT6 and FEK-4). The 
difference in the structure of these compounds lies in the terminal substituents of the 
thiosemicarbazide arms: a phenyl (compound 28) and an allyl group (compound 29). For the 
PC-3 and EMT6 cell lines, the toxicity levels of compounds 27, 28 and 29 are close when 
compared to compound 26. Furthermore, the overall toxicity of the four compounds is greater 
in EMT6 cells, followed by FEK-4 cells and finally they show less cytotoxicity when tested in 
PC-3 cells (Table 4.6).  
 
Table 4.6. Summary of compounds tested using crystal violet assays in PC-3, EMT6 and FEK-4 cells 
and IC50 value found for each of them after 24, 48 and 72 hours incubation periods. 





1620 ± 37 
98 ± 4 
310 ± 69 
115 ± 83 
84 ± 8 
273.9 ± 0.9 
3170 ± 15 
127 ± 38 





56 ± 4 
58 ± 7 
326 ± 65 
51 ± 2 
27 ± 2 
475 ± 38 
40 ± 2 
23 ± 3 





11 ± 4 
35 ± 3 
106 ± 21 
10 ± 6 
19 ± 3 
21 ± 7 
10 ± 1 
37 ± 2 





47 ± 2 
50.0 ± 0.9 
91 ± 7 
41 ± 5 
48 ± 5 
72 ± 6 
38 ± 2 
38 ± 3 
100 ± 21 
 
 





Figure 4.26. Crystal violet assays using (A) PC-3, (B) EMT6, and (C) FEK-4 cells incubated with 
compounds 26, 27, 28 and 29 (each as a 3 HBr salt) for 24, 48 and 72 hours.  
(The data were collected from six repeated measurements on the same day; N = 1).  




4.8. Summary of Chapter 4 
Four ligands based on a benzene ring trisubstituted with thiosemicarbazide derivatives were 
synthesised and characterised (compounds 26, 27, 28 and 29). Even though the initial thought 
was that an N-alkylation reaction was occurring on the thiosemicarbazide, after crystals 
suitable for single crystal X-ray diffraction were obtained for three of these ligands and their 
molecular structures elucidated, it was possible to see that what actually happened was an S-
alkylation of the complexes. The molecular structures of these compounds showed that a unit 
cell contains two triply protonated molecules and six Br- atoms that act as counter ions and are 
located at different places inside the cell, as well as a molecule of methanol (the solvent used 
to obtain the crystals). NOESY, ROESY and DOSY NMR experiments suggested the existence 
of a structure of higher molecular weight than a single molecule of the compound. Single crystal 
X-ray diffraction confirmed this by showing how several molecules in the solid state are 
interconnected by hydrogen bonding through the N-H and Br- atoms of the structure. In 
addition, 1H NMR spectroscopy did not show resonances with clear multiplicities, and for this 
reason variable temperature NMR experiments were performed to try to elucidate the expected 
multiplicity for each set of equivalent protons. It was seen that at higher temperatures the 
resonances showed better multiplicities, and this is likely due to the faster motion of the arms 
attached to the benzene ring when the temperature is higher, making the protons more 
equivalent between them due to having more similar environments. 
 
The complexation of this type of thiosemicarbazide ligands with metals was attempted. Many 
reactions were carried out using zirconium(IV), gallium(III), indium(III), copper(II), nickel(II) and 
zinc(II) salts, and several conditions were used. The colour change of the reaction and the final 
obtained solid were reported, and all the solids were characterised using a broad range of 
techniques. NMR spectroscopy did not show any conclusive results, as sometimes peaks 
could not be observed and other times peaks were observed as for the free ligands used as 
starting material. By mass spectrometry the isotopic pattern of the expected complex, or any 
other form of the final molecule containing a metal, could not be identified. IR and Raman 
spectroscopy showed bands corresponding to the ligand used for the synthesis in each case. 
Moreover, UV/visible spectroscopy was performed and the spectra revealed the existence of 
metal species in the complexes when compared to the free ligands. In many cases, highly 
complex polymeric species could have formed. 
 
A molecule with three L-cysteine arms was synthesised and characterised (compound 30) 
following the same reaction conditions that proved to work for the thiosemicarbazide ligands. 




This constitutes a promising finding towards the functionalisation of biomolecules with –SH 
functional groups. 
 
Crystal violet assays were performed using the ligands (compounds 26, 27, 28 and 29) in order 
to investigate their cell viability and cytotoxicity. It was seen that the ligand with the methyl 
substituent (compound 26) was the least toxic out of the four in all the cell lines tested (PC-3, 
EMT6 and FEK-4). Instead, the ligands with phenyl and allyl substituents (compounds 28 and 
29, respectively) showed to be the most toxic ones in all the tested cell lines. In general, 
however, all the compounds showed relatively high IC50 values in the micromolar scale, which 
suggests that they are largely non-toxic molecules under these conditions.  
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Chapter 5. Nanoparticles-based systems for optical imaging 
5.1. Overview of Chapter 5 
In the past few decades, silica materials with magnetic cores have attracted the attention of 
many different areas of research due to the broad range of potential applications that they can 
offer (Figure 5.1).1, 2 Iron oxide nanoparticles, in particular certain phases (e.g. γ-Fe2O3 
maghemite or Fe3O4 magnetite), are magnetic and can be used as contrast agents in magnetic 
resonance imaging. The use of silica as an outer layer improves their biocompatibility and 
stability in aqueous media.3 Among all the possible applications in life sciences, the attention 
of this chapter is focused on biomedical applications, both for therapy and diagnosis, thanks 
to the combined properties of all the agents involved in the nanocomposites. 
 
Figure 5.1. Most popular applications of silica nanomaterials with magnetic cores. Adapted from 
reference.4 
 
This Chapter describes efficient methods of synthesis of iron oxide nanoparticles and effective 
encapsulation inside silica particles. Such encapsulation is believed to provide a protective 
layer around the nanoparticles, reducing oxygen molecule penetration in both air and aqueous 
media and making the particles more kinetically stable.5 Furthermore, silica is resistant to 
swelling in organic or aqueous solvents, which means that the size of the silica particles 
remains unchanged in a wide range of solvents. Other advantages include the relatively easy 
functionalisation of the silica surface by a broad range of functional groups thanks to the readily 
available hydroxyl surface groups on the outer membrane of the silica, which provide intrinsic 




hydrophilicity and allow surface attachment of many biomolecules such as antibody fragments 
and peptides by covalent binding.5-8 
 
In this work, the iron oxide-silica core-shell nanoparticles were functionalised with two types of 
fluorophores. First, Cd0.1Zn0.9Se quantum dots (QDs) were synthesised and encapsulated by 
silica together with the iron oxide core. Additionally, the fluorescent molecule Zn(ATSM/A) 
[diacetyl-2-(4-N-methyl-3-thiosemicarbazonato)-3-(4-N-amino-3-thiosemicarbazonato) 
zinc(II)] (compound 35c) was synthesised and characterised and was attached to the surface 
of the silica nanoparticles.9 Iron oxide nanoparticles were also coated with citric acid to prove 
the posterior functionalisation of the carboxylic acid groups with a BODIPY derivative 
described in Section 2.3. The as-synthesised nanocomposites (Figure 5.2) were subsequently 
tested in cells for imaging applications using one-photon and two-photon confocal microscopy 
and fluorescence lifetime techniques, and their toxicity was evaluated using different assays. 
Radiolabelling experiments were carried out with 68Ga to test the potential applicability of such 
nanocomposites as synthetic scaffolds towards PET and SPECT imaging.  
 
The nanocomposites were characterised by a host of different techniques such as Fourier 
transform infrared spectroscopy, powder X-ray diffraction, X-ray energy dispersive analysis, 
transmission electron microscopy, dynamic light scattering, Raman spectroscopy, 
thermogravimetric analysis and BET surface area measurements, and these findings will be 
discussed below.  





Figure 5.2. Summary of the different nanoparticles-based systems synthesised and the modality of 
imaging that each of them offers. 
  




5.2. Synthesis and characterisation of iron oxide nanoparticles 
Iron oxide nanoparticles have a diameter between 1 and 100 nanometres. The two main forms 
are magnetite (Fe3O4) and its oxidised form maghemite (γ-Fe2O3). They have attracted 
extensive interest due to their potential applications in many fields. As stated in Section 5.1, 
Fe3O4 nanoparticles are known contrast agents currently of interest for magnetic resonance 
imaging (MRI), and they also have superparamagnetic properties.10-12 They are commonly 
used in a broad variety of therapeutic and diagnostic biomedical applications thanks to these 
properties, that enable tracking of theranostic nanomedicines by MRI. For in vivo applications, 
they can be administered intravenously into the body to detect and characterise lesions, 
tumours, and to visualise body tissues. When used for MRI in vivo, iron oxide nanoparticles 
cause a critical decrease in the relaxation rate of water protons due to their high magnetisation. 
This enhanced contrast allows MRI to differentiate between different organs in the body and 
also between several tissues. Furthermore, iron oxide nanoparticles benefit from high chemical 
stability, low toxicity and biocompatibility.10, 13 
 
Because of these attributes, iron oxide nanoparticles were chosen as the foundation for this 
multimodal system design and synthesis. They were therefore synthesised in the magnetite 
phase via a co-precipitation method.13 Among all the different methods of synthesis of iron 
oxide nanoparticles, this was chosen due to its simplicity and ease in controlling the particle 
size.14 Solutions of iron (II) and iron (III) chlorides were prepared using deoxygenated water 
and 2 M HCl(aq). They were mixed, and subsequently added dropwise with mechanical stirring 
to a basic solution of potassium hydroxide. The formation of the black nanoparticles occurred 
instantly, according to Equation 5.1. The nanoparticles were then collected by magnetic 
decantation and washed with water. 
Fe2+ + 2 Fe3+ + 8 OH-  Fe3O4 + 4 H2O 
Equation 5.1. Co-precipitation method of synthesis of magnetite Fe3O4 nanoparticles applied 
hereby. 
 
Transmission electron microscopy (TEM) was used to determine the size and morphology of 
the synthesised iron oxide nanoparticles core. In order to prepare the sample for analysis, a 
diluted solution of Fe3O4 in methanol was sonicated for 30 minutes. Then, a few drops of this 
solution were placed onto a copper grid and left to evaporate in air. The nanoparticles were 
shown to range between 5 and 10 nm in size with an almost spherical morphology. TEM 
observations reveal some degree of agglomeration (Figure 5.3). Nonetheless, the size and 
shape of this core was deemed promising for the next stage of the design strategy in core-
shell magnetic nanoparticles. 





Figure 5.3. TEM micrographs of Fe3O4 nanoparticles. Scale bar: (A) 50 nm, (B) 20 nm, (C) 50 nm, and 
(D) 100 nm. 
 
The elemental composition of the nanocomposites was analysed by energy dispersive X-ray 
spectroscopy (EDX), using EDX mapping assembled to the TEM instrument. As expected, 
both the EDX mapping (Figure 5.4) and the spectrum (Figure 5.5) showed that Fe and O were 
present in the sample, confirming the formation of iron oxide. In the EDX spectrum, peaks 
corresponding to Cu can be observed, which are due to the copper grid used as a support to 
analyse the sample.  





Figure 5.4. EDX mapping of Fe3O4 nanoparticles. TEM micrograph of the nanocomposite (left), colour 
code for each element (O: blue, Fe: red), and TEM micrograph with overlaid colours (right). 
 
 
Figure 5.5. EDX spectrum and elemental composition of Fe3O4 nanoparticles. 
   
  




5.3. Silica coating of iron oxide nanoparticles 
Silica is one of the most suitable and common coating layers for superparamagnetic iron oxide 
nanoparticles (SPIONs) due to its chemical stability, biocompatibility and versatility for surface 
modification. The addition of a silica shell also leaves silanol functional groups available on the 
surface of the nanoparticles for the immobilisation of biomolecules, and protects the iron oxide 
from degradation or aggregation, while reducing the toxicity of the core.15-18 
 
The previously synthesised magnetite Fe3O4 cores were coated with a silica shell via a 
microemulsion method of coating.19 A water-in-oil (W/O) or reverse microemulsion was used, 
in which a surfactant was dissolved in an organic solvent (oil) to create spherical aggregates 
that are known as reverse micelles, where the polar head groups point towards the inside of 
the core.20 In order to achieve this, the iron oxide nanoparticles were dispersed in oleic acid, 
added to a reaction vessel and dispersed in cyclohexane together with the surfactant 
polyoxyethylene(5)isooctylphenyl ether (IGEPAL CA-520), ammonium hydroxide and 
tetraethylorthosilicate, which was used as the silica precursor. The reaction mixture was 
mechanically stirred overnight, and after this time the Fe3O4@SiO2 core-shell nanoparticles 
were collected by magnetic decantation and washed with methanol.  
 
Achieving the desired transformation proved to be non-trivial, and many attempts of coating 
the nanoparticles ended unsuccessfully. In many cases, when the samples were analysed by 
TEM and the reaction was unsuccessful, it was noticed that the silica was present in the grid 
but it was not coating the nanoparticles (Figure 5.6). 
 
Figure 5.6. TEM micrographs of poorly coated Fe3O4@SiO2 nanoparticles. Scale bar: (A-B) 100 nm, 
and (C) 50 nm. 
 
 




After numerous attempts with varying reactant concentrations, the conditions that yielded the 
silica-coated nanoparticles with the desired morphology were found. 200 mg of Fe3O4 
nanoparticles dispersed in 5 mL of cyclohexane were added, followed by 22 g of surfactant, 
and the mixture was dispersed in 350 mL of cyclohexane. Subsequently, 3.85 mL of 
tetraethylorthosilicate and 4.72 mL of ammonium hydroxide solution were added, and the 
mixture was mechanically stirred for 16 hours at room temperature. TEM was used to observe 
the nanocomposites, and the micrographs showed that they have a spherical shape, with a 
core-shell structure consisting of a dark contrast metal core and a light contrast silica shell. 
Silica-coated Fe3O4 nanoparticles of approximately 50 nm of diameter were hence obtained 
(Figure 5.7). 
 
Figure 5.7. TEM micrographs of Fe3O4@SiO2 core-shell nanoparticles. Scale bar: (A) 20 nm, (B) 100 
nm, (C) 50 nm, and (D) 20 nm. 
 
These TEM images also reveal that the coated nanoparticles are much better dispersed and 
display a lower degree of agglomeration than the non-coated nanoparticles. This is due to the 
role of the silica coating agent which prevents the agglomeration of the nanoparticles.21  




EDX mapping was used to analyse the elemental composition of the nanocomposites (Figure 
5.8). It can be seen that Fe, O and Si are the predominant elements in the maps. The EDX 
spectrum shows, apart from these three elements, the presence of C and Cu, which are 
present in the TEM grid used to visualise the sample (Figure 5.9). 
 
Figure 5.8. EDX mapping of Fe3O4@SiO2 nanoparticles. TEM micrograph of the nanocomposite (left), 




Figure 5.9. EDX spectrum and elemental composition of Fe3O4@SiO2 nanoparticles. 
 
The crystal phase and structure of the as-prepared nanoparticles with and without a silica shell 
were determined by powder X-ray diffraction (XRD) (Figure 5.10). The red curve, for the naked 
Fe3O4 nanoparticles, can be indexed to the face-centered cubic structure of magnetite 
according to its ICDD file No. 019-0629.22 In this pattern, the peaks at 2θ = 30.2o, 35.5o, 43.2o, 
53.5o, 57.1o and 62.9o correspond to the (220), (311), (400), (422), (511), and (440) crystalline 
planes of magnetite phase, respectively. In the blue curve, corresponding to the 




nanocomposites after coating with silica, in addition to the diffraction peaks of Fe3O4 a new 
peak emerges at 2θ = 18.6o, most likely due to the holder used to analyse the sample. From 
this new pattern, it can be concluded that the obtained Fe3O4@SiO2 nanospheres still have a 
face-centered cubic (fcc) phase. In this context, the addition of a silica shell via the 
microemulsion method did not affect the phase structure of the magnetic core.  
 
From the X-ray spectra, it is noticeable that the synthesised nanoparticles do not show sharp 
and clear diffraction peaks corresponding to an extended crystalline structure. Instead, in both 
cases broad and poorly defined peaks appear in the spectra. This is typical for very small 
crystalline materials in which diffraction peaks cannot be well resolved.16  
 
Figure 5.10. Powder X-ray diffraction patterns of the prepared Fe3O4 (red) and Fe3O4@SiO2 (blue) 
nanoparticles. Black dots show diffractions of magnetite phase. 
 
    




5.4. Synthesis of Cd0.1Zn0.9Se quantum dots 
Quantum dots (QDs) have characteristic optical properties that make them excellent probes 
for bioimaging applications.23 Their narrow emission bands, continuous broad absorption band, 
high resistance to photo-bleaching, and higher extinction coefficients and quantum yields in 
comparison with organic dyes have attracted the attention of many researchers to use these 
nanocomposites as dyes for imaging applications.24-26 It is known that QDs containing 
cadmium are toxic, which is mainly due to the presence of free Cd2+ ions released when non-
coated QDs are exposed to an acidic microenvironment after cellular uptake.27 Moreover, 
recent studies have shown that the toxicity of nanoparticles can be exploited as a novel form 
of therapy to kill cancer cells, as shown by Pompa et al., who reported how ion-releasing 
nanoparticles can induce high levels of cytotoxicity due to the lysosome-enhanced Trojan 
horse effect.28 Recent investigations have demonstrated that the surface coating of QDs can 
substantially influence the toxicity of the particles.29, 30 In this context, Chu and collaborators 
demonstrated that the silica coating of CdSe quantum dots reduces the release of Cd2+ ions 
by up to 99.45%.31 Therefore, there is a need for encapsulation techniques using benign 
materials with retention of efficient emission in biological media, and silica is an attractive 
alternative since, as already mentioned, is biocompatible and can be easily functionalised.32 
  
Unlike the commercially available CdSe/ZnS quantum dots, in the Cd0.1Zn0.9Se system, the 
Zn(II) and Se(0) are not part of the protective shell of CdSe. Instead, they are effective 
elements of the quantum dot core, capable of emitting simultaneously in the blue and red 
regions of the spectrum. It was envisaged that these QDs could be incorporated into the iron 
oxide-silica conglomerate so as to form multimodal systems with fluorescent properties. 
 
In this context, Cd0.1Zn0.9Se quantum dots were synthesised according to a previously reported 
procedure,33 using stock solutions of Se and ZnEt2 prepared in a glovebox, cadmium stearate 
and organic reagents, that were mixed at 330 oC according to the already described synthesis. 
The quantum dots were finally precipitated using a mixture of methanol:acetone and isolated 
by centrifugation and decantation. They were further washed with the methanol:acetone  
mixture to remove the excess of organic ligands and isolate pure Cd0.1Zn0.9Se, which were 
then dispersed in n-hexane. 
 
The as-prepared Cd0.1Zn0.9Se quantum dots were characterised by powder X-ray diffraction 
(Figure 5.11). Peaks marked with black dots corresponding to (111), (200), (220) and (311) of 
the cubic structural phase can be observed at 2θ = 23.7, 25.8o, 42.2o and 50.1o, respectively.34 
When this spectrum is compared to those of pure CdSe and ZnSe, it can be observed that the 




values of the peaks are closer to those of ZnSe, as the concentration of this species is higher 
in the ternary system. 
 
Figure 5.11. Powder X-ray diffraction pattern of Cd0.1Zn0.9Se quantum dots. Black dots show peaks 









5.5. Silica coating of iron oxide nanoparticles and Cd0.1Zn0.9Se 
quantum dots 
In order to create a fluorescent nanocomposite, the same microemulsion reaction described in 
Section 5.3 was used (Scheme 5.1) to encapsulate simultaneously the Cd0.1Zn0.9Se quantum 
dots and the iron oxide nanoparticles within a silica layer.7, 32 
Scheme 5.1. Silica coating of Fe3O4 nanoparticles and Cd0.1Zn0.9Se quantum dots. 
 
IGEPAL CA-520 was used as the surfactant and dispersed in cyclohexane, together with the 
iron oxide nanoparticles and the quantum dots. Ammonium hydroxide was added and 
tetraethylorthosilicate was added next to act as the silica precursor. The reaction took place 
for 16 hours and, after this time, the nanocomposites were separated by centrifugation and 
washed with methanol.  
 
Infrared spectroscopy was used to visualise the stretching bands due to this nanocomposite 
and compare them to the free coated and non-coated nanoparticles, and the free Cd0.1Zn0.9Se 
quantum dots (Figure 5.12). Vibrational modes due to stretching bonds characteristics of every 
species could be identified (Table 5.1). 













Table 5.1. Band assignment for the FT-IR spectra of Fe3O4, Fe3O4@SiO2, Fe3O4/Cd0.1Zn0.9Se@SiO2 
and Cd0.1Zn0.9Se (Figure 5.12). 
Nanoparticles Wavenumber / cm-1 Vibrational mode 
Fe3O4 
3301 O-H st 
662 Fe-O st 
Fe3O4@SiO2 
3265 O-H st 
1043 Si-O-Si st 
932 Si-OH st 
658 Fe-O st 
Fe3O4/Cd0.1Zn0.9Se@SiO2 
3288 O-H st 
1010 Si-O-Si st 
949 Si-OH st 
696 Fe-O st 
 
The resulting Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles were analysed by TEM (Figure 5.13). 
These nanocomposites have spherical morphology and sizes of approximately 50 nm, and 
they are homogeneously dispersed, with a dark contrast core and a light contrast silica shell. 
These characteristics are maintained from the Fe3O4@SiO2 nanoparticles (Section 5.3). 
 
Figure 5.13. TEM micrographs of Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles. Scale bar: (A) 200 nm, (B) 
20 nm, (C) 100 nm, and (D) 50 nm. 




EDX mapping shows the elemental composition of these nanoparticles. Cd, Zn, Se, Fe, O and 
Si are present in the EDX images and spectrum, with the last three being the predominant 
species (Figure 5.14). The EDX spectrum and percentage content of each element confirm the 
successful incorporation of Fe3O4 and Cd0.1Zn0.9Se into silica shell nanoparticles (Figure 5.15). 
The atomic percentage of Fe and Se were found to be 5.98% and 1.01%, respectively, and by 
collecting a spectrum of the background it was possible to calculate that this corresponds to 
an approximately 2:1 ratio of Fe3O4:Cd0.1Zn0.9Se. 
 
Figure 5.14. EDX mapping of Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles. TEM micrograph of the 
nanocomposite (left), colour code for each element (Fe: yellow, O: pink, Si: blue, Se: green, Zn: orange, 
Cd: dark green), and TEM micrograph with overlaid colours (right). 
 
 
Figure 5.15. EDX spectrum and elemental composition of Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles.  




In order to determine the hydrodynamic diameter of the different nanoparticles prepared, 
dynamic light scattering (DLS) was used (Figure 5.16). Dispersions of 1 mg/mL of the 
corresponding nanocomposite in water were prepared and diluted as necessary to obtain the 
DLS spectra. The dispersions were first filtered with a filter of 0.45 μm in order to discard large 
particles of dust or large aggregations and obtain more reliable values.  
 
Figure 5.16. DLS spectra of Fe3O4, Fe3O4@SiO2, Cd0.1Zn0.9Se and Fe3O4/Cd0.1Zn0.9Se@SiO2 
nanoparticles, recorded using dispersions of the nanocomposites in water. 
 
This technique is based on the idea that particles in suspension undergo random thermal 
motion (Brownian motion). This is modelled by the Stokes-Einstein equation (Equation 5.2), 
which relates the measured diffusion coefficient to particle size. 




Equation 5.2. Stokes-Einstein equation. 
 
From this equation, Dh is the hydrodynamic diameter (particle size), Dt is the translational 
diffusion coefficient (determined by dynamic light scattering), kB is the Boltzmann’s constant, 
T is the thermodynamic temperature and η is the dynamic viscosity. 
 
As expected, the diameter values obtained by DLS are higher than those observed from the 
TEM micrographs of each sample.35, 36 This is due to the fact that in DLS the hydrodynamic 




diameter is measured, and this is defined as the size of a hypothetical hard sphere that diffuses 
in the same way as that of the particle being measured. However, in practice, particles in 
solution are not completely spherical, and they are dynamic and solvated, with solvent 
molecules surrounding them (hydration layer). Consequently, the calculated hydrodynamic 
diameter is only an indicative value of the apparent size of the dynamic hydrated/solvated 
particle.37 Considering this, diameters of 28 nm were obtained for Fe3O4, 43 nm for Cd0.1Zn0.9Se 
QDs, 122 nm for Fe3O4@SiO2 and 295 nm for Fe3O4/Cd0.1Zn0.9Se@SiO2, all of them higher 
than the ones observed by TEM (Table 5.2). This is due, as explained, to the solvation layer 
that surrounds the particles and the size of which is also included in the calculated diameter of 
these.  
 
Table 5.2. Diameter values of the different nanocomposites observed by TEM and by DLS. 
Nanoparticles TEM diameter / nm DLS diameter / nm 
Fe3O4 5-10 28 
Fe3O4@SiO2 50 122 
Cd0.1Zn0.9Se - 43 
Fe3O4/Cd0.1Zn0.9Se@SiO2 50 295 
  
The fluorescent properties of the Fe3O4/Cd0.1Zn0.9Se@SiO2 nanocomposite were studied by 
fluorescence spectroscopy (Figure 5.17). Both the freshly synthesised Cd0.1Zn0.9Se and the 
corresponding Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles showed fluorescence emissions 
assignable to these QDs. The fluorescence spectra of Cd0.1Zn0.9Se QDs and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 were recorded in 0.1 mg/mL hexane dispersions (λex = 350 nm and 
λex = 252 nm) and in 0.1 mg/mL methanol dispersions (λex = 252 nm), respectively. Free, non-
encapsulated quantum dots emit in wavelengths between 360 and 670 nm, with peaks of 
maximum emission at 395 and 607 nm, respectively. The fluorescence spectrum of 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles shows the characteristic peaks in the red (552 – 687 
nm) and blue (277 – 368 nm) regions of the spectrum, with maximum emission peaks at 593 
and 301 nm, respectively. Moreover, a new emission peak appears at 500 nm in this spectrum, 
which is due to the quantum dots in the nanocomposite containing QDs and iron oxide 
nanoparticles encapsulated by silica.   





Figure 5.17. Fluorescence spectra of Cd0.1Zn0.9Se (λex = 350 nm, red line; λex = 252 nm, blue line) and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (λex = 252 nm, black line). 
 
The relative fluorescence quantum yield (QY) for the Cd0.1Zn0.9Se QDs was calculated before 
and after encapsulation and was estimated with respect to anthracene in cyclohexane, which 
was used as a standard (Table 5.3).38, 39 The QY for the Fe3O4/Cd0.1Zn0.9Se@SiO2 
nanoparticles was also measured, and it can be observed that this is reduced by a factor of 
100 when the quantum dots are encapsulated within a silica shell. This is due to the fact that 
the Fe3O4 and the SiO2 shell present simultaneously act as passivating agents for the 
Cd0.1Zn0.9Se nanocrystals.40, 41 Despite showing a significantly reduced fluorescence quantum 
yield, the Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles were found to retain a luminescence 
emission profile which was traceable by confocal fluorescence microscopy. 
 
Table 5.3. Calculated fluorescence QY for the free and silica encapsulated QDs synthesised species at 
different excitation wavelengths. 




Fe3O4/Cd0.1Zn0.9Se@SiO2 252 0.0014 
 
  




5.6. Synthesis of the Zn(ATSM/A) molecular tag for hybrid magnetic 
nanoparticles 
Diacetyl-2-(4-N-methyl-3-thiosemicarbazonato)-3-(4-N-amino-3-thiosemicarbazonato) 
zinc(II), also known as Zn(ATSM/A), can be converted to a complex with potential selectivity 
for hypoxic tissue in vivo and in vitro when the zinc is replaced by a copper radioisotope.42-45 
 
Zn(ATSM/A) (compound 35c) was synthesised with the aim of using it to functionalise the silica 
shell of the nanoparticles. The synthesis took place via a three steps reaction previously 
reported by Holland et al. (Scheme 5.2).46 
Scheme 5.2. Synthesis of Zn(ATSM/A) (compound 35c). 
 
Step 1 consisted of the reaction between 4-methyl-3-thiosemicarbazide and 2,3-butanedione 
in deionised water with HCl as catalyst at 0 oC during 1 hour to give compound 35a. Step 2 
was carried out by adding thiocarbohydrazide and compound 35a to ethanol and stirring at 50 
oC for 5 hours under reflux with HCl as catalyst. A solid was obtained, which was filtered and 
washed to yield H2ATSM/A (compound 35b), as a pale yellow solid. Finally, to obtain 
compound 35c, H2ATSM/A and zinc(II) acetate dihydrate were added to a flask and dissolved 
in methanol, then heated and stirred under reflux for 4 hours. The mixture was filtered and the 
precipitate was washed with methanol and diethyl ether. Zn(ATSM/A) was isolated as a yellow 
solid at the end of this reaction. The overall yield of this multi-step reaction was 29%. 




Zn(ATSM/A) was analysed by 1H NMR spectroscopy in deuterated dimethylsulfoxide (Figure 
5.18). The two protons for the secondary amines can be found as two broad singlets at 8.24 
and 7.24 ppm for the one next to the primary amine and the one next to a methyl group, 
respectively. The protons of the terminal primary amine appear as a singlet corresponding to 
2 H at 4.76 ppm. The terminal methyl protons of the asymmetric arm appear as a singlet at 
2.83 ppm integrating for 3 H. Finally, the two methyl groups on the back-bone of the molecule 
appear as two close singlets between 2.22 and 2.20 ppm due to the almost symmetry plane 
of the molecule, which is only disturbed by having a terminal methyl group and a terminal 
primary amine, one in each arm of the molecule. 
 
Figure 5.18. 1H NMR (500 MHz, DMSO-d6, 298 K) of Zn(ATSM/A). 
 
The purity of this product was established by high-performance liquid chromatography (HPLC) 
with a solvent system of water and acetonitrile containing 0.1% of trifluoroacetic acid. When 
observing the absorbance at 280 nm, a unique peak can be seen at 8.8 minutes, and 
comparing it to the chromatograms of the starting materials it can be deduced that it 
corresponds to the compound of interest, proving that it does not contain any starting materials 
or other products as a mixture. However, peaks of very low intensity can be observed in the 
baseline between 2 and 12 minutes due to minor impurities, or to the possible protonation in 
the column due to the TFA present in the mobile phase.  
  




5.7. Incorporation of Zn(ATSM/A) into the Fe3O4@SiO2 core-shell 
nanoparticles 
Zn(ATSM/A) was synthesised with the aim of having a fluorophore and potential PET chelator 
to functionalise the silica shell of the nanoparticles (Scheme 5.3), and to demonstrate that the 
outer surface of the core-shell nanocomposites can be functionalised with a pendant amino 
group. It is unclear if what occurs is a condensation reaction to form Si-N bonds at the surface 
of the nanoparticles or, more likely, the Zn(ATSM/A) molecule is bound to the surface by 
hydrogen bonding between the hydroxyl groups of the silica and the terminal amino groups of 
the metal-ligand complex. 
Scheme 5.3. Reaction of functionalisation of the silica shell of Fe3O4 nanoparticles with Zn(ATSM/A).  
 
The reaction carried out to achieve this goal involved combining the Fe3O4@SiO2 nanoparticles 
and Zn(ATSM/A) in methanol. The reaction mixture was heated to 80 oC under reflux and 
mechanically stirred overnight. The mixture was left to cool to room temperature and the 
obtained nanocomposite was separated by centrifugation and washed with methanol. 
 
To confirm that the functionalisation of the silica shell with Zn(ATSM/A) had taken place, 
infrared spectroscopy analysis of the obtained nanocomposite and the starting materials was 
carried out in the solid state  (Figure 5.19). 





Figure 5.19. FT-IR spectra of Fe3O4@SiO2 (blue), Zn(ATSM/A) (grey) and Fe3O4@SiO2@Zn(ATSM/A) 
(purple).  
 
The band at approximately 1020 cm-1 in the Fe3O4@SiO2@Zn(ATSM/A) spectrum 
corresponds to the Si-O-Si stretching vibration. Bands between 1650 and 650 cm-1 can also 
be observed in the spectrum of the new nanocomposite, corresponding to expected vibrations 
emerging from the bonds within the Zn(ATSM/A) complex, and proving that the reaction took 
place (Table 5.4). 
 
  




Table 5.4. Band assignment for the FT-IR spectra of Fe3O4@SiO2 and Fe3O4@SiO2@Zn(ATSM/A) 
(Figure 5.19). 
Nanoparticles Wavenumber / cm-1 Vibrational mode 
Fe3O4@SiO2 
3265 O-H st 
1043 Si-O-Si st 
932 Si-OH st 
658 Fe-O st 
Fe3O4@SiO2@Zn(ATSM/A) 
3327  O-H st 
2947 C(sp3)-H st 
2826 C(sp2)-H st 
1020 Si-O-Si st 
 
Furthermore, TEM analysis and EDX mapping were carried out to study the morphology and 
composition of the new nanoparticles. TEM micrographs clearly show the addition of 
Zn(ATSM/A) onto the Fe3O4@SiO2 system, with some excess of the complex in the grid (Figure 
5.20). 
 
Figure 5.20. TEM micrographs of Fe3O4@SiO2@Zn(ATSM/A) nanoparticles. Scale bar: (A) 0.2 μm, 
(B) 100 nm, and (C) 0.2 μm. 
 
In this case, scanning transmission electron microscopy (STEM) was used in dark field mode 
and this allowed the three-dimensional distribution of these nanoparticles in the grid to be seen. 
This showed how some iron oxide-silica core-shell nanocomposites are packed and slightly 
aggregated, while the metal-ligand complex, Zn(ATSM/A), is freely distributed in the sample 
located around the almost spherical nanoparticles (Figure 5.21). 





Figure 5.21. STEM image of Fe3O4@SiO2@Zn(ATSM/A) nanoparticles using dark field mode. 
 
EDX mapping images (Figure 5.22) and spectrum (Figure 5.23) of Fe3O4@SiO2@Zn(ATSM/A) 
nanoparticles confirmed that the sample contains all the expected elements: Fe, Si, O, Zn, C, 
S and N (these last four pertaining to the Zn(ATSM/A) complex). 
 
Figure 5.22. EDX mapping of Fe3O4@SiO2@Zn(ATSM/A) nanoparticles. TEM micrograph of the 
nanocomposite (left), colour code for each element (Fe: orange, Si: green, O: light blue, Zn: yellow, N: 
blue, C: light green, S: pink), and TEM micrograph with overlaid colours (right). 
 





Figure 5.23. EDX spectrum and elemental composition of Fe3O4@SiO2@Zn(ATSM/A) nanoparticles. 
 
The hydrodynamic diameter was determined by DLS for the Fe3O4@SiO2@Zn(ATSM/A) 
nanoparticles as well, using a 0.01 mg/mL dispersion of the nanocomposite in water (Figure 
5.24). In this case, the molecule Zn(ATSM/A) is bound to the silica surface of the nanoparticles. 
For this reason, the obtained diameter size should include also the Zn(ATSM/A) that surrounds 
the nanoparticles, as this molecule is part of the system and moves with it. Consequently, an 
extended peak from 10 to 1000 nm can be observed. 
 
Figure 5.24. DLS spectrum of Fe3O4@SiO2@Zn(ATSM/A) nanoparticles, recorded using a 0.01 
mg/mL dispersion of the nanocomposite in water. 
 




Raman spectroscopy of the Fe3O4@SiO2@Zn(ATSM/A) nanoparticles and the starting 
materials, Fe3O4@SiO2 and Zn(ATSM/A), was carried out in the solid state using a laser of 
532 nm excitation wavelength in order to compare them to the new nanocomposite (Figure 
5.25). Vibrations due to Si-O-Si bonds can usually be observed between 450 and 550 cm-1. 
However, data was collected from 500 cm-1 and the Fe3O4@SiO2 spectrum did not show any 
peaks. Peaks were expected for the other two materials because they contain many bonds 
that are active to Raman spectroscopy. In this context, peaks between 2800 and 3100 cm-1 
can be assigned to vibrations of the C-H bonds, having sp3 and sp2 C atoms. The strong band 
at around 3200 cm-1 is due to the vibrations of the N-H functional group. Due to the small 
amount of sample that the specific Raman instrument analyses used, it was not possible to 
appreciate any sharp and well-defined peaks for any of the products and a baseline 
substraction needed to be carried out. Despite this, it is observable that the spectrum for 
Fe3O4@SiO2 is a flat straight line, while the spectra for Zn(ATSM/A) and 
Fe3O4@SiO2@Zn(ATSM/A) nanoparticles are not, showing some medium intensity peaks and 
presenting a similar aspect, which indicates that for the functionalised nanoparticles the 
Zn(ATSM/A) complex on the surface is being detected. 
 
Figure 5.25. Raman spectra showing Fe3O4@SiO2 (blue line), Zn(ATSM/A) (grey line), and 
Fe3O4@SiO2@Zn(ATSM/A) (purple line).  
  




5.8. Synthesis of citric acid-coated iron oxide nanoparticles and 
functionalisation with a BODIPY derivative 
Superparamagnetic iron oxide nanoparticles used in these experiments were synthesised and 
characterised as described in Section 5.2 and, in this case, citric acid was used to stabilise the 
magnetite particles. Citric acid was anchored onto the surface of freshly prepared 
nanoparticles by a direct addition method, with the carboxylic groups of this molecule making 
the nanoparticles more water-dispersible, and also providing sites for further functionalisation 
(Scheme 5.4).47 
 
Scheme 5.4. Coating of Fe3O4 nanoparticles with citric acid and subsequent addition of a mono-
functionalised BODIPY derivative (compound 5). 
 
Fe3O4 nanoparticles were dispersed in water and citric acid was dropwise added to the 
suspension until the pH was around 5 when measured with pH paper. The dark brown mixture 
was mechanically stirred for 3 hours at 85 oC, and after this time the resulting nanocomposite 
was isolated by centrifugation. 
 
In order to synthesise compound 38, the BODIPY derivative synthesised as described in 
Section 2.4 (compound 5) was used. A nucleophilic substitution reaction was carried out such 
that an ester bond was formed between the citric acid-coated nanoparticles and the tripodal 
core. Fe3O4 nanoparticles were added to a flask and dispersed in acetonitrile together with 
compound 5, then the temperature was set to 100 oC and the mixture was mechanically stirred 
overnight. After this time, the nanocomposite was collected by centrifugation and washed with 
methanol. 
 
Citric acid, citric acid-coated magnetic nanoparticles, and the coated nanoparticles 
incorporating the fluorophore were analysed by FT-IR (Figure 5.26). 





Figure 5.26. FT-IR spectra of citric acid (orange line), citric acid-coated Fe3O4 nanoparticles (blue line), 
and citric acid-coated nanoparticles functionalised with a BODIPY derivative (green line). 
 
The FT-IR spectrum for citric acid shows clear bands, but the one for the citric acid-coated 
Fe3O4 nanoparticles shows only a few broad bands. Bands assignable to the stretching 
vibrations of the carbonyl group and C-Br stretching bands confirm the formation of the 
expected product (Table 5.5). 
 
  




Table 5.5. Band assignment for the FT-IR spectra of citric acid, citric acid-coated Fe3O4 nanoparticles 
and citric acid-coated Fe3O4 nanoparticles containing a BODIPY derivative (Figure 5.26). 
Compound Wavenumber / cm-1 Vibrational mode 
Citric acid 
3281 O-H st 
1687 C=O st 
Citric acid-coated Fe3O4 
3296  O-H st 
1584 C=O st 
662 Fe-O st 
Citric acid-coated Fe3O4 
with a BODIPY derivative 





802 C-Br st 
683 Fe-O st 
 
DLS was used to measure the hydrodynamic diameter of the citric acid-coated Fe3O4 
nanoparticles (Figure 5.27). For this purpose, a 0.01 mg/mL dispersion of the nanocomposite 
in water was used. As for the Fe3O4@SiO2@Zn(ATSM/A) nanoparticles (Section 5.7), the citric 
acid molecules surrounding the nanoparticles are part of the same sphere, and for this reason 
the obtained value ranges from 10 to 1000 nm. 
 
Figure 5.27. DLS spectrum of citric acid-coated iron oxide nanoparticles, recorded using a 0.01 mg/mL 
dispersion of the nanocomposite in water. 
 




The porosity of this composite was checked by performing a detailed BET surface area 
analysis on magnetite Fe3O4 nanoparticles and citric acid-coated Fe3O4 nanoparticles. The 
specific surface area of these nanoparticles in the air-free powder state was measured by 
nitrogen physical adsorption, and calculated according to the Brunauer-Emmett-Teller (BET) 
equation. Prior to the measurements, the samples were degassed in vacuum at 90 oC for 4 
hours. Adsorption isotherms were obtained which were converted to BET surface plots to 
calculate the surface area (Table 5.6). It is clear from the surface area values that the 
magnetite nanoparticles alone have a low surface area (116.47 m2/g), whereas the surface 
area almost doubles after the coating with citric acid (206.58 m2/g). This indicates the role of 
this compound in increasing the surface area, and indicates that the coated nanocomposite is 
more porous.48 
 
Table 5.6. BET surface area and pore size obtained from BET measurements of citric acid-coated and 
uncoated Fe3O4 nanoparticles. 
Nanoparticles 









Fe3O4  116.47 8.54 nm 7.87 nm 
Citric acid-coated Fe3O4 206.58 5.09 nm 4.31 nm 
 
The isotherm linear absolute plot and the isotherm pressure composition curves show that the 
citric acid-coated nanoparticles have the ability to adsorb (and later desorb) a higher amount 
of nitrogen gas than the free nanoparticles (Figure 5.28). This could be due to the fact that the 
coated nanoparticles have a higher surface area.2 
 





Figure 5.28. Adsorption and desorption curves for citric acid-coated nanoparticles (CA-NPs) and Fe3O4 
nanoparticles (NPs). 
 
The BET surface area plot and the BJH adsorption and desorption cumulative pore volume 
curves show that the free nanoparticles have larger volume pores (Figure 5.29). 





Figure 5.29. (A) BET surface area plot, (B) BJH adsorption cumulative pore volume curve, and (C) 
BJH desorption cumulative pore volume curve for citric acid-coated nanoparticles (CA-NPs) and Fe3O4 
nanoparticles (NPs). 
 
Thermogravimetric analysis (TGA) was used on all the previously described nanocomposites 
to determine the changes in their chemical and physical properties that they experience when 
the temperature is increased. In order to carry out these experiments, each sample was loaded 
into an alumina crucible and the temperature program was applied, consisting of a heating 
ramp at a rate of 10 K/min from 30 to 800 oC. A cooling ramp started next, from 800 oC and 
back to 30 oC at a cooling rate of 20 K/min. Finally, the temperature was maintained at 30 oC 
before ending the program. Phenomena such as vaporisation, sublimation, 
desorption/adsorption, desolvation and decomposition can usually be identified from TGA 
curves.49 The TGA spectrum for Fe3O4 nanoparticles (red line) shows almost no loss of weight 
(less than 5%), indicating that this nanocomposite is stable up to 800 oC (Figure 5.30). For 
Fe3O4@SiO2 (blue line) and the citric acid-coated Fe3O4 nanoparticles (orange line) there is a 
weight loss of approximately 10%. This can be explained by the decomposition of the coating 
molecules in these two types of materials: the silica in one case, and the citric acid in the other 
case. For the Fe3O4@SiO2@Zn(ATSM/A) (purple line) and Fe3O4/Cd0.1Zn0.9Se@SiO2 
nanoparticles (yellow line) there is a significant decrease in the weight starting at approximately 
200 oC and going on until 500 oC in both cases, to lose around 30% and 50% of their initial 
weight, respectively. As expected, loss of solvents cannot be observed for any of the tested 




nanocomposites as these were previously dried, proving that there is no solvent adsorbed into 
the sample.  
 
Figure 5.30 Thermogravimetric analysis spectra of Fe3O4 (red line), Fe3O4@SiO2 (blue line), 
Fe3O4/Cd0.1Zn0.9Se@SiO2 (yellow line), Fe3O4@SiO2@Zn(ATSM/A) (purple line), and citric acid-coated 








5.9. Radiolabelling experiments with gallium-68 
5.9.1. Generator production of gallium-68 
In these experiments, the positron-emitting radiotracer [68Ga]GaCl3 was prepared at the 
Department of Surgery and Cancer of the Imperial College London using either a TiO2 or a 
SnO2-based column matrix 68Ge/68Ga generator via the (p,2n) reaction on gallium targets.  
 
5.9.2. Radio-incorporation: method development 
These radiolabelling experiments were carried out in order to confirm a general method 
established below (Scheme 5.5) for the incorporation of radioactive gallium into the silica shell 
of iron oxide nanoparticles. Taking into account the half-life of the 68Ga radionuclide (67.7 min), 
the labelling incorporation was estimated for all the samples using either radio-TLC or 
measuring the final activity of the nanocomposite, and it is denoted here as “encapsulation 
factor“. The reaction times and the buffer solution used were adjusted accordingly to the 
properties of this radioisotope.50 





Scheme 5.5. Methods developed for the incorporation of 68Ga into the nanoparticles-based systems 
previously described. 
 
(a) Method 1: adsorption of 68Ga within the silica matrix in Fe3O4@SiO2 and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 
Method 1 concerns the (non-covalent) adsorption of the radioisotope 68Ga onto the surface of 
the silica network of Fe3O4@SiO2 and Fe3O4/Cd0.1Zn0.9Se@SiO2, following a chelator-free 
radiolabelling strategy. The general procedure used was the same for the two species: 68Ga 
from a stock solution was added to a vial with ethanol, followed by the corresponding 
nanoparticles species and a sodium acetate buffer solution in order to adjust the pH to 
approximately 5, the optimum for this radioisotope. The reaction was carried out for 40 minutes 
at 90 oC, using a vortex stirrer to mix the contents every few minutes. The radiolabelled 
nanocomposites were isolated by centrifugation and washed with methanol and water. In order 
to establish the labelling incorporation factor, radio-TLC was performed and compared to the 




radio-TLC of the free 68Ga ions (Figure 5.31). For both the Fe3O4@SiO2 and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles, this factor was found to be ≥ 99.9%. This can be 
explained by the absence of a peak for the free 68Ga ions in the radio-TLC chromatogram, 
which would appear around 63 mm in the x axis, and the presence of a sharp peak for the 
radiolabelled nanocomposite near 10 mm (Figure 5.32). 
 
Figure 5.31. Radio-TLC chromatogram of aqueous 68Ga ions used as starting material. TLC was 
eluted using 0.25 M ethylenediaminetetraacetic acid (EDTA) as the mobile phase. 
 
 
Figure 5.32. Radio-TLC chromatogram of (A) Fe3O4@SiO2, and (B) Fe3O4/Cd0.1Zn0.9Se@SiO2 with 
68Ga suggesting a RCY ≥ 99.9%. TLC was eluted using 0.25 M ethylenediaminetetraacetic acid 
(EDTA) as the mobile phase. 
 
(b) Method 2: encapsulation of 68Ga ions within a second silica shell in 
Fe3O4@SiO2 and Fe3O4/Cd0.1Zn0.9Se@SiO2 
Method 2 involved the addition of a second silica shell in the Fe3O4@SiO2 and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles used to encapsulate the 68Ga radioisotope. The 
general procedure used was the same for the two species: IGEPAL CA-520 (the surfactant) 
was dispersed in cyclohexane in a vial, followed by the corresponding nanoparticles species, 
and the mixture was agitated with the help of a vortex stirrer. Next, an ammonium hydroxide 




solution was added to form a reverse microemulsion, followed by tetraethylorthosilicate, the 
silica precursor which forms the second silica shell. Finally, 68Ga was added from a stock 
solution together with a sodium acetate buffer and the reaction was carried out for 68 minutes 
at 90 oC, to produce the formation of a silica shell that would encapsulate the radioisotope. 
The radiolabelled nanocomposites were isolated by centrifugation and washed with methanol 
and water, then separated by magnetic decantation. To estimate the radiolabelling factor in 
the final product of these reactions, radio-TLC was not available in the facilities, so the 
calculation was carried out manually by isolating each nanocomposite and measuring the final 
activity. The radio-incorporation factor (also denoted “encapsulation factor”) was then 
calculated considering the initial and final activities of 68Ga in each case, and it was found to 
be 70% and 66% for Fe3O4@SiO2 and Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles, respectively. 
 
These lower radio-incorporation factors may be explained by the short time of the reaction. 
The coating reaction of the free nanoparticles takes place in 16 hours, so it would be expected 
that the formation of a second silica shell would need a similar amount of time to take place. 
However, due to the short half-life of the radioisotope 68Ga, the maximum time that can be 
used to carry out this reaction is 68 minutes. Due to this limitation, it is possible that the second 
silica shell was not successfully formed around the Fe3O4@SiO2 and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles to encapsulate the radioisotope, as desired. For this 
reason, free amounts of silica can be interacting with different amounts of 68Ga and this might 
reduce the radio-incorporation factor once the final nanocomposite was separated by 
centrifugation and decantation. Both the reaction with the Fe3O4@SiO2 and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles have a similar radiolabelling factor, as would be 
expected due to their similar sizes of approximately 50 nm, even though the core is constituted 
by iron oxide in one case and iron oxide and quantum dots in the other case. 
 
(c) Method 3: reaction between 68Ga and Fe3O4@SiO2@Zn(ATSM/A) 
Method 3 concerns the reaction between the radioisotope 68Ga and the 
Fe3O4@SiO2@Zn(ATSM/A) nanoparticles, which contain the metal-ligand complex 
Zn(ATSM/A) bond onto the silica surface. In this case, the Fe3O4@SiO2@Zn(ATSM/A) 
nanoparticles dispersed in dimethylsulfoxide were added to a vial along with a solution 
containing 68Ga, ethanol and a sodium acetate buffer to adjust the pH to 5. The mixture was 
heated at 90 oC for 40 minutes and, after this time, the nanocomposite was collected by 
centrifugation and washed with water and methanol. The labelling incorporation factor was 
determined by radio-TLC (Figure 5.33), and it was found to be ≥ 99.9% as for Method 1. 





Figure 5.33. Radio-TLC chromatogram of Fe3O4@SiO2@Zn(ATSM/A) with 68Ga suggesting a RCY ≥ 
99.9%. TLC was eluted using 0.25 M ethylenediaminetetraacetic acid (EDTA) as the mobile phase. 
 
The mechanism of this reaction is not well understood. It has been reported that the complex 
Zn(ATSM/A) cannot be radiolabelled with 68Ga via a transmetallation reaction when it is free 
in solution.42 In order to confirm this, a reaction between Zn(ATSM/A) and 68Ga was carried 
out, mixing these two products under the same conditions as described for the nanocomposite 
containing Zn(ATSM/A) (Method 3). The final product was analysed by radio-HPLC (Figure 
5.34). In the chromatogram, the only peak that can be seen is at approximately 2 minutes, 
corresponding to the free 68Ga ions, and thus confirming that Zn(ATSM/A) does not contain 
any amount of this radioisotope and it was not radiolabelled. 
 
Figure 5.34. Radio-HPLC chromatogram of the aqueous solution obtained from the reaction between 
[68Ga]GaCl3 and Zn(ATSM/A). From this trace no radiolabelled product could be identified except from 
the free hydrated 68Ga ions present at Rt = 2 minutes.  
 




It could be thought that the transmetallation reaction takes place thanks to the Fe3O4@SiO2 
support to which the Zn(ATSM/A) complex is linked. But seeing as the reactions involving the 
adsorption of the radioisotope within the silica matrix of Fe3O4@SiO2 and 
Fe3O4/Cd0.1Zn0.9Se@SiO2 also yield a labelling incorporation of ≥ 99.9%, it cannot be 
concluded whether Zn(ATSM/A) plays a role in this reaction, and more studies are needed in 
order to confirm this. However, as it has been already mentioned, this molecule is fluorescent 
and is also a potential hypoxia tracer when transmetallated with copper(II), properties that add 
advantages to the incorporation of this compound into the nanoparticles systems.  
  
(d) Summary of methods and results obtained in this section 
The methods used were designed with a general approach in mind, and they could be easily 
adapted to other radioisotopes taking into consideration the half-life and optimum pH of the 
nucleus used. So, if a radioisotope with a longer half-life was used, e.g., 64Cu (t1/2 = 12.7 hours), 
a similar radio-incorporation factor would be expected for Method 1, while if carrying out 
Method 2, this factor would be expected to be higher due to the longer half-life of the nucleus 
and the possibility of leaving the different components to react for a longer time. It is unclear if 
the radio-incorporation factor obtained in Method 3 would be affected as this would depend on 
whether it is the ATSM/A complex that is radiolabelled or whether adsorption onto the silica 
surface of the nanoparticles takes place. For other radioisotopes, considerations of changes 
in size and chemical properties would need to be taken into account in order to optimise the 
methods described in this section.50  
 
Regarding the results obtained from each method, Methods 1 and 3 gave a radio-incorporation 
factor ≥ 99.9%, while in Method 2 it was reduced to 66-70% (Table 5.7). 
 
Table 5.7. Summary of methods and nanoparticles systems used and their corresponding radio-
incorporation factors (also denoted “encapsulation factors”). 
Method Nanoparticles Radio-incorporation factor / % 
1 
Fe3O4@SiO2 ≥ 99.9 





Fe3O4@SiO2@Zn(ATSM/A) ≥ 99.9 
Zn(ATSM/A) 0 
  




5.10. Epi-fluorescence and confocal fluorescence tests of the 
nanocomposites on a thin film 
Single-photon laser scanning confocal microscopy imaging was carried out on thin films drying 
out on a glass bottom dish of Cd0.1Zn0.9Se, Fe3O4/Cd0.1Zn0.9Se@SiO2 and 
Fe3O4@SiO2@Zn(ATSM/A) obtained from dispersions in methanol. The fluorescence 
response of the QDs and nanocomposite materials was tested using 405, 488 and 561 nm 
lasers and the images for the individual channel emissions and the emission overlay of the 
blue-green-red and DIC channels were recorded. 
 
In the case of Cd0.1Zn0.9Se quantum dots (Figure 5.35), it can be seen that the emission lies 
mainly in the red channel at all the excitation wavelengths, with some emission observed in 
the green channel as well after 405 and 488 nm laser excitation. 
 
Figure 5.35. Single-photon laser scanning confocal microscopy of a Cd0.1Zn0.9Se thin film of a methanol 
suspension. a-e) λex = 405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) DIC channel; b, g, l) blue 
channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel (λem = 570-
750 nm); e, j, o) overlay of all the channels. Scale bar: 50 μm. 
 
For the Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles, the emission properties are the same as for 
the free Cd0.1Zn0.9Se quantum dots (Figure 5.36).  





Figure 5.36. Single-photon laser scanning confocal microscopy of a Fe3O4/Cd0.1Zn0.9Se@SiO2 thin film 
of a methanol suspension. a-e) λex = 405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) DIC channel; b, 
g, l) blue channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel 
(λem = 570-750 nm); e, j, o) overlay of all the channels. Scale bar: 50 μm. 
 
Fe3O4@SiO2@Zn(ATSM/A) nanoparticles emit in all the channels (blue, green and red) after 
excitation with a laser of 405 nm wavelength (Figure 5.37). When they are excited with lasers 
of 488 and 561 nm, the emission at the blue channel disappears, but they still show fluorescent 
properties in the green and red channels of the spectra. It can be noticed in the image that 
shows the overlay of all the channels that emission at 405 nm excitation wavelength does not 
colocalise (Figure 5.37(e)). This is probably due to the non-homogeneous distribution of the 
material in the thin film, caused by the drying method of the suspension used. 





Figure 5.37. Single-photon laser scanning confocal microscopy of a Fe3O4@SiO2@Zn(ATSM/A) thin 
film of a methanol suspension. a-e) λex = 405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) DIC 
channel; b, g, l) blue channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red 
channel (λem = 570-750 nm); e, j, o) overlay of the all the channels. Scale bar: 10 μm. 
 
  




5.11. In vitro epi-fluorescence and confocal fluorescence 
investigations of the nanocomposites  
In order to establish the potential of the nanocomposites as cancer imaging agents, PC-3 cells 
were incubated with a DMSO : serum-free medium (1:99) suspension of 10 µg/mL 
Fe3O4/Cd0.1Zn0.9Se@SiO2 to carry out epi-fluorescence microscopy experiments (Figure 
5.38(a-e)). Prostate cancer (PC-3) cells were grown according to standard serial passage 
protocols, placed onto glass bottom dishes and allowed to grow to a suitable confluence. 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles were taken up by PC-3 cells, with the main emission 
lying within the blue and green channels and some minor emission in the red channel.  
 
Further images were taken in order to gather more information regarding cellular internalisation 
and distribution of the compounds. PC-3 cells were incubated for 15 minutes with 
Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles and imaged using single-photon laser scanning 
confocal microscopy (Figure 5.38(f-t)). These images show that there is broad emission across 
all the visible wavelengths when the probe is excited at 405 nm, while only green-red and red 
emissions are visible using 488 and 561 nm lasers, respectively. This is consistent with the 
fluorescence studies carried out, whereby the Fe3O4/Cd0.1Zn0.9Se@SiO2 nanocomposite 
demonstrated emissive characteristics within the blue and red wavelength range of the visible 
spectrum. The confocal microscopy images show that Fe3O4/Cd0.1Zn0.9Se@SiO2 localise 
throughout the cell cytoplasm and no emission comes from the nuclear region of the cells. 
Therefore, while the Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles are effectively internalised within 
the cell, they do not penetrate the nuclear membrane. Furthermore, these nanocomposites do 
not seem to damage the morphology of the prostate cancer cells during the time of incubation 
and imaging studies. 
 
Encapsulating the Cd0.1Zn0.9Se nanocrystals in a thin silica matrix along with magnetic 
nanoparticles was performed to achieve a water-dispersible system, which retains the optical 
features of the free QDs as well as the magnetic properties of the iron oxide core. The fact that 
these nanoparticles are fully dispersible and kinetically stable in aqueous media, present 
fluorescent features, but they do not seem to penetrate the cellular membrane in short periods 
of time, constitutes a highly encouraging result for their use as synthetic scaffolds for 
bioimaging applications in vitro and makes these inorganic nanoparticles a unique and 
versatile device for such applications.  





Figure 5.38. a-e) Epi-fluorescence and f-t) single-photon laser scanning confocal microscopy of PC-3 
cells incubated for 15 minutes at 37 oC with Fe3O4/Cd0.1Zn0.9Se@SiO2 NPs. Final concentration: 10 
μg/mL in 1 : 99 DMSO : serum-free medium. . f-j) λex = 405 nm; k-o) λex = 488 nm; p-t) λex = 561 nm. a, f, 
k, p) DIC channel; b, g, l, q) blue channel (λem = 417-477 nm); c, h, m, r) green channel (λem = 500-550 
nm); d, i, n, s) red channel (λem = 570-750 nm); e, j, o, t) overlay of all the channels. Scale bar: 20 μm. 
 
 




Epi-fluorescence microscopy (Figure 5.39(a-e)) and single-photon laser scanning confocal 
microscopy (Figure 5.39(f-t)) images of PC-3 cells incubated with a DMSO : serum-free 
medium (1:99) suspension of 10 µg/mL Fe3O4@SiO2@Zn(ATSM/A) nanoparticles were 
gathered following the same protocol as for the nanoparticles and quantum dots. A 
homogeneous distribution of the particles is seen in the blue, green and red channels after 405 
nm laser excitation, while it is visible only in the green and red channels and only in the red, 
respectively, after 488 and 561 nm laser excitation. Aggregates of the fluorescent probes are 
particularly visible in the green and red channels using lasers of 488 and 561 nm excitation. 
As for the previous fluorescent probe, Fe3O4@SiO2@Zn(ATSM/A) nanoparticles are taken up 
by these types of cells, and they localise mainly in the cytoplasm without entering the nucleus 
and again they do not damage the cell morphology. This nanocomposite also presents 
fluorescent properties that make it a promising probe for bioimaging applications.  
 
PC-3 cells were also incubated with the citric acid-coated Fe3O4 nanoparticles containing a 
BODIPY derivative covalently linked on their surface, and single-photon laser scanning 
confocal microscopy images were collected (Figure 5.40). The fluorophore emits light slightly 
in the blue channel, and more strongly in the green and red channels when excited with lasers 
of 405, 488 and 561 nm wavelengths, respectively. This type of nanoparticles are taken up by 
the PC-3 cells, and they localise mainly in the cytoplasm without entering the nucleus and do 
not alter the cell morphology. 
 
Three dimensional confocal microscopy images can be used to show the distribution of a 
fluorophore within the cells. It can be observed in the case of the citric acid-coated Fe3O4 
nanoparticles containing a BODIPY derivative that the NPs are evenly distributed throughout 
the cytoplasm. The maximum fluorescence intensity comes from inside the cytoplasm, with 
some degree of aggregation (Figure 5.41).51  
 





Figure 5.39. a-e) Epi-fluorescence and f-t) single-photon laser scanning confocal microscopy of PC-3 
cells incubated for 15 minutes at 37 oC with Fe3O4@SiO2@Zn(ATSM/A) NPs. Final concentration: 10 
μg/mL in 1 : 99 DMSO : serum-free medium. . f-j) λex = 405 nm; k-o) λex = 488 nm; p-t) λex = 561 nm. a, f, 
k, p) DIC channel; b, g, l, q) blue channel (λem = 417-477 nm); c, h, m, r) green channel (λem = 500-550 
nm); d, i, n, s) red channel (λem = 570-750 nm); e, j, o, t) overlay of all the channels. Scale bar: 50 μm. 
 





Figure 5.40 a-e) Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 15 
minutes at 37 oC with citric acid-coated Fe3O4 NPs containing a BODIPY derivative covalently linked on 
their surface. Final concentration: 10 μg/mL in 1 : 99 DMSO : serum-free medium. a) DIC channel; b) 
blue channel (λem = 417-477 nm), λex = 405 nm; c) green channel (λem = 500-550 nm), λex = 488 nm; d) 
red channel (λem = 570-750 nm), λex = 561 nm; e) overlay of all the channels. Scale bar: 50 μm. 
 
 
Figure 5.41. 3D representation of the confocal microscopy images of citric acid-coated Fe3O4 NPs 
containing a BODIPY derivative in fixed PC-3 cells incubated for 15 minutes at 37 oC. The image shows 
the green channel, λex = 488 nm (λem = 500-550 nm).  




5.12. Two-photon fluorescence lifetime imaging microscopy 
Fluorescence lifetime imaging microscopy (FLIM) methods were applied to investigate the 
lifetime of the synthesised nanocomposites containing fluorophores, which would give an 
indication of their kinetic stability in cells. Experiments started with testing the lifetime of the 
compounds in solution using DMSO as a solvent. Time-correlated single-photon counting 
(TCSPC) was used to measure lifetime decays, followed by an in vitro FLIM investigation. 
These experiments were carried out at the Rutherford Appleton Laboratory (RAL) in the Central 
Laser Facilities (CLF) with the assistance of Prof. Stanley W. Botchway and Dr. Vincenzo 
Mirabello. Fluorescence lifetime investigations were carried out and reported following a 
previously described protocol.51, 52 
 
The fluorescence lifetimes of the free Zn(ATSM/A) tag, the as-synthesised Cd0.1Zn0.9Se QDs, 
and the Fe3O4@SiO2@Zn(ATSM/A) nanoparticles were investigated in solution by TCSPC 
using two-photon excitation techniques (Table 5.8).53 Each photon detected and collected in 
TCSPC was plotted to calculate the fluorescence lifetime. The results obtained from TCSPC 
(Figure 5.42) consist of three components (χ
2, ԏn (ps), and ԏn (%)). ԏn represents the duration 
within which the corresponding nanocomposite exists in an excited state, and ԏm is the overall 
lifetime, which is the average between all the different individual lifetime components. For all 
the compounds tested except for the Cd0.1Zn0.9Se quantum dots the number of counts for the 
lifetime is quite low, meaning that there is not much of each compound being detected in the 
solution. Therefore, only the data collected for the Cd0.1Zn0.9Se QDs can be considered reliable 
and is reported here. 
 
Table 5.8. Two-photon TCSPC data for Cd0.1Zn0.9Se QDs, using a 1 mg/mL suspension in DMSO. The 
compound was excited at λex = 810 nm, with a laser power of 12.4 mW. 
Compound χ
2
 ԏ1 (ps) ԏ1 (%) ԏ2 (ps) ԏ2 (%) ԏm 
Cd0.1Zn0.9Se 1.00 1243 54.1 6884 45.9 3831 
 
The tested Cd0.1Zn0.9Se quantum dots are shown to contain two lifetime components, with ԏ1 
being the main one but existing in an almost 1:1 ratio. This means that for this species there is 
more than one component that is fluorescent and the fluorescence lifetimes are individually 
different. The ԏ2 can be due to several reasons, such as the existence of isomers, 
conformational changes in the solvent, or pH-dependent protonated and non-protonated forms 
of a molecule.51 
 




As explained in Chapter 2 (Section 2.12), if the value found for χ2 falls within the 1.0 – 1.3 
range, the data can be considered reliable.54 According to this, the results shown for the tested 
nanocomposites are reliable. 
 
Figure 5.42. TCSPC decay and fitting curve for Cd0.1Zn0.9Se QDs tested using a 1 mg/mL dispersion in 
DMSO excited at 810 nm with a laser power of 12.4 mW. Black dots are the measured counts at 
different times and the red line is the fitting curve. 
 
The two-photon FLIM mapping and intensities in PC-3 cells were measured for Zn(ATSM/A) 
and the Fe3O4@SiO2@Zn(ATSM/A) nanocomposite. It was observed that these compounds 
enter the cells and they seem to accumulate on the cell membrane. Fluorescence lifetime 
distribution curves are the overall fluorescence summarised from the fluorescence lifetime 
mapping in PC-3 cells (Figure 5.43). From the plot, it can be observed that the fluorescence 
lifetime distribution of Zn(ATSM/A) is between 1 and 1500 ps, and that of 
Fe3O4@SiO2@Zn(ATSM/A) is between 1 and 2000 ps when they are both incubated in PC-3 
cells. The distribution of lifetime in this curve is based on the corresponding components, that 
is, the proportion of individual lifetime. In both cases the lifetime distribution is broad, but in the 
case of Zn(ATSM/A) there is only an intense peak between 1 and 500 ps and a tail with less 
counts that follows until 1500 ps. The ԏm in cells when measured at the maximum number of 
counts (around 350 counts) for Zn(ATSM/A) is around 250 ps. Regarding the 
Fe3O4@SiO2@Zn(ATSM/A) nanoparticles, the maximum number of counts reaches only up to 
35, which means that this nanocomposite is less detected in cells, and corresponds to a ԏm in 
cells of approximately 750 ps. 





Figure 5.43. (A, D) Two-photon fluorescence intensity diagram; (B, E) fluorescence lifetime mapping of 
ԏm, and (C, F) fluorescence lifetime distribution curves of PC-3 cells treated with 1 mg/mL dispersions of 
each compound in 1% DMSO. λex = 810 nm. Cells were incubated at 37 oC for 15 minutes with (A-C) 
Zn(ATSM/A), and (D-F) Fe3O4@SiO2@Zn(ATSM/A). Scale bar: 50 μm. 
  




5.13. MTT assays with nanocomposites 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were carried out 
with the assistance of Dr. Haobo Ge in order to determine the IC50 value for the functionalised 
iron oxide nanoparticles and starting materials and evaluate the toxicity of each of them in 
prostate cancer cells (Figure 5.44). The IC50 corresponds to the half maximal inhibitory 
concentration, and it is a measure that indicates how effectively a drug inhibits a specific 
biological process. In this case it refers to what concentration of compound is needed to kill 
half of the population of cells, i.e., to reduce the cell viability to 50%. 
 
In order to carry out these assays, 96 well plates containing PC-3 cells were treated with each 
of the nanocomposites at different concentrations for 48 hours at 37 oC. Then, MTT was added 
to the cells and incubated for 2 hours. The insoluble formazan species was solubilised with 
DMSO. To quantify the absorbance of the solution by the cells, a spectrophotometer was used 
(with an absorption wavelength of 570 nm) and a dose response curve was plotted to calculate 
the IC50 of each of the products (Table 5.9). 
 
Figure 5.44. IC50 in PC-3 cells after 48 hours of treatment at 37 oC with Fe3O4@SiO2@Zn(ATSM/A), 
Cd0.1Zn0.9Se, Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles and Zn(ATSM/A). 
(The data was collected from six repeated measurements on the same day; N = 1). 
  




Table 5.9. Summary of compounds tested in MTT assays using PC-3 cells and IC50 values found for 
each of them. 
Compound IC50 / mg/mL IC50 / M 
Fe3O4@SiO2@Zn(ATSM/A) (6.8 ± 1.6)·10-5 - 
Cd0.1Zn0.9Se (5.1 ± 0.9)·10-5  -  
Fe3O4/Cd0.1Zn0.9Se@SiO2 (6.7 ± 0.1)·10-4  -  
Zn(ATSM/A) (5.9 ± 1.6)·10-3  1.9 ± 0.5 
 
Out of all the tested compounds, the one with the highest IC50 value and, consequently, the 
least toxic, is Zn(ATSM/A). This result was expected, as it is known that thiosemicarbazones 
are very biocompatible.55 It is also confirmed that the encapsulation of the Cd0.1Zn0.9Se 
quantum dots within a silica shell with iron oxide nanoparticles significantly decreases their 
toxicity. It is known that cadmium is a toxic metal, as it can be seen by the low IC50 value of 
the free quantum dots, but this study proves that thanks to the silica coating, which is a 
biocompatible material, the quantum dots can be safely encapsulated with no apparent 
leakage. It is unexpected to see such a low IC50 value for the Fe3O4@SiO2@Zn(ATSM/A) 
nanoparticles, especially when compared to the one for the free Zn(ATSM/A).56 In conclusion, 
MTT assays show that the biocompatibility of the system is improved when the fluorophores 
are encapsulated within a silica shell. 
 
The same data collected from MTT assays performed in PC-3 cells were plotted as the 
normalised cell viability (%) as a function of the concentration (mg/mL) (Figure 5.45). Fe3O4 
and Fe3O4@SiO2 were included in this study also for comparison.  





Figure 5.45. Normalised cell viability (%) of different nanocomposites depending on the concentration 
(mg/mL) and compared to dimethylsulfoxide (control).  
 
At low concentrations (10-9 – 10-7 mg/mL) all the products show very low toxicity when 
compared to dimethylsulfoxide, which is used as a control and is given a normalised cell 
viability of 100%. When the concentration increases slightly to 10-5 – 10-3 mg/mL, the 
functionalised nanomaterials Fe3O4@SiO2@Zn(ATSM/A) and Fe3O4/Cd0.1Zn0.9Se@SiO2 
prove to be more toxic than the coated and uncoated nanoparticles without any fluorophore 
attached. Finally, when the concentration is of the order of 10-2 mg/mL, the iron oxide-silica 
core-shell nanoparticles are the least toxic and still present a normalised cell viability of almost 
100% on the timescale of the observation. 
 
In conclusion, since imaging techniques use very low concentrations, of the order of 0.01 
mg/mL, it appears that all the synthesised nanocomposites would be suitable and relatively 








5.14. Crystal violet assays for hypoxia testing 
As described in the previous section, MTT assays were used to test the cytotoxicity of the 
synthesised nanoparticles in PC-3 cells. This type of assay uses mitochondrial activity to 
convert MTT into formazan, a purple dye.57 Under hypoxia, mitochondrial activity is reduced, 
hence MTT assays are not suitable for determining the cell viability or cell survival rate under 
hypoxic conditions. For this reason, to test how the synthesised nanocomposites behave in 
cells under hypoxic conditions, another type of assay was carried out: crystal violet, which does 
not depend on mitochondrial activity.58 These assays were carried out by Dr. Haobo Ge 
 
In order to study whether some of the synthesised and functionalised nanoparticles (especially 
those containing Zn(ATSM/A)) have potential selectivity for hypoxic tissue in vitro, crystal violet 
assays were carried out in prostate cancer cells under normoxic and hypoxic conditions, using 
a crystal violet solution to stain the cells. After it was removed and the cells were left to dry, 
the well plates were read by a spectrophotometer reader at an absorption wavelength of 570 
nm. In order to chemically induce hypoxia, a solution of cobalt (II) chloride hexahydrate in water 
was used in the regular cell media, which was later added to the cells and these were incubated 
overnight at 37 oC under an atmosphere of 5% carbon dioxide. CoCl2·6H2O works as a 
chemical inducer of the hypoxia-inducible factor-1 (HIF-1), which is the major transcription 
factor that is specifically activated during hypoxia.59, 60 These assays were carried out using 
Fe3O4@SiO2@Zn(ATSM/A) and Fe3O4/Cd0.1Zn0.9Se@SiO2 dispersions, and Zn(ATSM/A) 
solutions under normoxic and hypoxic conditions (Figure 5.46), in order to compare the effects 
of the different nanocomposites in cells under different conditions. 





Figure 5.46. Crystal violet assays under normoxic (purple) and hypoxic (orange) conditions using PC-3 
cells incubated with Fe3O4@SiO2@Zn(ATSM/A) and Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles, and 
Zn(ATSM/A). (The data was collected from six repeated measurements on the same day; N = 1). 
 
Crystal violet assays show that under normoxic conditions, the Fe3O4/Cd0.1Zn0.9Se@SiO2 
nanoparticles have a lower IC50 value than the other two compounds, being more toxic (Table 
5.10). However, when the assays were carried out under hypoxic conditions, the 
Fe3O4@SiO2@Zn(ATSM/A) nanocomposite was found to be more toxic than the nanoparticles 
and quantum dots, and the IC50 value for the free Zn(ATSM/A) complex also diminishes. Under 
both normoxic and hypoxic conditions, Zn(ATSM/A) has a high IC50 value, which makes it very 
non-toxic. 
 
Table 5.10. Summary of compounds tested with crystal violet assays using PC-3 cells under normoxic 
and hypoxic conditions and IC50 value found for each of them.  
Compound IC50 normoxia / mg/mL IC50 hypoxia / mg/mL 
Fe3O4@SiO2@Zn(ATSM/A) (2.01 ± 0.2)·10-2  (1.09 ± 0.01)·10-3  
Fe3O4/Cd0.1Zn0.9Se@SiO2 (1.2 ± 0.2)·10-3  (9 ± 2)·10-3  
Zn(ATSM/A) (3.6 ± 0.3)·10-1  (1.92 ± 0.04)·10-2  
 
The same nanocomposites were tested in mice breast cancer (EMT6) cells using crystal violet 
assays under normoxic and hypoxic conditions to check their toxicity and IC50 values in this 
other cell line type (Figure 5.47). The same conditions and concentrations were used and 
hypoxia was chemically induced following the same protocol with CoCl2·6H2O. 





Figure 5.47. Crystal violet assays under normoxic (purple) and hypoxic (orange) conditions using 
EMT6 cells incubated with Fe3O4@SiO2@Zn(ATSM/A) and Fe3O4/Cd0.1Zn0.9Se@SiO2 nanoparticles, 
and Zn(ATSM/A). (The data was collected from six repeated measurements on the same day; N = 1). 
 
Crystal violet assays carried out in EMT6 cells show that under normoxic conditions there is a 
similar trend as for PC-3 cells, with Fe3O4/Cd0.1Zn0.9Se@SiO2 having a lower IC50 value than 
Fe3O4@SiO2@Zn(ATSM/A) and Zn(ATSM/A). When the assays were carried out under 
hypoxic conditions, the trend in EMT6 cells is different to that in PC-3 cells: 
Fe3O4/Cd0.1Zn0.9Se@SiO2 is the product with the lowest IC50 value and, for this reason, the 
most toxic one. The complex Zn(ATSM/A) keeps its high IC50 value in both cases, making it 
non-toxic for this type of cells as well. The main difference when compared to the studies 
carried out in PC-3 cells, is that for the Fe3O4@SiO2@Zn(ATSM/A) nanoparticles and the 
Zn(ATSM/A) complex there is less of a difference between the IC50 values in hypoxic and 
normoxic conditions. (Table 5.11). 
 
Table 5.11. Summary of compounds tested with crystal violet assays using EMT6 cells under normoxic 
and hypoxic conditions and IC50 value found for each of them. 
Compound IC50 normoxia / mg/mL IC50 hypoxia / mg/mL 
Fe3O4@SiO2@Zn(ATSM/A) (7.4 ± 0.2)·10-2 (9 ± 2)·10-3  
Fe3O4/Cd0.1Zn0.9Se@SiO2 (1.0 ± 0.2)·10-3  (1.3 ± 0.1)·10-3  
Zn(ATSM/A) (2.1 ± 0.1)·10-2  (1.6 ± 0.2)·10-2  
  




5.15. Summary of Chapter 5 
Chapter 5 describes an investigation into the synthesis and characterisation of iron oxide 
nanoparticles-based materials, including three types of fluorophores (i. e., Cd0.1Zn0.9Se QDs, 
Zn(ATSM/A) and a  BODIPY derivative), which can be used as potential multimodal tools for 
magnetic resonance imaging, bioimaging applications and PET imaging.  
 
Iron oxide nanoparticles were synthesised via a co-precipitation method and a silica layer was 
added by a reverse microemulsion method of coating. These nanocomposites were then 
functionalised using two different types of fluorophores. On one hand, Cd0,1Zn0.9Se quantum 
dots, which have characteristics that make them good probes for imaging applications. On the 
other hand, the metal-ligand complex Zn(ATSM/A), which is a weak fluorophore and emits at 
some channels of the visible spectrum, with potential selectivity for hypoxic tissue when it is 
labelled with specific radioisotopes. For all the products, TEM was used to study their 
morphology and size, and EDX mapping was carried out to identify their elemental 
composition, among other techniques that were used to confirm the formation of such 
nanocomposites and study their properties (powder X-ray diffraction, IR spectroscopy, DLS, 
Raman spectroscopy, TGA, BET surface area analysis and epi-fluorescence and confocal 
microscopy). Consequently, water-dispersible, biocompatible and luminescent 
nanocomposites with dimensions of around 50 nm were obtained, which retained the magnetic 
properties of the iron oxide nanoparticles core. These were found to also retain some of the 
emissive characteristics of the encapsulated quantum dots. 
 
Radiolabelling experiments using the radioisotope 68Ga were carried out following three 
different methods: (i) adsorption of the radionucleus into the silica shell of the nanoparticles, 
(ii) encapsulation of 68Ga within a second silica shell that coats the nanoparticles, and (iii) 
reaction between nanoparticles containing Zn(ATSM/A) bound onto their surface and 68Ga. 
The first and last method used gave radio-incorporation factors of ≥ 99.9% when measured by 
radio-TLC, while the formation of a second silica shell to encapsulate the radioisotope gave a 
lower yield, probably due to the short time allowed for the reaction to take place due to the 
short half-life of 68Ga (67.7 min). Overall, it was demonstrated that it is possible to radiolabel 
the magnetic and fluorescent nanocomposites with 68Ga via the general methods developed, 
in some cases using chelator-free strategies.  
 
Cellular imaging experiments in a PC-3 cell line were carried out using laser scanning confocal 
microscopy and FLIM, with single-photon and two-photon excitation techniques. The confocal 
microscopy results show that the functionalised nanoparticles are taken up by cells, with good 




penetrability through the cell membrane, although they do not enter the nuclear membrane of 
the cells and therefore do not enter the nucleus. All of these compounds are retained in the 
cytoplasm and they do not damage or alter the cell morphology.  
 
Regarding the FLIM experiments, the fluorescence lifetime and components distribution were 
measured for dispersions of the fluorescent nanocomposites in DMSO. Using TCSPC, the 
fluorescence lifetime was observed for the Cd0.1Zn0.9Se quantum dots, with two components 
exponential fitting functions. The measured χ2 value was within the acceptable range (< 1.5), 
making the values obtained reliable. 
 
Toxicity assays were also carried out on these nanocomposites, and they showed that by 
adding a silica shell and encapsulating the different components inside of this, the toxicity 
decreases significantly, making the materials more in vitro biocompatible and non-toxic. 
Consequently, the materials were shown to be safe-to-handle and benign hybrid nanoparticles 
of potential utility as trimodal medical imaging probes that allow simultaneous PET, MRI and 
fluorescence imaging. MTT and crystal violet assays were carried out using prostate cancer 
cells and mice breast cancer cells. For the crystal violet studies, hypoxia was chemically 
induced in some cells and these were cultivated with the corresponding nanocomposites. 
Those compounds containing Zn(ATSM/A) tags seemed to show more toxicity for prostate 
cancer cells grown under hypoxia, with a lower IC50 value under these type of conditions, 
making them interesting agents for hypoxic therapy. 
 
Another nanoparticles system, based on a citric acid layer coating the nanoparticles was also 
synthesised and characterised. This nanomaterial was functionalised with a BODIPY 
derivative based on a monofunctionalised tripodal ligand with two free arms, making the whole 
system highly fluorescent most likely due to the properties of this dye to act as a bio-orthogonal 
unit, and further investigations are necessary.  
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Chapter 6. Conclusions and future work 
Medical imaging includes a broad variety of techniques such as PET, SPECT and MRI, and is 
a potent tool for the diagnosis, follow-up and treatment of many diseases and tumours. The 
development of new multimodal systems to apply in these different techniques has been 
studied in this thesis, as described below chapter by chapter. 
 
Chapter 2 describes the synthesis of potential multimodal systems based on a tripodal organic 
core: a benzene ring with three alternated CH2Br arms that can be functionalised. BODIPY 
was the fluorophore of choice to give fluorescent properties to the system due to its many 
advantages (e.g., high quantum yields and low cytotoxicity). Accordingly, a BODIPY derivative 
with a carboxylic acid pendant group was synthesised and characterised. The conditions to 
functionalise the tripodal starting material via a nucleophilic substitution reaction were found 
after several attempts, and also for the posterior purification to separate the potential mono-, 
di- and trisubstituted products present in the final mixture. First, the reaction was attempted 
with benzoic acid due to the simplicity of the molecule and its ready availability, and mono- 
and disubstituted products were isolated from the final mixture. Accordingly, a mono- and 
disubstituted BODIPY derivatives were synthesised and characterised. Two different linkers 
were also attached to the tripodal core: one of them, with a terminal protected carboxylic acid 
group will later be used to attach a peptide, and the other one, with an azido terminal group, 
was attached with the aim of performing “click” chemistry using a dibenzocyclooctyne (DBCO) 
acid derivative. For this purpose, a reaction to try to couple a deferoxamine (DFO) molecule to 
a DBCO acid was attempted, although unsuccessfully, and this would have later been used to 
attach on the azido terminal linker via a strain-promoted alkyne-azide cycloaddition (SPAAC) 
(copper-free) reaction. More efforts should be made in the future to carry out this reaction, 
finding the right conditions and following its progress at each step. The optimisation of the 
reaction conditions for the functionalisation of the tripodal core was carried out, to investigate 
the effects that changing a parameter would have in the mono- : disubstituted ratio in the final 
mixture, and also to make the reaction more accessible to biomolecules, which often cannot 
react at high temperatures for long periods of time. Therefore, three parameters were 
investigated: time, temperature and the stoichiometry of the starting materials. Regarding time, 
it was found that the distribution of the products is achieved after a short period of time, and 
the ratio obtained after one hour does not change significantly when compared to the final one, 
after 26 hours. Regarding the temperature at which the reaction takes place, it was found that 
a lower temperature favours the formation of the monosubstituted product in the final mixture 
and there is a minor amount of unreacted tripodal ligand. When the stoichiometry of the starting 




materials is modified so that the number of equivalents of the tripodal ligand is bigger than for 
the carboxylic acid used, it was seen that the amount of monosubstituted product in the final 
mixture is higher in comparison to the amount of disubstituted product, which decreases 
considerably. MTT assays were performed to study the cell viability of the BODIPY derivatives 
and the starting tripodal ligand, and it was seen that the cytotoxicity of the latter decreases 
dramatically when the terminal bromide atoms are substituted by one and two BODIPY 
molecules, respectively. Moreover, colocalisation studies were carried out using single-photon 
laser scanning confocal microscopy with LysoTracker Red and ER-Tracker Red. It was 
concluded that BODIPY derivatives localise mainly in the cytoplasm, especially in the 
endoplasmic reticulum. Moreover, two-photon fluorescence lifetime imaging microscopy 
investigations were carried out to study the lifetime properties of the BODIPY derivatives both 
in solution and in PC-3 cells. All the compounds showed to exhibit one or more components 
for the fluorescence lifetime. Less successfully, functionalisation reactions of the tripodal core 
with fluorescein-5-thiosemicarbazide and Zn(ATSM/A) were attempted, unsuccessfully due to 
the complexity of these compounds. Two deferoxamine derivatives were synthesised and they 
were radiolabelled with zirconium-89 (t1/2 = 78.4 h) following an established protocol in use at 
PETIC, leading to a nearly quantitative radiochemical yield. 
 
Chapter 3 describes the synthesis of the [7-13] bombesin fragment using solid-state phase 
peptide synthesis with a Rink amide resin and Fmoc-protected amino acids, and its subsequent 
purification using a semi-preparative HPLC. The deprotection of the tripodal-linker compound 
synthesised in Chapter 2 was carried out to achieve the free carboxylic acid group, although 
unsuccessfully, due to the breakage of the ester linkage that binds the linker to the tripodal 
core, consistent with the behaviour of various succinate prodrugs. Another strategy was 
followed, attaching the peptide sequence to the same linker and performing its deprotection, 
which was achieved without major difficulties. The coupling of the bombesin-deprotected linker 
compound to the tripodal ligand containing two BODIPY units synthesised in Chapter 2 was 
carried out, but the desired trisubstituted product could not be isolated from the final reaction 
mixture. More attempts should be carried out in the future to identify the successful conditions 
to accomplish this reaction. Moreover, if this compound could be synthesised, it would be 
interesting to perform confocal fluorescence studies to investigate where it localises within the 
cells, as it is known that BODIPY is a targeting molecule for the endoplasmic reticulum, while 
the bombesin peptide tends to bind with strong affinity to the gastrin-releasing peptide receptor 
existing in the cellular membrane. Additionally, a molecule consisting of the [7-13] bombesin 
fragment attached to a deferoxamine derivative was synthesised. The coupling was performed 
using both HATU/DIPEA and HBTU/DIPEA, and both sets of conditions proved to work. In the 
future, it would be promising to perform radiolabelling experiments using this molecule and 




zirconium-89, as it should have a high radiochemical yield due to the presence of DFO, a 
strong chelator for such radioisotope. Moreover, MTT assays should be carried out to 
investigate the cell viability of this conjugate. 
 
Chapter 4 describes the synthesis and structural characterisation of ligands based on 
thiosemicarbazides. In this context, four ligands were synthesised using the symmetric tripodal 
core and creating systems with three thiosemicarbazide derivatives arms. Compounds with 
methyl, ethyl, phenyl and allyl terminal groups were synthesised. NMR spectroscopy was 
performed in order to characterise these ligands and study their orientation in space. For this 
purpose, 1H NMR spectra were recorded and the resonances were assigned, showing the 
thiosemicarbazide arms as two groups, one set of resonances integrating for two of them and 
the other set integrating for the third arm. NOESY NMR spectroscopy was also carried out and 
a surprise raised to see positive peaks that indicate chemical exchange between different 
groups in the molecule, such as CH2 and CH3 in the ethyl arms of the compound. Next, a 
ROESY NMR experiment was performed to try to understand whether the positive peaks in 
the NOESY spectrum actually corresponded to exchange. Instead, the ROESY spectrum 
showed negative peaks, which indicate spatial proximity between protons. This suggested for 
the first time that such molecules have a size bigger than expected, so that they cannot be 
properly analysed by NOESY NMR. Moreover, 1H DOSY NMR experiments were carried out, 
and the molecules showed to be pure. The diffusion coefficients were calculated for the four 
ligands, and their values were smaller than expected, suggesting that a bigger size molecule 
than it was originally thought happens in the solutions used for the NMR experiments. Variable 
temperature NMR was carried out at higher and lower temperatures than room temperature to 
try to elucidate the multiplicity of the peaks, and it was seen that at higher temperatures the 
resulting spectra were more good looking than at lower temperatures, due to the higher speed 
and motion of the arms at higher temperatures, which make the different protons more 
magnetically and chemically equivalent. Crystals suitable for single crystal X-ray diffraction 
were obtained for three of the four ligands as HBr salts. They were analysed, and the molecular 
structures showed how a unit cell contained two molecules of the ligand, each triply protonated, 
and forming a cage-like structure. Six Br- counter ions in total, as well as a molecule of 
methanol, the solvent used to achieve the crystals, were localised within the unit cell. Hydrogen 
bonding was observed through the N-H atoms of the molecules and the Br- ions located around 
the unit cell. Moreover, the distance of the bonds between the atoms that form the 
thiosemicarbazide were measured and compared to those in one of the starting materials, 4-
methyl-3-thiosemicarbazide. They did not show to change significantly, suggesting that the 
delocalised double bond existing in the starting material is conserved, in the S-C, C-N and C-
N system. Attempted complexation reactions of the ligands with metals were attempted using 




Zr(IV), Ga(III), In(III), Cu(II), Ni(II) and Zn(II) salts. In all the cases, solids of different colours 
were obtained, which were characterised by MS, NMR, Raman and IR spectroscopy, 
elemental analysis and UV/visible spectroscopy. The presence of a metal in most of the 
compounds is evidenced through these techniques, although the final structure cannot be 
elucidated. Furthermore, the formation of a complex with three L-cysteine arms was 
accomplished, showing promising results for the functionalisation of biomolecules. Anion 
exchange reactions were carried out without clear results. Finally, crystal violet assays were 
performed using the four ligands in PC-3, EMT6 and FEK-4 cells after 24, 48 and 72 hours of 
incubation, evidencing the low toxicity of the products in the micromolar concentration range. 
Chapter 5 describes the synthesis and characterisation of imaging agents based on magnetite 
phase iron oxide nanoparticles. This type of nanoparticles were chosen due to their magnetic 
properties, which allow them to be used as contrast agents for magnetic resonance imaging, 
and their low toxicity levels. The nanoparticles were coated with a silica shell and two types of 
fluorophores were used: on one side, inorganic Cd0.1Zn0.9Se quantum dots nanocrystals, and 
on the other side, a slightly fluorescent and potential hypoxia targeting molecule, Zn(ATSM/A). 
The nanocomposites were characterised by TEM, EDX, powder X-ray diffraction, IR and 
Raman spectroscopy, DLS, fluorescence spectroscopy, BET surface area analysis and TGA, 
accordingly. Moreover, a nanocomposite consisting of the iron oxide nanoparticles with a citric 
acid coating and a monofunctionalised BODIPY derivative was synthesised. Radiolabelling 
experiments using the radioisotope gallium-68 (t1/2 = 67.7 min) were carried out and three 
different methods were developed: (i) the adsorption of the radioisotope onto the silica matrix, 
(ii) the encapsulation of the radioisotope within a second silica shell, and (iii) the possible 
transmetallation of the Zn(ATSM/A) complex attached onto the surface of the nanoparticles. 
The radiochemical incorporation factors were found to be: (i) ≥ 99.9%, (ii) 66-70%, and (iii) ≥ 
99.9%, respectively. One-photon and two-photon confocal fluorescence investigations were 
carried out on thin films and in vitro using PC-3 cells, and the nanocomposites containing 
quantum dots and Zn(ATSM/A) showed to emit light in the green and red channels of the 
spectrum. FLIM studies were performed as well. MTT cell viability assays were carried out and 
they showed that when the nanoparticles are coated with a silica matrix their cytotoxicity 
decreases dramatically. Crystal violet assays were performed under normoxic and hypoxic 
conditions on PC-3 and EMT6 cells with the compounds containing Zn(ATSM/A) and quantum 
dots. The results showed that the compounds incorporating Zn(ATSM/A) are more toxic for 
hypoxic cells in PC-3 cells, but the trend is not conserved in EMT6 cells. 
 
Overall, the work presented herein constitutes promising results towards the synthesis of new 
potential multimodal tools for in vitro and in vivo imaging, including fluorescent materials both 




based in single molecules and nanocomposites, with the potential of being radiolabelled with 
high radiochemical yields. 




Chapter 7. Experimental Section 
7.1. Materials and Methods 
All solvents and reagents for the synthesis and characterisation of the compounds described 
in this section were purchased from commercial sources (Sigma Aldrich, Alfa Aesar, Acros 
Organics, Merck Chemicals, Fluorochem or Fisher Scientific) and used without further 
purification unless otherwise stated. Commercial solvents were reagent or HPLC grade 
obtained from Sigma Aldrich or VWR. The water used was from a Millipore milli-Q purification 
system. Anhydrous solvents were obtained from a PS-400-7 Innovative technologies Solvent 
Purification System. Reactions executed under nitrogen atmosphere using Schlenk line 
techniques are indicated.  
 
Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded at 298 K on either a 300 MHz (1H) 
Bruker Avance or a 500 MHz (1H) Agilent ProPulse spectrometers, using the solvent indicated 
in each case. 1H and 13C{1H} chemical shifts are referenced to tetramethylsilane (TMS). 
Chemical shifts are given in ppm and multiplicities are described as singlet (s), doublet (d), 
triplet (t), quartet (q) or multiplet (m). Broad peaks are described as (br). Coupling values, J, 
are given in Hz. NOESY, ROESY and variable temperature NMR experiments were carried 
out using a 500 MHz Bruker Avance II+ NMR instrument. Variable temperature NMR spectra 
were recorded with the assistance of Dr. John Lowe. 
 
Mass Spectrometry 
Mass spectra were recorded either at the University of Bath or at the EPSRC UK National 
Mass Spectrometry Facility in Swansea. When carried out at the university, the mass spectra 
were conducted on either an ESI-TOF or a LC-QTOF mass spectrometer and solutions of 1 
ng/mL were prepared using methanol or acetonitrile as a solvent. When recorded at the NMSF 
in Swansea, the method used is indicated in each case. 
 
Fourier Transform Infrared Spectroscopy 
FT-IR spectra in the 4000 – 650 cm-1 range were recorded on a Perkin Elmer Frontier FT-IR 
instrument. Wavenumbers are given in cm-1, and vibrational modes are described as 









Raman spectroscopy measurements were carried out in the solid state on a Renishaw inVia 
system using a laser of 532 nm excitation wavelength.  
 
High-Performance Liquid Chromatography 
HPLC analyses were performed on an analytical reverse-phase Dionex UltiMate 3000 HPLC 
system, using a Dionex C18 Acclaim column. The solvent system was formed by water and 
acetonitrile, each containing 0.1% of trifluoroacetic acid.  
Method A: Gradient; t = 0 min, AcCN = 5%; t = 1 min, AcCN = 5%; t = 6 min, AcCN = 95%, t = 
13 min, AcCN = 95%; t = 16 min, AcCN = 95%; t = 20 min, AcCN = 5%. Flow rate = 0.8 mL/min. 
Method B: Gradient; t = 0 min, AcCN = 5%; t = 7.5 min, AcCN = 95%; t = 15 min, AcCN = 95%, 
t = 18 min, AcCN = 95%. Flow rate = 0.8 mL/min. 
 
Flash Chromatography 
Where products required purification by flash chromatography, a Biotage Isolera automatic 
purification system was used, with the solvent system indicated in each case, using 10, 25 or 
50 g Biotage SNAP silica cartridges.  
 
Powder X-ray diffraction 
Analyses of crystalline structure and phase identification of materials were performed by X-ray 
diffraction on a XRD Bruker AXS D8-Advance with a monochromatised source of Cu-Kα1 
radiation (λ = 1.54018 Å) at 1.6 kW (40 kV, 40 mA). A 2theta/omega scan was performed with 
a step width of 0.033o (2θ) and step time of 1345.1 s. Samples were prepared by placing a 
drop of a methanol dispersion of particles onto a single crystal silicon plate. Powder X-ray 
diffraction analyses were carried out with the assistance of Dr. Gabrielle Kociok-Köhn. 
 
Transmission Electron Microscopy 
TEM images were obtained mostly on a JEOL JEM1200EXII operating at 120 kV at the 
Microscopy and Analysis Suite at the University of Bath. A high resolution JEOL JEM-2100Plus 
operating at 200 kV in the same facility was also used to acquire some images. Samples were 
prepared by placing a drop of a diluted dispersion of the nanocomposite in an appropriate 
solvent onto a 400-mesh carbon-coated copper grid and left to dry on air overnight. 
 
Energy Dispersive X-ray Spectroscopy 
EDX data was collected from a JEOL JEM-2100Plus transmission electron microscope 
coupled with energy dispersive X-ray spectroscopy at the Microscopy and Analysis Suite at 
the University of Bath, using the same grids as for TEM. 




Dynamic Light Scattering 
DLS data was acquired on a Malvern Zetasizer Nano ZS instrument in the Department of 
Chemistry at the University of Bath, using disposable polystyrene cuvettes. 
 
Circular Dichroism 
CD data was acquired from a Chirascan (Applied Photophysics) instrument connected to a 
nitrogen gas unit (Claino Brezza) in the Department of Chemistry at the University of Bath. 
 
Brunauer, Emmet and Teller (BET) Surface Area Analysis and Barrett-Joyner-Halenda 
(BJH) Pore Size and Volume Analysis 
In order to carry out BET measurements, approximately 300 mg of sample were inserted into 
a glass tube and degassed at 90 oC for 4 hours to remove any solvent, moisture or contaminant 
molecules that might be adsorbed and prevent the surface of the nanocomposite from being 
fully accessible to the nitrogen molecules. Nitrogen adsorption was performed on a 3Flex unit 
from Micromeritics. All the calculations (BET, DFT, BJH, etc.) were done using the program 
MicroActive. BET measurements were carried out with the assistance of Dr. Rémi Castaing. 
 
Thermogravimetry with Evolving Gas Analysis 
Thermogravimetric analysis was carried out on a Setsys Evolution TGA 16/18 from Setaram. 
The program Calisto was employed to collect and process the data. The sample was loaded 
into a 170 μL alumina crucible. The temperature program consisted of a succession of 
isothermal steps and heating and cooling ramps. The temperature was set at 30 oC initially 
and maintained for 120 seconds. Following this, a heating ramp took place at a rate of 10 K/min 
until 800 oC were reached, which lasted for 4620 seconds. Next, a cooling ramp started at a 
rate of 20 K/min until the temperature was again 30 oC, after 2310 seconds. This final 
temperature was maintained for 900 seconds. All the mentioned steps were performed under 
an air flow, which was then stopped and the sample was left at 30 oC for 15 more seconds. 
TGA was carried out with the assistance of Dr. Rémi Castaing. 
 
Single Crystal X-Ray Diffraction  
X-ray crystallography data were collected at 150(2) K on an Agilent SuperNova Dual 
diffractometer, using monochromated Cu-Kα radiation (λ = 1.54184 Å). All structures were 
solved with SHELXT and refined by a full-matrix least-squares procedure based on F2. Single 









CHN analyses were carried out at London Metropolitan University. 
 
Peptide Synthesiser 
Peptides were synthesised on a Biotage Initiator+ Alstra automated microwave peptide 
synthesiser, using the resin type and method indicated in each case. 
 
UV/visible Spectroscopy 
UV/visible spectra were acquired from a Perkin Elmer Lambda 35 Spectrometer or from a 
Perkin Elmer Lambda 650 Spectrometer using two 1 cm quartz cuvettes.  
 
Fluorescence Spectroscopy 
Fluorescence spectra were acquired on a Perkin Elmer LS55 Luminescence Spectrometer 
using a 1 cm quartz cuvette. 
 
Cell culturing and cell plate preparation 
Cell lines used in this project included prostate cancer cells (PC-3), epithelial fibroblast cells 
(FEK-4) and mice breast cancer cells (EMT6). Cells were normally frozen at -196 oC under 
liquid nitrogen until they were required to use, then cells were thawed quickly and incubated 
at 37 °C under a 5% carbon dioxide environment. Different cell lines required different solvent 
systems to grow: FEK-4 cells were incubated in an Eagle’s Minimum Essential Medium 
(EMEM), whilst both PC-3 and EMT6 cells were cultured in Roswell Park Memorial Institute 
(RPMI) medium. All media contained activated foetal calf serum (FCS) (10% for PC-3 and 
EMT6, and 15% for FEK-4), 0.5% penicillin/streptomycin (10,000 IU·mL-1/10,000 mg·mL-1) and 
1% L-glutamine. Cell culturing was carried out with the assistance of Dr. Haobo Ge. 
 
MTT Assays 
After splitting the cells, cells (3 x 103 cells per well) were seeded on a sterile 96 well plate and 
incubated for 48 hours in order to let the cells adhere to the plates. The compound of interest 
was then subsequently loaded at different concentrations into the wells and incubated for 48 
hours more. The concentrations used ranged between 250 μM or 0.01 mg/mL and 1 nM or 1 
ng/mL (1% DMSO with compound, 99% RPMI (10% FCS) for PC-3 and EMT6 cells). 
Subsequently, cells were washed three times with PBS, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added (0.5 mg/mL in serum-free medium (SFM)), 
followed by a two hours incubation. After aspiration to remove the serum-free medium, 100 μL 
of DMSO was added to solubilise the precipitated formazan species, and 96 well plates were 
read by an ELISA plate reader, Molecular Devices Versa Max (BN02877). The absorption 




wavelength was 570 nm, and 690 nm wavelength was used as a reference. Cell viability 
studies were carried out with the assistance of Dr. Haobo Ge. 
 
Crystal Violet Assays 
After splitting the cells, cells (3 x 103 cells per well) were seeded on a sterile 96 well plate and 
incubated for 48 hours in order to let the cells adhere to the plates. The compound of interest 
was then subsequently loaded at different concentrations into the wells and incubated for 48 
hours more. The concentrations used ranged between 250 μM or 0.01 mg/mL and 1 nM or 1 
ng/mL (1% DMSO with compound, 99% RPMI (10% FCS) for PC-3 and EMT6 cells, and 1% 
DMSO with compound, 99% EMEM (15% FCS) for FEK-4 cells). Subsequently, the medium 
from the plates was carefully aspirated so as not to disturb the colonies, and the plates were 
gently washed with PBS. Next, a mixture of methanol:PBS (1:1) was added in a sufficient 
volume to cover the colonies, and it was left for 15 minutes. After this time, it was removed and 
100% methanol was added for a further 15 minutes. The methanol was then removed and 
0.5% crystal violet solution (in 20% methanol and 80% water) was added and left to allow 
sufficient staining. The crystal violet solution was removed by carefully rinsing the cell plates 
with an indirect flow of tap water. The plates were inverted and left on the bench at room 
temperature to dry the water. Methanol (200 μL) was added to each well, and the plate was 
incubated with its lid on for 20 minutes at room temperature on a bench rocker with a frequency 
of 20 oscillations per minute. The 96 well plates were then read by an ELISA plate reader, 
Molecular Devices Versa Max (BN02877). The absorption wavelength was 570 nm, and 690 
nm wavelength was used as a reference. This was carried out by Dr. Haobo Ge. 
 
Chemically Induced Hypoxia 
A 25 mM stock solution of cobalt (II) chloride hexahydrate (CoCl2·6H2O) in water was prepared 
immediately before use. CoCl2 at a final concentration of 100 μM was used in the regular cell 
culture media to induce hypoxia in cells. The CoCl2-containing media was then added to the 
cells and these were incubated for 24 hours at 37 oC under a 5% carbon dioxide environment. 
This step was carried out before adding the compounds of interest to the cells, as a pre-
incubation of the cells with a hypoxia inducing agent. This was carried out by Dr. Haobo Ge. 
 
Laser Scanning Confocal Microscopy 
Laser scanning confocal microscopy was performed using a Nikon A1Rsi Laser Scanning 
Confocal Microscope System fitted with 60X oil objective lens, and equipped with three lasers 
of 405, 488 and 561 nm. The microscope was also fitted with a motorised piezo z-stage, 
halogen lamp and mercury lamp for epi-fluorescence microscopy. All the images were 
processed using functions within the NIS elements software package. 




Two-Photon Fluorescence Lifetime Imaging Microscopy 
Two-photon excitation experiments were performed at the Rutherford Appleton Laboratory 
(Central Lasers Facility, Research Complex at Harwell) by Dr. Vincenzo Mirabello and Dr. 
Haobo Ge. A mode-locked Mira titanium sapphire laser (Coherent Lasers Ltd, USA), 
generating 180-fs pulses at 75 MHz and emitting light at a wavelength of 710 – 970 nm was 
used for the two-photon excitation experiments. The laser was pumped by a solid state 
continuous wave 532 nm laser (Verdi V18, Coherent Laser Ltd), with the oscillator fundamental 
output of 915 ± 2 nm or 810 ± 2 nm. The laser beam was focused to a diffraction limited spot 
through a water immersion ultraviolet corrected objective (Nikon VC x60, NA1.2) and 
specimens were illuminated at the microscope stage of a modified Nikon TE2000-U with UV 
transmitting optics. The focused laser spot was raster scanned using an XY galvanometer (GSI 
Lumonics). Fluorescence emission was collected and passed through a coloured glass filter 
(BG39) and detected by fast microchannel plate photomultiplier tube used as the detector 
(R3809-U, Hamamatsu, Japan). These were linked via a TCSPC PC module SPC830. Lifetime 
calculations were obtained using SPCImage analysis software. 
 
Quantum Yield calculation 
Room temperature fluorescence QY was calculated according to the following equation: 













Equation 7.1. Formula employed to calculate the quantum yield of the new fluorescent compounds. 
 
In this equation, the subscript r refers to the reference (Ru(bpy)32+), while s refers to the other 
compounds. Φr and Φs are the fluorescence QY of Ru(bpy)32+ (0.042) and unknown, 
respectively. A is the absorbance of the solution, E is the corrected emission intensity, I is the 
relative intensity of the exciting light and n is the average refractive index of the solutions. 
 
Radiolabelling experiments 
Experiments involving 68Ga were performed at the Department of Surgery and Cancer of the 
Imperial College London with the assistance of Sophia Sarpaki, and those involving 89Zr were 
carried out at the Wales Research and Diagnostic Positron Emission Tomography Imaging 
Centre (PETIC) with the assistance of Dr. Stephen Paisey.  
 
  




7.2. Experimental procedures 
7.2.1. Synthesis of compounds from Chapter 2  
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (1) 
 
This synthesis was carried out following a previously reported procedure with some 
modifications,1 as described below. 
 
Zinc powder (3.36 g, 51.30 mmol) was dissolved in 33 mL of acetic acid in a three-neck round-
bottom flask under nitrogen and stirring. When the zinc was dissolved, HBr in acetic acid (33% 
wt) (34.5 mL) was added slowly through an addition funnel. Triethylbenzene (8.0 mL, 42.40 
mmol), paraformaldehyde (13.80 g) and HBr in acetic acid (33% wt) (103 mL) were then added 
to the solution. The mixture was heated to 90 oC under reflux and stirred for 48 hours. After 
this time, heat was stopped and the solution was left to cool for 2 hours. When it had cooled, 
the precipitate was filtered and washed three times with water, then the solid was left on the 
freeze-drier overnight. The red-brown filtrate was heated again to 90 oC and stirred for 24 more 
hours. The new precipitate was then filtered and again the filtrate was left to react for 24 more 
hours at 90 oC. Finally, a white powder was obtained, which was left on the freeze-drier 
overnight to dry.  
 
Yield: 49% (9.11 g). 
1H NMR (300 MHz, CDCl3, 298 K): δ (ppm) 4.58 (s, 6H, CH2Br), 2.94 (q, J = 7.6 Hz, 6H, 
CH2CH3), 1.34 (t, J = 7.6 Hz, 9H, CH2CH3).  
13C{1H} NMR (75 MHz, CDCl3, 298 K): δ (ppm) 145.1, 132.8, 28.7, 22.9, 15.8.  
nESI-MS+: m/z calculated for C15H21Br3: 457.9511, found 457.9507 [M+NH4]+ (for 
C15H2179Br79Br81Br). 
IR: ṽ (cm-1): 2966, 2872, 2300-1900, 1570, 957, 901, 703. 
HPLC (Method A): Rt (min): 12.4. 
 
  





10-yl)benzoic acid (2) 
 
This synthesis was carried out following a previously reported procedure with some 
modifications,2, 3 as described below. 
 
2,4-dimethylpyrrole (1.99 mL, 19.40 mmol, 2.25 eq) and 4-formylbenzoic acid (1.30 g, 8.63 
mmol, 1 eq) were dissolved in 1 L of dichloromethane under a nitrogen in a round-bottom flask. 
Two drops of trifluoroacetic acid were added, and the solution was stirred at room temperature 
for 1 hour. After this time, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ; 1.96 g, 8.63 
mmol, 1 eq) was added dissolved in 20 mL of dichloromethane and the purple reaction mixture 
was stirred for another hour. Next, triethylamine (20 mL) and boron trifluoride diethyl etherate 
(20 mL) were added and the reaction mixture was stirred for 3 hours, after which it was 
quenched by the addition of water (500 mL) and extracted with dichloromethane (3 x 200 mL). 
The combined organic extracts were dried with anhydrous MgSO4, filtered and concentrated 
under reduced pressure. The purple crude slurry was purified by silica gel chromatography (0-
8% methanol in dichloromethane), and the different fractions were collected and analysed. The 
desired fractions were recrystallised from THF/hexane to give a red solid.   
 
Yield: 19% (0.60 g). 
1H NMR (500 MHz, DMSO-d6, 298 K): δ (ppm) 8.10 (d, J = 8.3 Hz, 2H, o-ArH), 7.53 (d, J = 8.2 
Hz, 2H, m-ArH), 6.19 (s, 2H, NC(CH3)CHC(CH3)), 2.46 (s, 6H, NC(CH3)CHC(CH3)), 1.33 (s, 
6H, NC(CH3)CHC(CH3)). 
19F NMR (470 MHz, DMSO-d6, 298 K): δ (ppm) -143.7 (q, J = 32.0 Hz, 2F, BF2). 
13C{1H} NMR (126 MHz, DMSO-d6, 298 K): δ (ppm) 166.8, 155.2, 150.2, 142.6, 138.4, 135.5, 
131.5, 130.1, 128.4, 121.6, 14.2, 14.0. 
ESI-MS-: m/z calculated for C20H19BF2N2O2: 367.1438, found 367.1455 [M-H]-. 
IR: ṽ (cm-1): 3109, 2922, 1878, 1681, 1191. 
HPLC (Method B): Rt (min): 9.9. 
 
  




General procedure (A) for the synthesis of monosubstituted compounds 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene, a carboxylic acid derivative and potassium 
carbonate were added to a round-bottom flask, followed by acetonitrile. The reaction mixture 
was stirred and heated to 100 oC, then connected to a reflux condenser. The reaction was 
monitored by TLC, and after 16 hours heating was stopped. The mixture was left to cool to 
room temperature, and the solvent was removed under reduced pressure. The product was 
dissolved in dichloromethane and washed three times with NaOH(aq) 1 M. The organic layers 
were collected and dried with anhydrous MgSO4, then the solvent was removed under reduced 
pressure to yield a powder. In all the cases, TLC showed three spots. The final product was 
purified by silica gel column chromatography with a solvent system of ethyl acetate in hexane 
in different ratios as specified in each case. In some occasions it was possible to isolate the 
disubstituted product as well as the monosubstituted material. 
 
3,5-bis(bromomethyl)-2,4,6-triethylbenzyl benzoate (3) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.25 g, 0.56 mmol, 1 eq), 
benzoic acid (0.07 g, 0.56 mmol, 1 eq) and potassium carbonate (0.12 g, 0.85 mmol, 1.5 eq) 
were dissolved in 20 mL of acetonitrile and were reacted as per General procedure (A). The 
final product was purified by silica gel column chromatography with a solvent system of 4% 
ethyl acetate in hexane. 
 
Yield: 38% (0.10 g).  
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.06 – 8.03 (m, 2H, o-ArH), 7.58 – 7.53 (m, 1H, p-
ArH), 7.44 – 7.40 (m, 2H, m-ArH), 5.44 (s, 2H, CH2O), 4.64 (s, 4H, CH2Br), 3.00 (q, J = 7.6 Hz, 
2H, p-CH2CH3), 2.93 (q, J = 7.6 Hz, 4H, o-CH2CH3), 1.39 (t, J = 7.6 Hz, 3H, p-CH2CH3), 1.29 
(t, J = 7.6 Hz, 6H, o-CH2CH3).  
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 166.8, 146.2, 145.2, 145.1, 133.2, 132.4, 
130.9, 129.8, 128.5, 61.2, 28.9, 22.9, 22.9, 16.1, 15.8. 
APCI-MS+: m/z calculated for C22H26Br2O2: 505.0178, found 505.0185 [M+Na]+ (for 
C22H2679Br81BrO2). 
IR: ṽ (cm-1): 2961, 2870, 2300-1900, 1717, 1450, 1266, 1024, 953, 904, 706. 
HPLC (Method B): Rt (min): 7.9. 
  




(5-(bromomethyl)-2,4,6-triethyl-1,3-phenylene)bis(methylene) dibenzoate (4) 
 
This product was obtained from the synthesis and purification of compound 3.  
 
Yield: 21% (0.06 g).  
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.05 (d, J = 7.8 Hz, 4H, o-ArH), 7.58 – 7.51 (p, 2H, 
p-ArH), 7.42 (t, J = 7.7 Hz, 4H, m-ArH), 5.48 (s, 4H, CH2O), 4.68 (s, 2H, CH2Br), 2.97 (q, J = 
7.6 Hz, 4H, CH2CH3), 2.89 (q, J = 7.5 Hz, 2H, CH2CH3), 1.32 (t, J = 7.6 Hz, 6H, CH2CH3), 1.24 
(t, J = 7.5 Hz, 3H, CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 166.8, 147.3, 146.3, 133.2, 132.1, 130.6, 
130.1, 129.9, 128.5, 61.4, 29.3, 23.1, 23.0, 16.5, 16.2. 
APCI-MS+: m/z calculated for C29H31BrO4: 542.1734, found 542.1732 [M+NH4]+; 547.1288, 
found 547.1289 [M+Na]+. 
IR: ṽ (cm-1): 2961, 2870, 2300-1900, 1717, 1450, 1266, 1024, 953, 904, 706. 
HPLC (Method B): Rt (min): 6.5. 
 
  







1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.25 g, 0.56 mmol, 1 eq), 4-(5,5-
difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoic 
acid (compound 2) (0.21 g, 0.56 mmol, 1 eq) and potassium carbonate (0.12 g, 0.85 mmol, 1.5 
eq) were dissolved in 20 mL of acetonitrile and were reacted as per General procedure (A). 
The final product was purified by silica gel column chromatography with a solvent system of 
10-20% ethyl acetate in hexane. 
 
Yield: 20% (0.08 g).  
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.16 (d, J = 8.3 Hz, 2H, o-ArH), 7.38 (d, J = 8.3 
Hz, 2H, m-ArH), 5.98 (s, 2H, NC(CH3)CHC(CH3)), 5.48 (s, 2H, CH2O), 4.63 (s, 4H, CH2Br), 
2.99 (q, J = 7.6 Hz, 2H, CH2CH3), 2.94 (q, J = 7.7 Hz, 4H, CH2CH3), 2.54 (s, 6H, 
NC(CH3)CHC(CH3)), 1.38 (t, J = 7.6 Hz, 2H, CH2CH3), 1.35 (s, 6H, NC(CH3)CHC(CH3)), 1.30 
(t, J = 7.5 Hz, 4H, CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 166.2, 156.1, 146.2, 145.4, 142.9, 140.2, 
140.1, 132.5, 131.0, 130.7, 130.6, 128.6, 121.6, 61.5, 53.5, 28.9, 23.0, 22.9, 16.2, 15.8, 14.6, 
14.3. 
nESI-MS+: m/z calculated for C35H39BBr2F2N2O2: 729.1501, found 729.1490 [M+H]+ (for 
C35H39B79Br81BrF2N2O2).  
IR: ṽ (cm-1): 2965, 1726, 1541, 1189, 737. 
HPLC (Method B): Rt (min): 13.9. 
 
  









This product was obtained from the synthesis and purification of compound 5.  
 
Yield: 13% (0.08 g).  
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.16 (d, J = 8.3 Hz, 4H, o-ArH), 7.38 (d, J = 8.2 
Hz, 4H, m-ArH), 5.96 (s, 4H, NC(CH3)CHC(CH3)), 5.53 (s, 4H, CH2O), 4.68 (s, 2H, CH2Br), 
3.00 (d, J = 7.6 Hz, 4H, CH2CH3), 2.95 (d, J = 7.4 Hz, 2H, CH2CH3), 2.54 (s, 12H, 
NC(CH3)CHC(CH3)), 1.43 – 1.23 (m, 21H, CH2CH3, NC(CH3)CHC(CH3), CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 171.2, 166.1, 156.1, 147.2, 146.5, 142.9, 
140.2, 140.2, 132.3, 130.6, 128.6, 121.6, 61.6, 60.5, 53.5, 29.8, 23.1, 21.1, 16.5, 16.2, 14.6, 
14.3. 
nESI-MS+: m/z calculated for C55H57B2BrF4N4O4: 1033.4072, found 1033.4051 [M+NH4]+ (for 
C55H57B279BrF4N4O4). 
IR: ṽ (cm-1): 2926, 1714, 1543, 1189, 735. 
HPLC (Method A): Rt (min): 7.5. 
 
  




6-azidohexanoic acid (7) 
 
Bromohexanoic acid (0.25 g, 1.28 mmol, 1 eq) was added to a round-bottom flask and 
dissolved in 20 mL of dimethylsulfoxide. Next, sodium azide (0.12 g, 1.92 mmol, 1.5 eq) was 
added to the flask, and the reaction mixture was stirred at room temperature for 16 hours. After 
this time, 50 mL of water was added to the flask and it was extracted with diethyl ether (3 x 
150 mL). The organic phases were collected and dried over MgSO4, then filtered and 
concentrated under reduced pressure to yield a yellow oil. 
 
Yield: 66% (0.13 g). 
1H NMR (500 MHz, CDCl3, 298 K): δ 10.62 (s, 1H, COOH), 3.24 (t, J = 6.9 Hz, 2H, CH2N3), 
2.33 (t, J = 7.4 Hz, 2H, CH2COOH), 1.66 – 1.60 (m, 2H, CH2CH2N3), 1.60 – 1.54 (m, 2H, 
CH2CH2COOH), 1.47 – 1.34 (m, 2H, N3CH2CH2CH2). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ 179.9, 51.2, 33.8, 28.5, 26.1, 24.1. 
nESI-MS-: m/z calculated for C6H11N3O3: 156.0781, found 156.0778 [M-H]-. 
IR: ṽ (cm-1): 2942, 2091, 1705, 1250. 
HPLC (Method B): Rt (min): 8.4. 
   
  




3,5-bis(bromomethyl)-2,4,6-triethylbenzyl 6-azidohexanoate (8) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.23 g, 0.53 mmol, 1 eq), 6-
azidohexanoic acid (compound 7) (0.08 g, 0.53 mmol, 1 eq) and potassium carbonate (0.11 g, 
0.79 mmol, 1.5 eq) were dissolved in 20 mL of acetonitrile and were reacted as per General 
procedure (A). The final product was purified by silica gel column chromatography with a 
solvent system of 2-20% ethyl acetate in hexane. 
 
Yield: 29% (0.08 g). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 5.18 (s, 2H, CH2O), 4.60 (s, 4H, CH2Br), 3.26 (t, J 
= 6.9 Hz, 2H, CH2N3), 2.96 (q, J = 7.6 Hz, 2H, p-CH2CH3), 2.84 (q, J = 7.6 Hz, 4H, o-CH2CH3), 
2.35 (t, J = 7.5 Hz, 2H, COCH2), 1.71 – 1.64 (m, 2H, COCH2CH2), 1.64 – 1.56 (m, 2H, 
CH2CH2N3), 1.44 – 1.39 (m, 2H, CH2CH2CH2N3), 1.35 (t, J = 7.6 Hz, 3H, p-CH2CH3), 1.25 (t, J 
= 7.7 Hz, 6H, o-CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 173.6, 145.9, 145.1, 132.4, 130.9, 60.6, 51.3, 
34.2, 28.9, 28.6, 26.3, 24.6, 22.9, 22.7, 16.1, 15.7. 
nESI-MS+: m/z calculated for C21H31Br2N3O2: 535.1102, found 535.1085 [M+NH4]+ (for 
C21H3179Br81BrN3O2). 
IR: ṽ (cm-1): 2969, 2095, 1732, 1243. 
HPLC (Method A): Rt (min): 7.2. 
 
  




3,5-bis(bromomethyl)-2,4,6-triethylbenzyl tert-butyl succinate (9) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.25 g, 0.56 mmol, 1 eq), 4-(tert-
butoxy)-4-oxobutanoic acid (0.10 g, 0.56 mmol, 1 eq) and potassium carbonate (0.12 g, 0.85 
mmol, 1.5 eq) were dissolved in 20 mL of acetonitrile and were reacted as per General 
procedure (A). The final product was purified by silica gel column chromatography with a 
solvent system of 10% ethyl acetate in hexane. 
 
Yield: 30% (0.09 g). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 5.20 (s, 2H, CH2O), 4.59 (s, 4H, CH2Br), 2.95 (q, 
J = 7.7 Hz, 2H, p-CH2CH3), 2.84 (q, J = 7.6 Hz, 4H, o-CH2CH3), 2.60 (s, 2H, COCH2), 2.54 (s, 
2H, CH2CO), 1.42 (s, 9H, C(CH3)3), 1.35 (t, J = 7.6 Hz, 3H, p-CH2CH3), 1.25 (t, J = 7.6 Hz, 6H, 
o-CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 172.7, 171.5, 146.0, 145.2, 132.4, 130.8, 80.9, 
60.9, 30.4, 29.6, 28.9, 28.2, 22.9, 22.9, 16.1, 15.8. 
nESI-MS+: m/z calculated for C23H34Br2O4: 552.1143, found 552.1132 [M+NH4]+ (for 
C23H3479Br81BrO4). 
IR: ṽ (cm-1): 2965, 1718, 1260, 997, 796. 
HPLC (Method B): Rt (min): 12.3. 
 
  




3,5-bis(bromomethyl)-2,4,6-trimethylbenzyl benzoate (10) 
 
1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene (0.20 g, 0.50 mmol, 1 eq), benzoic acid (0.06 
g, 0.50 mmol, 1 eq) and potassium carbonate (0.10 g, 0.75 mmol, 1.5 eq) were dissolved in 
20 mL of acetonitrile and were reacted as per General procedure (A). The final product was 
purified by silica gel column chromatography with a solvent system of 10% ethyl acetate in 
hexane. 
 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.07 – 7.98 (m, 2H, o-ArH), 7.60 – 7.52 (m, 1H, p-
ArH), 7.48 – 7.37 (m, 2H, m-ArH), 5.48 (s, 2H, CH2O), 4.61 (s, 4H, CH2Br), 2.51 ( s, 6H, o-
CH3), 2.50 (s, 3H, p-CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 166.6, 139.0, 138.2, 133.2, 131.6, 130.0, 
129.8, 128.5, 61.9, 31.0, 30.3, 15.9, 15.5. 
nESI-MS+: m/z calculated for C19H20Br2O2: 458.0148, found 458.0143 [M+NH4]+ (for 
C19H2079Br81BrO2). 
IR: ṽ (cm-1): 2922, 1713, 1451, 1259, 1024, 936, 711. 
HPLC (Method B): Rt (min): 14.9. 
 
  




(5-(bromomethyl)-2,4,6-trimethyl-1,3-phenylene)bis(methylene) dibenzoate (11) 
 
This product was obtained from the synthesis and purification of compound 10. 
 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.07 – 8.02 (m, 4H, o-ArH), 7.60 – 7.52 (m, 2H, p-
ArH), 7.46 – 7.39 (m, 4H, m-ArH), 5.51 (s, 4H, CH2O), 4.65 (s, 2H, CH2Br), 2.56 (s, 3H, CH3), 
2.55 (s, 6H, CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 166.7, 140.0, 139.2, 133.2, 133.0, 131.4, 
130.1, 129.8, 128.5, 62.1, 30.5, 16.4, 15.9. 
nESI-MS+: m/z calculated for C26H25BrO4: 500.1255, found 500.1250 [M+NH4]+ (for 
C26H2579BrO4). 
IR: ṽ (cm-1): 2922, 1715, 1269, 1106, 932, 703. 
HPLC (Method B): Rt (min): 16.5. 
 
  




3,5-bis(bromomethyl)-2,4,6-trimethylbenzyl tert-butyl succinate (12) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (0.25 g, 0.62 mmol, 1 eq), 4-(tert-butoxy)-4-
oxobutanoic acid (0.11 g, 0.62 mmol, 1 eq) and potassium carbonate (0.13 g, 0.93 mmol, 1.5 
eq) were dissolved in 20 mL of acetonitrile and were reacted as per General procedure (A). 
The final product was purified by silica gel column chromatography with a solvent system of 
10% ethyl acetate in hexane. 
 
Yield: 22% (0.07 g). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 5.23 (s, 2H, CH2O), 4.58 (s, 4H, CH2Br), 2.61 – 
2.56 (m, 2H, COCH2), 2.56 – 2.49 (m, 2H, CH2CO), 2.46 (s, 3H, p-CH3), 2.42 (s, 6H, o-CH3), 
1.41 (s, 9H, C(CH3)3). 
13C{1H}  NMR (126 MHz, CDCl3, 298 K): δ (ppm) 172.5, 171.4, 138.9, 138.1, 133.1, 131.4, 
80.8, 61.5, 30.4, 30.2, 29.4, 28.1, 15.8, 15.4. 
nESI-MS+: m/z calculated for C20H28Br2O4: 510.0673, found 510.0655 [M+NH4]+ (for 
C20H2879Br81BrO4). 
IR: ṽ (cm-1): 2931, 1727, 1148, 962, 731. 









General procedure (B) for the synthesis of disubstituted compounds 
The monosubstituted tripodal ester derivative, the new carboxylic acid derivative and 
potassium carbonate were added to a round-bottom flask, followed by acetonitrile. The 
reaction mixture was stirred and heated to 100 oC, then connected to a reflux condenser. The 
reaction was monitored by TLC, and after 16 hours heating was stopped. The mixture was left 
to cool to room temperature, and the solvent was removed under reduced pressure. The 
product was dissolved in dichloromethane and washed three times with NaOH(aq) 1 M. The 
organic layers were collected and dried with anhydrous MgSO4, then the solvent was removed 
under reduced pressure to yield a powder. The final product was purified by silica gel column 
chromatography with a solvent system of ethyl acetate in hexane in different ratios as specified 













dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (compound 5) (25 mg, 30 μmol, 1 eq), 
4-(tert-butoxy)-4-oxobutanoic acid (6 mg, 30 μmol, 1 eq) and potassium carbonate (7 mg, 50 
μmol, 1.5 eq) were dissolved in 10 mL of acetonitrile and were reacted as per General 
procedure (B). The final product was purified by silica gel column chromatography with a 
solvent system of 15-45% ethyl acetate in hexane. 
 
Yield: 18% (5 mg). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.16 (d, J = 8.3 Hz, 2H, o-ArH), 7.38 (d, J = 8.5 
Hz, 2H, m-ArH), 5.98 (s, 2H, NC(CH3)CHC(CH3)), 5.51 (s, 2H, CH2Br), 5.26 (s, 4H, CH2O), 
2.86 (q, J = 7.6 Hz, 4H, CH2CH3), 2.78 (q, J = 7.5 Hz, 2H, CH2CH3), 2.61 – 2.56 (m, 4H, 
COCH2CH2CO), 2.55 (s, 6H, NC(CH3)CHC(CH3)), 1.42 (s, 9H, C(CH3)3), 1.34 (s, 6H, 
NC(CH3)CHC(CH3)), 1.25 – 1.18 (m, 9H, CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 207.0, 172.7, 171.5, 166.2, 156.2, 147.2, 
147.1, 142.8, 140.2, 131.1, 130.8, 130.6, 130.2, 130.0, 128.6, 121.6, 80.9, 61.7, 61.1, 31.1, 
30.4, 29.5, 28.2, 23.1, 23.1, 16.6, 16.5, 14.8, 14.7. 
EI-MS+: m/z calculated for C43H52BBrF2N2O6: 820.3, found 820.4 [M]+· (for C43H52B79BrF2N2O6). 
IR: ṽ (cm-1): 2923, 1731, 1546, 1148, 739. 
HPLC (Method B): Rt (min): 7.1. 
 
  







3,5-bis(bromomethyl)-2,4,6-triethylbenzyl tert-butyl succinate (compound 9) (0.24 g, 0.45 
mmol, 1 eq), 6-azidohexanoic acid (compound 7) (0.07 g, 0.45 mmol, 1 eq) and potassium 
carbonate (0.09 g, 0.67 mmol, 1.5 eq) were dissolved in 25 mL of acetonitrile and were reacted 
as per General procedure (B). The final product was purified by silica gel column 
chromatography with a solvent system of 5-20% ethyl acetate in hexane. 
 
Yield: 30% (0.08 g). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 5.19 (d, J = 10.1 Hz, 4H, CH2O), 4.61 (s, 2H, 
CH2Br), 3.25 (t, J = 6.9 Hz, 2H, COCH2CH2CH2CH2CH2N3), 2.85 (q, J = 6.1 Hz, 4H, CH2CH3), 
2.73 (q, J = 7.6 Hz, 2H, CH2CH3), 2.58 (d, J = 7.0 Hz, 2H, COCH2CH2CO), 2.54 (d, J = 5.8 Hz, 
2H, COCH2CH2CO), 2.34 (t, J = 7.5 Hz, 2H, CH2N3), 1.67 (p, J = 7.5 Hz, 2H, CH2CH2N3), 1.59 
(p, J = 7.1 Hz, 2H, COCH2CH2CH2CH2CH2N3), 1.44 – 1.37 (m, 11H, CH2CH2CH2N3, C(CH3)3), 
1.29 – 1.21 (m, 6H, CH2CH3), 1.16 (t, J = 7.5 Hz, 3H, CH2CH3).  
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 173.5, 172.6, 171.4, 146.7, 145.9, 145.9, 
132.0, 130.5, 130.4, 80.8, 60.9, 60.7, 51.2, 34.1, 30.3, 29.5, 29.1, 28.6, 28.1, 26.3, 24.5, 22.9, 
16.3, 16.1. 
nESI-MS+: m/z calculated for C29H44BrN3O6: 627.2752, found 627.2740 [M+NH4]+ (for 
C29H4479BrN3O6).  
IR: ṽ (cm-1): 2974, 2095, 1728, 1143. 
HPLC (Method B): Rt (min): 12.3. 
 
  




3,5-bis(((6-azidohexanoyl)oxy)methyl)-2,4,6-triethylbenzyl tert-butyl succinate (15) 
 
This product was obtained from the synthesis and purification of compound 14.  
 
Yield: 35% (0.11 g).  
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 5.22 (s, 2H, CH2O), 5.20 (s, 4H, CH2O), 3.24 (t, J 
= 6.9 Hz, 4H, COCH2CH2CH2CH2CH2N3), 2.74 (q, J = 7.5 Hz, 6H, CH2CH3), 2.60 – 2.51 (m, 
4H, COCH2CH2CO), 2.33 (t, J = 7.5 Hz, 4H, CH2N3), 1.66 (p, J = 7.6 Hz, 4H, CH2CH2N3), 1.59 
(p, J = 7.6 Hz, 4H, COCH2CH2CH2CH2CH2N3), 1.43 – 1.37 (m, 13H, CH2CH2CH2N3, C(CH3)3), 
1.17 (t, J = 7.5 Hz, 9H, CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 173.5, 172.5, 171.3, 146.7, 146.7, 130.1, 80.7, 
77.4, 77.1, 76.9, 60.9, 60.7, 51.2, 34.1, 30.3, 29.4, 28.6, 28.0, 26.3, 24.5, 22.9, 16.3. 
APCI-MS+: m/z calculated for C35H54N6O8: 704.4347, found 704.4345 [M+NH4]+, 709.3901, 
found 709.3901 [M+Na]+. 
IR: ṽ (cm-1): 2935, 2095, 1728, 1144. 
HPLC (Method B): Rt (min): 12.3. 
 
 
General procedure (C) for the synthesis of trisubstituted compounds 
The disubstituted tripodal ester derivative, the new carboxylic acid derivative and potassium 
carbonate were added to a round-bottom flask, followed by acetonitrile. The reaction mixture 
was stirred and heated to 100 oC, then connected to a reflux condenser. The reaction was 
monitored by TLC, and after 16 hours heating was stopped. The mixture was left to cool to 
room temperature, and the solvent was removed under reduced pressure. The product was 
dissolved in dichloromethane and washed three times with NaOH(aq) 1 M. The organic layers 
were collected and dried with anhydrous MgSO4, then the solvent was removed under reduced 
pressure to yield a powder. The final product was purified by silica gel column chromatography 
with a solvent system of ethyl acetate in hexane in different ratios as specified in each case. 
 






tert-butyl succinate (16) 
 
3-(((6-azidohexanoyl)oxy)methyl)-5-(bromomethyl)-2,4,6-triethylbenzyl tert-butyl succinate 
(compound 14) (39 mg, 60 μmol, 1 eq), 4-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoic acid (compound 2) (24 mg, 60 μmol, 1 
eq) and potassium carbonate (13 mg, 90 μmol, 1.5 eq) were dissolved in 10 mL of acetonitrile 
and were reacted as per General procedure (C). The final product was purified by silica gel 
column chromatography with a solvent system of 15-35% ethyl acetate in hexane. 
 
Yield: 6% (3 mg). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.15 (d, J = 8.0 Hz, 2H, o-ArH), 7.38 (d, J = 8.3 
Hz, 2H, m-ArH), 5.98 (s, 2H, NC(CH3)CHC(CH3)), 5.51 (s, 2H, CH2O-BODIPY), 5.23 (s, 2H, 
CH2O), 5.21 (s, 2H, CH2O), 3.26 (t, J = 6.9 Hz, 2H, COCH2CH2CH2CH2CH2N3), 2.90 – 2.82 
(m, 2H, CH2CH3), 2.75 (q, J = 7.5 Hz, 4H, CH2CH3), 2.62 – 2.57 (m, 4H, COCH2CH2CO), 2.55 
(s, 6H, NC(CH3)CHC(CH3)), 2.34 (t, J = 7.5 Hz, 2H, CH2N3), 1.68 (p, J = 7.6 Hz, 2H, 
CH2CH2N3), 1.60 (p, J = 7.1 Hz, 2H, COCH2CH2CH2CH2CH2N3), 1.42 (s, 9H, C(CH3)3), 1.40 – 
1.13 (m, 17H, CH2CH2CH2N3, CH2CH3, NC(CH3)CHC(CH3), CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 173.7, 172.7, 171.5, 146.9, 146.8, 130.6, 
130.2, 130.2, 128.6, 80.9, 61.0, 60.9, 51.3, 34.2, 31.6, 31.1, 30.4, 30.3, 29.8, 29.5, 28.7, 28.2, 
26.4, 24.6, 23.0, 16.5, 14.7. 
IR: ṽ (cm-1): 2935, 2095, 1727, 1145, 949. 















tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (compound 6) 
(46 mg, 40 μmol, 1 eq) and 4-methyl-3-thiosemicarbazide (5 mg, 40 μmol, 1 eq) were added 
to a flask and dissolved in 10 mL of acetonitrile. The solution was heated to 100 oC under reflux 
and stirred for 16 hours. After this time, heating was stopped and the reaction mixture was left 
to cool down. The solvent was removed under reduced pressure and the resulting solid was 
dissolved in chloroform and washed with water (3 x 30 mL). Chloroform was removed under 
reduced pressure and a brown-red solid was obtained, which was dried under vacuum. 
 
Yield: 95% (44 mg). 
1H NMR (500 MHz, CDCl3, 298 K): δ (ppm) 8.22 – 8.10 (m, 4H, o-ArH), 7.36 (d, J = 8.2 Hz, 
4H, m-ArH), 5.96 (s, 4H, NC(CH3)CHC(CH3)), 5.53 (s, 4H,), 4.67 (s, 2H, CH2O-S), 2.98 – 2.91 
(m, 6H, CH2CH3), 2.89 – 2.82 (m, 3H, SCNHCH3), 2.53 (s, 12H, NC(CH3)CHC(CH3)), 1.32 (s, 
12H, NC(CH3)CHC(CH3)), 1.28 – 1.20 (m, 9H, CH2CH3). 
13C{1H} NMR (126 MHz, CDCl3, 298 K): δ (ppm) 166.2, 156.1, 146.7, 142.9, 140.1, 131.0, 
130.6,128.5, 121.6, 61.8, 32.0, 31.5, 31.1, 30.8, 30.3, 29.8, 25.2, 23.4, 23.2, 22.8, 21.5, 17.9, 
16.6, 14.6. 
LC-MS+: m/z calculated for C57H63B2F4N7O4S: 1040.4874, found 1040.4874 [M+H]+. 
IR: ṽ (cm-1): 2981, 1628, 1521, 1158, 731. 
HPLC (Method B): Rt (min): 11.1. 
  




Reaction conditions optimisation 
General Procedure 
1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene or 1,3,5-tris(bromomethyl)-2,4,6-
triethylbenzene (compound 1) (in the case of the reaction time study), benzoic acid and 
potassium carbonate were added to a round-bottom flask, followed by acetonitrile. The 
reaction mixture was stirred at the temperature and for the time specified in each case. The 
ratio of the different products in the final mixture was measured in different ways according to 
each factor screen. 
 
Temperature screen 
In this case, after cooling to room temperature, the solvent was removed under reduced 
pressure. The product was dissolved in dichloromethane and washed three times with 
NaOH(aq) 1 M. The organic phase was evaporated to dryness and the products were isolated 









RT (25) 12 60 28 
40 27 42 31 
60 42 26 32 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene stoichiometry 
As for the temperature screen, after cooling to room temperature, the solvent was removed 
under reduced pressure. The product was dissolved in dichloromethane and washed three 
times with NaOH(aq) 1 M. The organic phase was evaporated to dryness and the products 
were isolated by silica gel column chromatography (10% ethyl acetate in hexane). 
 
 












2 9 77 14 
5 34 66 - 
 
Reaction time 
To obtain the ratio of products at each time of interest, an aliquot of the reaction mixture at 
such time was taken. It was filtered through cotton wool, and dried. 1H NMR spectroscopy was 
then carried out, and from the integration of three peaks corresponding to the starting material, 










0 49 40 11 
1 41.5 44 14.5 
2 42 45 13 
3 43 43 14 
4 42 45 13 
6 42 45 13 
8 43 44 13 
24 40 46 14 












Radiolabelling experiments involving zirconium-89 
3,14,25-trihydroxy-2,10,13,21,24,32-hexaoxo-3,9,14,20,25,31-hexaazapentatriacontan-
35-oic acid (18) 
 
Deferoxamine mesylate salt (100 mg, 150 μmol, 1 eq) was added to a Schlenk flask and 
dissolved in 20 mL of N,N’-dimethylformamide under a flow of nitrogen. Next, succinic 
anhydride (18 mg, 180 μmol, 1.2 eq) dissolved in 10 drops of dimethylsulfoxide was dropwise 
added, followed by triethylamine (20 μL, 143 μmol). The reaction mixture was stirred at room 
temperature for 48 hours. After this time, the solvent was removed under vacuum and the oil 
obtained was washed with petroleum ether a few times until it yielded a light brown powder. 
 
Yield: 79% (79 mg). 
ESI-MS: m/z calculated for C29H52N6O11: 659.3621, found 659.3631 [M-H]-; 661.3767, found 
661.3763 [M+H]+; 683.3586, found 683.3625 [M+Na]+. 






Deferoxamine mesylate salt (30 mg, 54 μmol, 1 eq) was added to a Schlenk flask and dissolved 
in 10 mL of N,N’-dimethylformamide under a flow of nitrogen. While stirring at 25 oC, 1,3,5-
tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (24 mg, 55 μmol, 1.2 eq) was added, 
followed by triethylamine (6 μL, 43 μmol). After 48 hours stirring at this temperature, the 
reaction was stopped and the solvent was removed under vacuum. The oil obtained was 
washed with diethyl ether a few times until it yielded a pale brown powder.  
 
ESI-MS-: m/z calculated for C40H68Br2N6O8: 919.3377, found 919.3429 [M-H]- (for 
C40H6879Br81BrN6O8). 
HPLC (Method A): Rt (min): 7.4.  




Synthesis of zirconium-89 
The positron-emitting radiotracer 89Zr was prepared at the Wales Research and Diagnostic 
Positron Emission Tomography Imaging Centre via the 89Y(p,n)89Zr reaction using the 
cyclotron CYCLONE 18/9. 
 
General procedure for the radiolabelling of DFO-based compounds (20 and 21) 
The radioisotope zirconium-89 was obtained in 1 M (aq) oxalic acid, and in order to be suitable 
for radiolabelling the compounds of interest, the pH was adjusted to 6.8 - 7.5 by the addiction 
of a 1 M solution of sodium carbonate. Next, the pH-adjusted 89Zr4+ solution was added to each 
of the two compounds (compounds 18 and 19) separately in dimethylsulfoxide, and the two 
reaction mixtures were stirred at room temperature for 1 hour. After this time, the radiolabelling 
efficiency was determined by radio-TLC using an eluent of 50 mM DTPA (pH 5.5). The 
radiolabelling efficiency for both compounds was shown to be 100%. 
  




7.2.2. Synthesis of compounds from Chapter 3  
[7-13] Bombesin fragment [Leu-His-Gly-Val-Ala-Trp-Gln] (22) 
 
First, the Rink amide resin (1.00 g, loading: 0.59 mmol/g) was swelled for 1 hour in 
dichloromethane at room temperature, followed by 30 minutes in N,N’-dimethylformamide at 
60 oC. After swelling, the resin was deprotected with a solution of 20% piperidine in N,N’-
dimethylformamide for 5 and 10 minutes, and then the coupling with the first amino acid, Fmoc-
Leu-OH (3 eq) was carried out with solutions of HBTU (0.6 M in DMF), HOBt (0.5 M in DMF) 
and DIPEA (2 M in DMF), for 5 minutes at 75 oC. After the coupling, the amino acid was 
deprotected with a solution of 20% piperidine in N,N’-dimethylformamide for 3 and 10 minutes, 
and then the coupling with the second amino acid, Fmoc-His(Trt)-OH (3 eq), was performed 
using HBTU (0.6 M in DMF), HOBt (0.5 M in DMF) and DIPEA (2 M in DMF) for 60 minutes at 
room temperature. The following amino acids (Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Ala-OH, 
Fmoc-Trp(Boc)-OH, Fmoc-Gln(Trt)-OH, each 3 eq) were coupled to the peptide following the 
same conditions as for Fmoc-Leu-OH, for 5 minutes at 75 oC. Finally, the peptide was 
deprotected and a pre-cleavage wash with dichloromethane was performed. Cleavage of the 
peptide from the resin was achieved by treatment with TFA / water / phenol / TIPS (5 mL, 
88:5:5:2, v/v/v/v) for 2 hours. After this time, the suspension of the resin in the cleavage 
“cocktail” was filtered and the peptide was precipitated by adding cold diethyl ether. The 
peptide was collected by centrifugation and washed further with diethyl ether to yield a white 
solid.  
 
Yield: 76% (0.36 g). 
nESI-MS+: m/z calculated for C38H56N12O8: 809.4417, found 809.4417 [M+H]+, 831.4236, 
found  831.4227 [M+Na]+. 
HPLC (Method A): Rt (min): 7.1. 
 
  









oic acid (compound 18) (16 mg, 25 μmol, 1 eq)  was added to a Schlenk flask and dissolved 
in 1 mL of N,N’-dimethylformamide. HATU (9 mg, 25 μmol, 1 eq) was added to the flask and 
the mixture was stirred at 25 oC for 10 minutes under a nitrogen atmosphere. Next, the [7-13] 
bombesin fragment (compound 22) (20 mg, 25 μmol, 1 eq) was added and the solution was 
stirred under the same conditions for 20 minutes. After this time, N,N’-diisopropylethylamine 
(4 μL, 25 μmol, 1 eq) was added and the reaction mixture was stirred for 16 hours. Finally, the 
solvent was removed under reduced pressure and a pale pink solid was obtained. 
 
ESI-MS+: m/z calculated for C67H105N17O19: 1451.7773, found 1451.8061 [M]+·, 1474.7665, 
found 1474.7894 [M+Na]+.  








The [7-13] bombesin fragment (compound 22) (20 mg, 25 μmol, 1.1 eq) and 4-(tert-butoxy)-4-
oxobutanoic acid (4 mg, 23 μmol, 1 eq) were added to a Schlenk flask and dissolved in 1 mL 
of N,N’-dimethylformamide under a flow of nitrogen. Next, N,N’-diisopropylethylamine (12 μl, 
68 μmol, 3 eq) and HBTU (13 mg, 34 μmol, 1.5 eq) were added to the flask and the reaction 
mixture was stirred for 16 hours at 25 oC. After this time, 2 mL of water was added and 
extractions with ethyl acetate were carried out (3 x 10 mL). The organic phase was finally 
washed with 10 mL of water, before removing the solvent under reduced pressure. A pale pink 
solid was obtained.  
 
























heptaoxo-5,8,11,14,17,20,23-heptaazaheptacosanoate (compound 24) (11 mg, 11 μmol) was 
added to a flask and dissolved in 2 mL of dichloromethane. Next, 2 mL of trifluoroacetic acid 
was added and the reaction mixture was stirred for 16 hours at 25 oC. After this time, the 
solvent was removed under reduced pressure to yield a yellowish solid.  
 
Yield: 85% (9 mg). 
ESI-MS+: m/z calculated for C42H60N12O11: 909.4577, found 909.4608 [M+H]+, 931.4397, found  
931.4421 [M+Na]+. 
HPLC (Method B): Rt (min): 6.9. 
 
  




7.2.3. Synthesis of compounds from Chapter 4  
(2,4,6-triethyl-5-((((Z)-N-methylcarbamohydrazonoyl)thio)methyl)-1,3-
phenylene)bis(methylene) (1E,1'E)-bis(methylcarbamohydrazonothioate) (26) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (2.13 g, 4.80 mmol, 1 eq) and 4-
methyl-3-thiosemicarbazide (2.03 g, 19.30 mmol, 4 eq) were added to a Schlenk flask and 
dissolved in 50 mL of acetonitrile under a nitrogen atmosphere. The flask was connected to a 
reflux condenser and the solution was heated to 70 oC and stirred for 48 hours. After this time, 
the precipitate was filtered and washed with acetonitrile (6 x 10 mL), and it was left on the 
freeze-drier for 16 hours. A white powder was obtained. 
 
Yield: 69% (2.50 g). 
1H NMR (300 MHz, CD3OD, 298 K): δ (ppm) 4.59 (s, 4H, CH2S), 4.37 (s, 2H, CH2S), 3.13 (s, 
3H, NHCH3), 3.08 – 2.99 (m, 6H, NHCH3), 2.94 – 2.83 (m, 6H, CH2CH3), 1.41 – 1.28 (m, 9H, 
CH2CH3). 
13C{1H} NMR (75 MHz, CD3OD, 298 K): δ (ppm) 172.2, 169.1, 147.6, 147.4, 146.9, 129.1, 
129.0, 128.9, 31.8, 31.1, 30.6, 24.2, 16.9, 16.8. 
nESI-MS+: m/z calculated for C21H39N9S3: 514.2563, found 514.2533 [M+H]+. 
IR: ṽ (cm-1): 3161, 2965, 1650, 739, 664. 
HPLC (Method A): Rt (min): 7.6.  
E.A. (C21H39N9S3 · 3 HBr): Calculated: C, 33.34%; H, 5.60%; N, 16.66%. Found: C, 31.69%; 









phenylene)bis(methylene) (1E,1'E)-bis(ethylcarbamohydrazonothioate) (27) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (1.00 g, 2.26 mmol, 1 eq) and 4-
ethyl-3-thiosemicarbazide (1.18 g, 9.07 mmol, 4 eq) were added to a Schlenk flask and 
dissolved in 25 mL of acetonitrile under a nitrogen atmosphere. The flask was connected to a 
reflux condenser and the solution was heated to 70 oC and stirred for 48 hours. After this time, 
the precipitate was filtered and washed with acetonitrile (6 x 10 mL), and it was left on the 
freeze-drier for 16 hours. A white powder was obtained.  
 
Yield: 85% (1.54 g). 
1H NMR (300 MHz, CD3OD, 298 K): δ (ppm) 4.55 (s, 6H, CH2S), 3.47 (q, J = 7.2 Hz, 6H, 
NHCH2CH3), 2.91 (q, J = 8.0 Hz, 6H, CCH2CH3), 1.39 – 1.30 (m, 9H, CCH2CH3), 1.30 – 1.16 
(m, 9H, NHCH2CH3). 
13C{1H} NMR (75 MHz, CD3OD, 298 K): δ (ppm) 168.3, 147.7, 129.3, 40.3, 31.9, 24.3, 16.8, 
15.1. 
nESI-MS+: m/z calculated for C24H45N9S3: 556.3033, found 556.3023 [M+H]+. 
IR: ṽ (cm-1): 3144, 2965, 1652, 723. 
HPLC (Method A): Rt (min): 6.6. 
E.A. (C24H45N9S3 · 3 HBr): Calculated: C, 36.10%; H, 6.06%; N, 15.79%. Found: C, 34.08%; 











1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.50 g, 1.13 mmol, 1 eq) and 4-
phenyl-3-thiosemicarbazide (0.76 g, 4.53 mmol, 4 eq) were added to a Schlenk flask and 
dissolved in 20 mL of acetonitrile under a nitrogen atmosphere. The flask was connected to a 
reflux condenser and the solution was heated to 70 oC and stirred for 48 hours. After this time, 
the precipitate was filtered and washed with acetonitrile (6 x 10 mL), and it was left on the 
freeze-drier for 16 hours. A clear brown powder was obtained.  
 
Yield: 48% (0.52 g). 
1H NMR (500 MHz, CD3OD, 298 K): δ (ppm) 7.74 – 7.03 (m, 15H, Ar-H), 4.55 – 4.20 (m, 4H, 
CH2S), 3.85 – 3.68 (m, 2H, CH2S), 2.98 – 2.55 (m, 6H, CH2CH3), 1.33 – 1.01 (m, 9H, CH2CH3). 
13C{1H} NMR (126 MHz, CD3OD, 298 K): δ (ppm) 131.9, 131.3, 131.1, 130.7, 130.6, 130.2, 
130.0, 127.9, 124.1, 121.1, 119.2, 32.3, 23.8, 23.0, 16.6.  
nESI-MS+: m/z calculated for C36H45N9S3: 700.3033, found 700.3017 [M+H]+. 
IR: ṽ (cm-1): 2928, 1494, 736. 
HPLC (Method B): Rt (min): 3.3. 
E.A. (C36H45N9S3 · 3 HBr): Calculated: C, 45.87%; H, 5.13%; N, 13.37%. Found: C, 40.87%; 
H, 5.15%; N, 13.32%. 
 
  





phenylene)bis(methylene) (1E,1'E)-bis(allylcarbamohydrazonothioate) (29) 
 
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.50 g, 1.13 mmol, 1 eq) and 4-
allyl-3-thiosemicarbazide (0.48 g, 4.53 mmol, 4 eq) were added to a Schlenk flask and 
dissolved in 20 mL of acetonitrile under a nitrogen atmosphere. The flask was connected to a 
reflux condenser and the solution was heated to 70 oC and stirred for 48 hours. After this time, 
the precipitate was filtered and washed with acetonitrile (6 x 10 mL), and it was left on the 
freeze-drier for 16 hours. A pale pink powder was obtained.  
 
Yield: 89% (0.84 g). 
1H NMR (500 MHz, CD3OD, 298 K): δ (ppm) 6.03 – 5.93 (m, 1H, CH=CH2), 5.91 – 5.81 (m, 
2H, CH=CH2), 5.39 – 5.30 (m, 2H, CH=CH2), 5.30 – 5.21 (m, 4H, CH=CH2), 4.54 (s, 4H, CH2S), 
4.10 (d, J = 5.5 Hz, 2H, NHCH2CH), 4.07 (d, J = 5.0 Hz, 4H, NHCH2CH), 3.31 (s, 2H, CH2S), 
2.95 – 2.83 (m, 6H, CH2CH3), 1.43 – 1.27 (m, 9H, CH2CH3). 
13C{1H} NMR (126 MHz, CD3OD, 298 K): δ (ppm) 167.8, 146.3, 132.0, 130.9, 128.0, 116.7, 
116.6, 46.0, 45.7, 30.7, 23.0, 15.4. 
nESI-MS+: m/z calculated for C27H45N9S3: 592.3033, found 592.3010 [M+H]+. 
IR: ṽ (cm-1): 3137, 2968, 1656, 737. 
HPLC (Method B): Rt (min): 6.6. 
E.A. (C27H45N9S3 · 3 HBr): Calculated: C, 38.85%; H, 5.80%; N, 15.10%. Found: C, 37.70%; 
H, 5.72%; N, 14.10%. 
  







1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene (compound 1) (0.25 g, 0.56 mmol, 1 eq) and L-
cysteine (0.27 g, 2.26 mmol, 4 eq) were added to a Schlenk flask and dissolved in 20 mL of 
acetonitrile under a nitrogen atmosphere. The flask was connected to a reflux condenser and 
the solution was heated to 70 oC and stirred for 48 hours. After this time, the precipitate was 
filtered and washed with acetonitrile (6 x 10 mL), and it was left on the freeze-drier for 16 hours. 
A white powder was obtained. 
 
 nESI-MS-: m/z calculated for C24H39N3O6S3: 560.1935, found 560.1928 [M-H]-. 
  




7.2.4. Synthesis of compounds from Chapter 5  
Iron oxide nanoparticles – Fe3O4 (31) 
 
This synthesis was carried out following a previously reported procedure with some 
modifications,4 as described below. 
 
In one flask, 10 mL of an aqueous acid solution of FeCl3·6H2O 1 M (2.73 g, 10.00 mmol) was 
prepared with deoxygenated water under a nitrogen atmosphere. In another flask, 2.5 mL of 
an aqueous acid solution of FeCl2·4H2O 2 M (0.99 g, 5.00 mmol) was prepared with 
deoxygenated water under a nitrogen atmosphere and using a glovebox to avoid the oxidation 
of Fe2+. Both compounds were dissolved in HCl 2 M. Then, 10 mL of the FeCl3 solution were 
added to the 2.5 mL of the FeCl2 solution in a Schlenk flask, under a nitrogen atmosphere and 
stirring. Immediately after mixing, the solution containing the iron chlorides was added 
dropwise to 125 mL of potassium hydroxide solution (0.7 M) prepared with deoxygenated 
water. The flask was mechanically stirred during the addition and for the next 30 minutes. After 
this time, the black precipitate formed was separated with a magnet and washed with water (3 
x 250 mL). The obtained nanoparticles were further washed with water and centrifuged. Finally, 
oleic acid (1 mL, 3.16 mmol) dissolved in 5 mL of acetone was added dropwise.  
 
IR: ṽ (cm-1): 3239, 601. 
XRD: 2θ = 30.2o, 35.5o, 43.2o, 53.5o, 57.1o and 62.9o, corresponding to the (220), (311), (400), 
(422), (511), and (440) crystalline planes of magnetite phase, respectively. 
 
  




Coating of IONPs with a silica shell using a microemulsion method – Fe3O4@SiO2 (32) 
 
This synthesis was carried out following a previously reported procedure with some 
modifications,5 as described below. 
  
Polyoxyethylene(5)isooctylphenyl ether (IGEPAL CA-520) (44.60 g) was dispersed in 700 mL 
of cyclohexane. Then, 200 mg of Fe3O4 nanoparticles dispersed in cyclohexane (20 mg·mL-1) 
was added. The mixture was stirred until it became transparent. After this step, 9.4 mL of 
ammonium hydroxide (29% aqueous solution) was added to form a reverse microemulsion. 
Finally, 7.7 mL of tetraethylorthosilicate (TEOS) was added as a silica precursor. The solution 
was mechanically stirred for 16 h. After this time, the nanocomposite was precipitated with 
methanol and separated by magnetic decantation.  
 
IR: ṽ (cm-1): 3239, 1045, 950, 601. 
XRD: 2θ = 30.2o, 35.5o, 43.2o, 53.5o, 57.1o and 62.9o, corresponding to the (220), (311), (400), 
(422), (511), and (440) crystalline planes of magnetite phase, respectively. New peak emerges 
at 2θ = 18.6o, corresponding to the (111) crystalline plane. 
 
  




Synthesis of Cd0.1Zn0.9Se quantum dots (33) 
 
This synthesis was carried out following a previously reported procedure with some 
modifications,6 as described below. 
 
Stock solutions of Se and ZnEt2 were prepared in a glovebox under argon. Cadmium stearate 
(0.20 g, 0.30 mmol), stearic acid (0.17 g, 0.60 mmol), TOPO (5.00 g), and ODA (5.00 g) were 
added to a flask, and the mixture was heated to 330 oC while stirring under a flow of argon until 
a clear solution formed. At this temperature, a solution containing Se (0.12 g, 1.50 mmol) 
dissolved in TOP was injected into the reaction flask and the temperature was set to 290 °C. 
After 5-10 minutes under stirring, the heating was removed to stop the reaction and allow the 
flask to cool to room temperature. After 1 hour, the mixture of CdSe and organic ligands was 
heated up to 300 °C again.  An aliquot (3 mL) of the as-prepared crude CdSe reaction mixture, 
containing 0.10 mmol of CdSe, was transferred into a three-neck round-bottom flask and 
heated to 300 °C. At this temperature, 450 μL of ZnEt2 (TOP solution, 0.2 M) and 450 μL of Se 
(TOP solution, 0.2 M) were injected. After the addition, the reaction mixture was heated for 6 
minutes, and then heating was removed to stop the reaction. Once the mixture reached room 
temperature, 9 mL of chloroform was added under stirring. Quantum dots were precipitated 
using a mixture of 1:1 methanol : acetone and isolated by centrifugation and decantation. The 
same mixture of 1:1 methanol : acetone (5 x 25 mL) was used to wash the QDs from the 
excess of organic ligands. Finally, Cd0.1Zn0.9Se nanocrystals were dispersed in 9 mL of n-
hexane. 
 








Synthesis of Cd0.1Zn0.9Se QDs modified silica-coated magnetic IONPs (34) 
 
IGEPAL CA-520 (2.23 g) was dispersed in 35 mL of cyclohexane. Then, 5 mg of Fe3O4 
nanoparticles dispersed in cyclohexane (20 mg·mL-1) was added, followed by 1 mL of 
Cd0.1Zn0.9Se QDs. The mixture was mechanically stirred until it became transparent. After this 
step, 485 μL of ammonium hydroxide (29% aqueous solution) was added to form a reverse 
microemulsion. Finally, 385 μL of TEOS was added as the silica precursor. The solution was 
mechanically stirred for 16 h. After this time, the nanocomposite was separated and washed 
with methanol by centrifugation and magnetic decantation. 
 
IR: ṽ (cm-1): 3318, 1633, 1013, 651. 
 
  




Synthesis of diacetyl-2-(4-N-methyl-3-thiosemicarbazonato)-3-(4-N-amino-3-thiosemi 
carbazonato) zinc(II), Zn(ATSM/A) (35) 
This synthesis was carried out following a previously reported procedure with some 
modifications,7 as described below. 
 
 Step 1: Synthesis of diacetyl-2-(4-N-methyl-3-thiosemicarbazone) (35a) 
4-methyl-3-thiosemicarbazide (3.45 g, 32.80 mmol, 1 eq) was added to 100 mL of deionised 
water and vigorously stirred at strictly 0 oC. Next, 5 drops of concentrated HCl was added 
followed by the rapid addition of 2,3-butanedione (3.5 mL, 39.90 mmol, 1.2 eq) from a syringe. 
The yellow solution quickly became opaque as a white precipitate formed. After 1 hour of 
stirring at 0 oC, the precipitate was collected by filtration, washed thoroughly with cold water (5 
x 30 mL) and dried on air over filter paper overnight. The compound was recrystallised from 
hot aqueous ethanol and a fluffy white solid was obtained.  
 
Yield: 56% (3.18 g). 
1H NMR (300 MHz, DMSO-d6, 298 K): δ (ppm) 10.59 (s, 1 H, CSNHN), 8.59 (s, 1 H, 
CH3NHCS), 3.04 (s, 3 H, CH3NH), 2.40 (s, 3 H, CH3CO), 1.94 (s, 3 H, CH3CN).  
13C{1H} NMR (75 MHz, DMSO-d6, 298 K): δ (ppm) 197.8, 179.3, 145.8, 31.7, 25.1, 10.3.  
nESI-MS+: m/z calculated for C6H11N3OS: 196.0515, found 196.0513 [M+Na]+. 
 
 Step 2: Synthesis of diacetyl-2-(4-N-methyl-3-thiosemicarbazone)-3-(4-N-amino-3-
thiosemicarbazone), H2ATSM/A (35b) 
Thiocarbohydrazide (1.96 g, 18.51 mmol, 1 eq) was added to 105 mL of ethanol in a 3-neck 
round-bottom flask and the suspension was stirred at 50 oC. 4-N-substituted 
monoketothiosemicarbazone (compound 35a) (3.21 g, 18.51 mmol, 1 eq) was added in small 
portions over 2 hours. After the final addition, 5 drops of 10% HCl(aq) was added and the 
reaction mixture was heated under reflux for 5 hours. During this time a cream/white 
suspension formed. The mixture was allowed to cool to room temperature, and then the 
precipitate was collected by filtration, washed with ethanol (2 x 30 mL) and diethyl ether (5 x 
30 mL), and dried under vacuum. The product was recrystallised from warm DMSO/water, and 
a pale yellow powder was obtained.  
 
 




Yield: 80% (3.89 g). 
1H NMR (300 MHz, DMSO-d6, 298 K): δ (ppm) 10.23 (s, 2 H, NHCSNHN), 9.70 (s, 1 H, 
NHNH2), 8.36 (s, 1 H, CH3NHCS), 4.96 (s, 2 H, NHNH2), 3.00 (d, 3 H, J = 4.43 Hz, NHCH3), 
2.18 (s, 3 H, CH3CN), 2.18 (s, 3 H, CH3CN).  
13C{1H} NMR (75 MHz, DMSO-d6, 298 K): δ (ppm) 178.7, 176.2, 148.4, 148.4, 31.5, 11.9, 11.9. 
EI-MS+: m/z calculated for C7H15N7S2: 261.1, found 261.0 [M]+·. 
 
 Step 3: Synthesis of diacetyl-2-(4-N-methyl-3-thiosemicarbazonato)-3-(4-N-amino-3-
thiosemicarbazonato) zinc(II), Zn(ATSM/A) (35c) 
H2ATSM/A (compound 35b) (3.50 g, 13.39 mmol, 1 eq) was added to 74 mL of methanol in a 
round-bottom flask and the suspension was stirred. Zinc(II) acetate dihydrate (3.53 g, 16.07 
mmol, 1.2 eq) was added to the flask, and the mixture was heated under reflux for 4 hours. 
After this time, the suspension was left to cool down and the precipitate was then filtered and 
washed with methanol (3 x 30 mL) and diethyl ether (7 x 30 mL). The yellow-green precipitate 
was left to dry on the freeze-drier overnight.  
 
Yield: 65% (2.18 g). 
1H NMR (500 MHz, DMSO-d6, 298 K): δ (ppm) 8.22 (br s, 1 H, NHNH2), 7.21 (s, 1 H, CH3NH), 
4.80 (s, 2 H, NHNH2), 2.83 (d, 3 H, J = 3.98 Hz, CH3NH), 2.23 (s, 3 H, CH3CN), 2.21 (s, 3 H, 
CH3CN).  
13C{1H} NMR (126 MHz, DMSO-d6, 298 K): δ (ppm) 178.3, 177.2, 145.8, 145.8, 29.2, 13.9, 
13.9. 
APCI-MS+: m/z calculated for C7H13N7S2Zn: 324.0038, found 324.0037 [M+H]+. 
IR: ṽ (cm-1): 3236, 2925, 1426, 1039. 
HPLC (Method A): Rt (min): 8.1. 
 
  




Zn(ATSM/A) modified silica-coated magnetic IONPs (36) 
 
Fe3O4@SiO2 nanoparticles (0.10 g) were added to a round-bottom flask and dispersed in 200 
mL of methanol. Next, Zn(ATSM/A) (compound 35c) (0.10 g, 0.31 mmol) was added to the 
flask and the mixture was mechanically stirred and heated to 80 oC under reflux. After 16 hours, 
the mixture was left to cool to room temperature, then the nanocomposite was separated by 
magnetic decantation and centrifugation and it was further washed with methanol. 
 
IR: ṽ (cm-1): 3327, 2947, 2826. 
 
Citric acid-coated magnetic IONPs (37) 
 
This synthesis was carried out following a previously reported procedure with some 
modifications,8 as described below. 
  
Dry Fe3O4 nanoparticles (1.20 g, 5.20 mmol) were dispersed in 85 mL of milli-Q water. Then, 
a 0.1 g/mL citric acid aqueous solution was added to the nanoparticles dispersion while this 
was mechanically stirred, until pH 5 was achieved. The mixture was heated to 85 °C and stirred 
for 3 hours. After this time, it was left to cool to room temperature and the nanocomposites 
were isolated by centrifugation.  
 
IR: ṽ (cm-1): 3359, 2955, 2939, 1462, 1130, 1032, 663. 
 
  





4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate functionalised citric 
acid-coated magnetic IONPs (38) 
 
3,5-bis(bromomethyl)-2,4,6-triethylbenzyl 4-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (compound 5) (50 mg, 70 μmol) and 
citric acid-coated Fe3O4 nanoparticles (100 mg) were mixed in a round-bottom flask and 
dispersed in 25 mL of acetonitrile. The reaction mixture was heated to 100 oC under reflux and 
it was mechanically stirred for 16 hours. After this time, the mixture was left to cool to room 
temperature and it was centrifuged. The obtained nanocomposite was washed with methanol 
twice and isolated by centrifugation. 
 
IR: ṽ (cm-1): 2972, 2138, 1654, 1601, 1569, 1388, 1263, 1098, 806, 656. 
 
  




Radiolabelling experiments involving gallium-68 
Synthesis of gallium-68 
The positron-emitting radiotracer [68Ga]GaCl3 was prepared at the Department of Surgery and 
Cancer of the Imperial College London using either a TiO2 or a SnO2-based column matrix 
68Ge/68Ga generator via the (p,2n) reaction on gallium targets. 
 
General procedure for Method 1:  Fe3O4@SiO2@68Ga (39) and 
Fe3O4/Cd0.1Zn0.9Se@SiO2@68Ga (40) 
    
The nanoparticles system (Fe3O4/Cd0.1Zn0.9Se@SiO2 or Fe3O4@SiO2) (1 mg) dispersed in 
dimethylsulfoxide (1 mg/mL) was centrifuged and 30 μL of the precipitated nanocomposite was 
added to a Wheaton vial along with 0.2 mL of ethanol, 50 μL of [68Ga]GaCl3 solution (from a 
133 MBq stock solution) and 0.1 mL of a sodium acetate buffer solution in order to adjust the 
pH to approximately 5. The reaction was carried out for 40 minutes at 90 oC, using a vortex 
stirrer to mix the contents every 10 minutes. After this time, the radiolabelled nanocomposites 
were isolated by centrifugation and washed with methanol and water. Then, the radiolabelling 
efficiency was determined by radio-TLC. 
 
RCY (Fe3O4@SiO2@68Ga) ≥ 99.9 % 
RCY (Fe3O4/Cd0.1Zn0.9Se@SiO2@68Ga) ≥ 99.9 % 
 
  




General procedure for Method 2:  Fe3O4@SiO2@68Ga@SiO2 (41) and 
Fe3O4/Cd0.1Zn0.9Se@SiO2@68Ga@SiO2 (42) 
    
The nanoparticles system (Fe3O4/Cd0.1Zn0.9Se@SiO2 or Fe3O4@SiO2) (1 mg) dispersed in 
dimethylsulfoxide (1 mg/mL) was centrifuged and 30 μL of the precipitated nanocomposite was 
added to a Wheaton vial along with 3.5 mL of cyclohexane, 50 μL of [68Ga]GaCl3 solution (from 
a 133 MBq stock solution) and 24 μL of tetraethylorthosilicate. The reaction mixture was heated 
to 90 °C and reacted for 68 minutes, using a vortex stirrer to mix the contents every 10 minutes. 
The resulting nanocomposite was transferred to centrifuge vials and washed once with 
methanol and three more times with water, then separated by magnetic decantation. 
 
RCY (Fe3O4@SiO2@68Ga@SiO2) = 70 % 
RCY (Fe3O4/Cd0.1Zn0.9Se@SiO2@68Ga@SiO2) = 66 % 
 
  




General procedure for Method 3: Fe3O4@SiO2@Zn(ATSM/A)@68Ga (43) 
 
Fe3O4@SiO2@Zn(ATSM/A) nanoparticles (1 mg) dispersed in dimethylsulfoxide (1 mg/mL) 
were centrifuged and 50 μL of the precipitated nanocomposite was added to a Wheaton vial 
along with 0.1 mL of [68Ga]GaCl3 solution (from a 133 MBq stock solution), 0.2 mL of ethanol 
and 0.1 mL of a sodium acetate buffer solution in order to adjust the pH to approximately 5. 
The reaction was carried out for 40 minutes at 90 °C, using a vortex stirrer to mix the contents 
every 10 minutes. The resulting nanocomposite was transferred to centrifuge vials and washed 
once with methanol and three more times with water, then separated by magnetic decantation. 
After this time, the radiolabelling efficiency was determined by radio-TLC. 
 
RCY (Fe3O4@SiO2@Zn(ATSM/A)@68Ga) ≥ 99.9 % 
 
Reaction between Zn(ATSM/A) and [68Ga]GaCl3: Zn(ATSM/A)@68Ga (44) 
 
Zn(ATSM/A) (1 mg) dispersed in dimethylsulfoxide (1 mg/mL) was centrifuged and 50 μL of 
the precipitate was added to a Wheaton vial along with 0.1 mL of [68Ga]GaCl3 solution (from a 
133 MBq stock solution), 0.2 mL of ethanol and 0.1 mL of a sodium acetate buffer solution in 
order to adjust the pH to approximately 5. The reaction was carried out for 40 minutes at 90 
°C, using a vortex stirrer to mix the contents every 10 minutes. The resulting product was 
transferred to centrifuge vials and washed once with methanol and three more times with 
water, then separated by centrifugation. After this time, the radiolabelling efficiency was 
determined by radio-HPLC. 
 
RCY (Zn(ATSM/A)@68Ga) = 0 % 
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Figure A.3. FT-IR spectrum of compound 1. 
 
 
Table A.1. Band assignment for the FT-IR spectrum of compound 1 (Figure A.3). 
Wavenumber (cm-1) Peak intensity Vibrational mode 
2966 Multiplet, strong ar. C – H st 
2872 Multiplet, medium C – H st (alkyl) 
2300 – 1900 Very weak Overtones and comb 
1570 Medium ar. C – C st 
957 Medium ar. C – H δ oop 
901 Weak C = C δ 
































Figure A.8. (A) Mass spectrum of compound 14 using nESI+, and (B) mass spectrum of compound 15 






















Figure A.12. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 15 minutes 
at 37 oC with compound 5. Final concentration: 100 μM in serum-free medium (1% DMSO). a-e) λex = 
405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-green-red channels; b, g, l) blue 
channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) red channel (λem = 570-







Figure A.13. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 30 minutes 
at 37 oC with LysoTracker Red, and 20 minutes with compound 5. Final concentration: 100 μM in 
serum-free medium (1% DMSO) solution of compound 5, with a 100 nM concentration solution of 
LysoTracker Red. a-e) λex = 405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-
green-red channels; b, g, l) blue channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 







Figure A.14. Single-photon laser scanning confocal microscopy of PC-3 cells incubated for 30 minutes 
at 37 oC with ER-Tracker Red, and 20 minutes with compound 5. Final concentration: 100 μM in serum-
free medium (1% DMSO) solution of compound 6, with a 100 nM concentration solution of ER-Tracker 
Red. a-e) λex = 405 nm; f-j) λex = 488 nm; k-o) λex = 561 nm. a, f, k) overlay of DIC-blue-green-red 
channels; b, g, l) blue channel (λem = 417-477 nm); c, h, m) green channel (λem = 500-550 nm); d, i, n) 







Appendix B.1 (Chapter 4) 
Crystallographic data for Compound 26 
Table B.1. Crystal data and structure refinement for compound 26. 
Identification code  s17sip9 
Empirical formula * C12.20 H25.98 Br1.30 N4.50 O1.08 S1.50 
Formula weight  404.76 
Temperature  150(2) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 12.0106(3) Å      a = 114.815(2)° 
 b = 13.7028(3) Å      b= 94.995(2)° 
 c = 13.9941(3) Å      g = 111.719(2)° 
Volume 1860.12(8) Å3 
Z 1 
Density (calculated) 1.445 Mg/m3 
Absorption coefficient 5.371 mm-1 
F(000) 835 
Crystal size 0.200 x 0.080 x 0.080 mm3 
Theta range for data collection 3.633 to 73.133°. 
Index ranges -14<=h<=14, -16<=k<=16, -17<=l<=17 
Reflections collected 33227 
Independent reflections 7397 [R(int) = 0.0425] 
Completeness to theta = 67.684° 100.0 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7397 / 78 / 522 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0443, wR2 = 0.1276 
R indices (all data) R1 = 0.0481, wR2 = 0.1320 
Extinction coefficient n/a 
Largest diff. peak and hole 1.121 and -0.509 e.Å-3 
 
* Moiety formula (estimated from “checkcif”): 2 (C21 H40 N9 S3), 2 (C2 H6 O), 0.5 (C2 H3 





Crystallographic data for Compound 27 
Table B.2. Crystal data and structure refinement for compound 27. 
Identification code  s17sip8 
Empirical formula * C51 H108 Br5 N18 O4 S8 
Formula weight  1693.58 
Temperature  150(2) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 12.5296(5) Å                      a = 112.797(3)° 
b = 13.5000(5) Å                      b = 98.550(3)° 
c = 13.9378(4) Å                      g = 109.516(4). 
Volume 1940.77(13) Å3 
Z 1 
Density (calculated) 1.449 Mg/m3 
Absorption coefficient 5.552 mm-1 
F(000) 875 
Crystal size 0.180 x 0.060 x 0.040 mm3 
Theta range for data collection 3.631 to 73.066°. 
Index ranges -15<=h<=15, -16<=k<=15, -17<=l<=16 
Reflections collected 13739 
Independent reflections 7543 [R(int) = 0.0333] 
Completeness to theta = 67.684° 99.0 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7543 / 13 / 544 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0476, wR2 = 0.1332 
R indices (all data) R1 = 0.0553, wR2 = 0.1401 
Extinction coefficient n/a 
Largest diff. peak and hole 1.144 and -1.154 e.Å-3 
 
* Moiety formula (estimated from “checkcif”): 2 (C24 H48 N9 S3), O S2, C H4 O2, C H4 O, C 







Crystallographic data for Compound 29 
Table B.3. Crystal data and structure refinement for compound 29. 
Identification code  s17sip11 
Empirical formula * C55 H100 Br6 N18 O S6 
Formula weight  1701.34 
Temperature  150.00(10) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions 
a = 12.0882(4) Å                        a = 96.535(3)° 
b = 13.7029(4) Å                        b = 112.376(3)° 
c = 14.4245(4) Å                        g = 114.554(3)° 
Volume 1901.63(11) Å3 
Z 1 
Density (calculated) 1.486 Mg/m3 
Absorption coefficient 5.734 mm-1 
F(000) 870 
Crystal size 0.100 x 0.100 x 0.050 mm3 
Theta range for data collection 3.502 to 73.158°. 
Index ranges -13<=h<=14, -16<=k<=16, -17<=l<=16 
Reflections collected 16908 
Independent reflections 7539 [R(int) = 0.0310] 
Completeness to theta = 67.684° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.83398 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7539 / 14 / 531 
Goodness-of-fit on F2 1.071 
Final R indices [I>2sigma(I)] R1 = 0.0429, wR2 = 0.1105 
R indices (all data) R1 = 0.0494, wR2 = 0.1158 
Extinction coefficient n/a 
Largest diff. peak and hole 1.515 and -0.807 e.Å-3 
 









Figure B.1. Crystal structure for compound 26 (generated from “checkcif”). 
 
 






























Appendix B.2 (Chapter 4) 
Attempted complexation to metals 
 Attempted complexation with zirconium(IV) 
Zirconium exists in aqueous solutions mainly as Zr(IV), with an oxidation state of +4. This 
cation is a hard (Lewis) acid and has an ionic radius of 0.74-0.84 Å.1 The tetravalent cation 
Zr4+ usually forms 6- and 8-coordinate complexes.2, 3 Zirconium is an early transition metal and, 
for this reason, its ion presents relatively low effective nuclear charge. Zr has high oxidation 
states and the electron configuration for Zr(IV) consists in the loss of all the valence d-
electrons, 4d0. The large charge density of Zr(IV) is strongly polarising, and this leads to a 
dramatic increase in acidity of the coordinated aqua ligands, with a strong tendency of forming 
oxides and hydroxides, which quickly undergo hydrolysis to form highly insoluble polymeric 
and colloidal species.4 
 
For the purpose of coordinating Zr4+ to the thiosemicarbazide derivatives, ZrCl4 was used to 
try to form a coordination complex with the tripodal thiosemicarbazide ligands synthesised in 
this chapter. The stoichiometry and geometry of the obtained compounds are difficult to predict 
as these will depend on a number of things: reaction kinetics, synthesis, analysis, etc. 
Accordingly, and considering that Zr(IV) is oxophilic, a couple of structures were considered. 
Among other possibilities, a complex consisting in a Zr4+ ion surrounded by one molecule of 
the ligand, with the metal coordinated on the N atoms of the latter, and with two extra water 
molecules attached to Zr(IV) to complete the octa-coordination would be possible, as would 
be a complex containing one Zr4+ ion and two molecules of the ligand, encapsulating the metal 






Figure B.4. Proposed structures of two complexes between Zr(IV) and a tripodal thiosemicarbazide 
ligand, one involving one unit of the latter (left), and the other one involving two units of the ligand 
forming a cage (right).  
 
Three different reaction conditions were tried to coordinate Zr(IV) using compounds 26 and 27, 
respectively. In all the cases, a yellow/brown solid was obtained. It was characterised by mass 
spectrometry using different methods: electrospray and nanoelectrospray ionisation, matrix-
assisted laser desorption/ionisation (MALDI), and atmospheric-pressure chemical ionisation 
(APCI) with an atmospheric solids analysis probe (ASAP) in case the products were sensitive 
to water. No evidence of the target materials could be found in the APCI and MALDI analyses 
of these samples, the latter one being performed with two different matrices. Therefore, none 
of the data gave any indication of the target compounds, or the presence of the metal used for 
these reactions, Zr(IV). Using ESI+ and nESI+ on the products obtained from the reactions 2 
and 3 (Table 4.4), a high intensity peak at m/z = 556.3019 could be identified in the spectra, 
which corresponds to the ligand used as starting material (compound 27) with an extra proton, 






Figure B.5. Mass spectrum of the product from reaction 2 using nESI+, and amplification of the isotopic 
pattern found for the starting material (compound 27). 
  
 Attempted complexation with gallium(III) and indium(III)  
Elements in the Group 13 of the Periodic Table, especially gallium and indium, have atoms 
with similar properties. The most common ions for these elements, Ga3+ and In3+, have valence 
electrons with the configuration nd10. Both elements have radioisotopes that can be used in 
PET and SPECT imaging: gallium-68 and indium-111, respectively. The coordination 
chemistry of gallium and indium is dominated by the +3 oxidation state. They are both hard 
Lewis acids and tend to form six-coordinate complexes, producing thermodynamically stable 
complexes with ligands that are hard Lewis bases. Such ligands should contain oxygen and 
nitrogen donor atoms.5-7 Gallium can form, in some occasions, four- and five-coordinate 
complexes, while indium can only form six-coordinated species due to the larger ionic radii.6 
 
In aqueous solutions, the only stable oxidation state of gallium is +3, and the free hydrated 
Ga3+ ion is stable only under acidic conditions. It can easily form the insoluble complex 
Ga(OH)3 in an aqueous environment, while at the physiological pH the solubility is high due to 





by adding stabilising weak ligands such as acetate or citrate in the preparation of the 
complexes.8 It has already been mentioned that thiosemicarbazide derivatives have many 
advantages, including their anti-microbial properties. Thanks to this, gallium complexes with 
this type of compounds can present anti-microbial effects and the activities of the metal and 
the ligand are enhanced.9  
 
The ion Ga3+ has similar properties to the high spin Fe3+ with respect to their coordination 
chemistry and the majority of chelators being hexadentate. They have similar ionic radii: 62 
pm for Ga3+ and 65 pm for Fe3+, and the same preferred coordination number of six, although 
gallium complexes can also be four- or five-coordinated, but they are not so common.2, 8 When 
using a Ga3+ chelate for radiopharmaceutical purposes in a physiological environment, it is 
important for the complex to be thermodynamically stable towards hydrolysis and be kinetically 
inert during the period of clinical use, in a way such that ligand exchange with the blood serum 
protein transferrin can be avoided. Transferrin has a high affinity for Fe3+, and also for Ga3+ at 
the physiological environment. For this reason, in order to use a gallium complex for clinical 
purposes, the Ga3+-ligand complexes should be more stable than the Ga3+-transferrin complex 
or be kinetically inert so that they do not exchange with this protein.8 
 
GaCl3 and InCl3 were used as sources of Ga(III) and In(III), respectively, to coordinate them to 
a tripodal thiosemicarbazide ligand under a variety of conditions, both anhydrous and in 
aqueous solvents. Gallium and indium compounds usually form complexes with 
thiosemicarbazide derivatives being coordinated by the S and N donor atoms of the ligand, 
with a remaining Cl- atom coordinated to the metal centre that still remains from the metal salt 
used as starting material (Figure B.6).  
 







Four different reaction conditions using GaCl3 were tested, and other two using InCl3. When 
the conditions shown in the entry 4 of the table were used, a brown solid was isolated, while a 
white solid was obtained using the reaction conditions shown in the entries [5-9]. All the 
products were characterised by mass spectrometry using the same methods as before (ESI, 
nESI, MALDI and APCI). Ions correlating with the proposed molecular structure or variations 
of this were not observed, neither ions that correspond to two ligands encapsulating one metal 
atom or other more complex structures of the kind. Moreover, there was no evidence of Ga-
containing species. However, for reactions [5-9] a peak could be observed in the mass 
spectrum due to the protonated ligand used as starting material, [M+H]+, which are compounds 
26 and 27, accordingly (Figure B.7). 
 
Figure B.7. Mass spectrum of the product from reaction 5 using nESI+, and amplification of the isotopic 
pattern found for the starting material (compound 26). 
 
Reactions 5 and 8 were carried out adding a sodium acetate buffer solution to control the pH 
of the reaction mixture and adjust it to approximately 4, the optimum pH for these two different 
metal ions to react and be chelated to form a metal-ligand complex. 
 
Metal ions from the Group 13 of the Periodic Table (Al, Ga, In and Tl) do not have a main 
biological role. However, they are all NMR active nuclides, and as such they can be used in 
nuclear magnetic resonance spectroscopy of biologically relevant systems. Except thallium, all 





type and coordination geometry.10 In the case of gallium, there are two quadrupolar NMR active 
nuclei of this element: 69Ga and 71Ga. Even though 71Ga is less naturally abundant, it is 
generally the isotope of choice to perform NMR spectroscopy due to its sensitivity and lower 
quadrupolar moment. 
 
In this work, 71Ga NMR spectroscopy was performed at the University of Oxford by Dr. Nick 
Rees to try to identify the presence of this metal in the product from reaction 4 (Figure B.8). 
Gallium seems to be present in the molecule, as the spectrum is not a flat line. However, as 
71Ga NMR spectra can only be obtained when the Ga(III) ions are in a highly symmetrical local 
environment (e.g., in octahedral [Ga(H2O)6]3+ or in tetrahedral [Ga(OH)4]-), it is not possible to 
identify any peak in the spectrum for this molecule.11, 12  
 
Figure B.18. 71Ga NMR (152 MHz, 298 K) spectra of GaCl3 (DMSO-d6) (red line), GaCl4- (CD2Cl2) 
(green line), and the product from reaction 4 (DMSO-d6) (blue line). 
 
 Attempted complexation with copper(II), nickel(II) and zinc(II)  
Copper is a biologically active and essential ion, whose chelating ability and its positive redox 
potential allow the participation of this species in biological transport reactions.13 The most 
important oxidation state of copper to form complexes is the divalent Cu(II), as it has a greater 





techniques such as NMR spectroscopy due to copper(II) complexes being paramagnetic. For 
this reason, reactions with nickel(II) and zinc(II) were also performed as the resulting 
compounds should be, a priori, easier to characterise as both elements are diamagnetic in 
these oxidation states.14 
 
Accordingly, three different reaction conditions were tested using Cu(OAc)2 and Zn(OAc)2, and 
two different ones using Ni(OAc)2·4H2O. Solids of different brownish tones were obtained for 
Cu(II) and Ni(II), while the solids resulting from the reactions with Zn(II) were all yellow or white. 
The proposed structure resulting from the complexation of the tripodal thiosemicarbazide 
ligands with these metal salts is a tetra-coordinated system where the metal is bound to the 
chelator by the two N and the two S atoms of the latter (Figure B.9).  
 
Figure B.9. Proposed structure of a complex between a M(II), which can be Cu2+, Ni2+ or Zn2+, and a 
tripodal thiosemicarbazide ligand.  
 
All the solids obtained were characterised by mass spectrometry using ESI, nESI, MALDI and 
APCI methods. No evidence of ions that correspond to the proposed molecule or ions with 
isotope profiles that show the incorporation of the metal ions were observed. In this case, it 
was not possible to find either peaks corresponding to the tripodal thiosemicarbazide ligand 
used as starting material. Since none of the starting materials could be identified through the 
characterisation techniques, there is the possibility that a complex polymeric structure was 
formed. 
 
 Further characterisation of the compounds and discussion 
Elemental analysis was carried out on the ligands (compounds 26, 27, 28 and 29), considering 
that they are tri-HBr salts, and the products resulting from reactions 14 and 15 (Table B.4). 
The percentages found for C, H and N for the ligands are close to the expected percentages, 





percentages were calculated adding to the system 3 HBr molecules, which can be found in the 
crystal structures of the products and remain from the triply brominated starting material. 
 
Table B.4. Elemental analysis results and expected values for the tripodal thiosemicarbazide ligands 
and two complexes with Ni(II) and Cu(II). 
 Found (%) / Expected (%) 
Compound C H N 
26 · 3 HBr 31.69 33.34 5.77 5.60 15.67 16.66 
27 · 3 HBr 34.08 36.10 5.87 6.06 14.33 15.79 
28 · 3 HBr 40.87 45.87 5.15 5.13 13.32 13.37 
29 · 3 HBr 37.70 38.85 5.72 5.80 14.10 15.10 
Reaction 14 47.13 46.75 7.15 7.68 8.94 20.45 
Reaction 15 46.07 46.25 6.62 7.60 6.44 20.23 
 
The ligands (compounds 26, 27, 28 and 29) and the products from the complexation reactions 
were characterised by Raman spectroscopy (Figure B.10). The spectra of compounds 26 and 
27 are alike, with similar peaks and intensities. This is due to the similarity in the structure of 
these two compounds, which only differ in three extra methyl groups at the end of each 
thiosemicarbazide arm for compound 27. However, the spectra of compounds 28 and 29 are 
different among them and in comparison to the previous two ligands, as these two molecules 
have a phenyl and an allyl group, respectively, at the end of each of the three 
thiosemicarbazide arms. Regarding the products obtained from some of the reactions, those 
of reactions 5 and 6 have similar Raman spectra, as they are both solids coming from a 
reaction between compound 26 and GaCl3. The solids from reactions 8 and 9 are both 
potentially InCl3 derivatives with compound 26, and their spectra also present many similarities 
in peaks and intensities. The solid from reaction 12 is a Cu(II) derivative with compound 29, 
and the one from reaction 16 is a Zn(II) derivative with the same compound. These two solids 
have different Raman spectra. The solid from reaction 12 has a high intensity peak at around 
650 cm-1, while the solid from reaction 16 does not have it. All the products have a very high 








Figure B.10. Raman spectra of compounds 26 (red), 27 (black), 28 (purple), 29 (orange), and products 
from reactions 5 (blue), 6 (yellow), 8 (dark grey), 9 (green), 12 (pink) and 16 (grey). 
 
Table B.5. Band assignment for the Raman spectra of compounds 26, 27, 28, and 29, and products 
from reactions 5, 6, 8, 9, 12 and 16 (Figure B.10).15, 16 
Wavenumber / cm-1 Vibrational mode 
~ 1650 ν(NC) 
1600 - 1400 ν(CC), δ(HCC), δ(HCH), δ(CCC) 
1315 - 1200 ν(NC), δ(HNC) 
~ 1100 
1000 - 990 
~ 720 
~ 430 














Infrared spectroscopy was also carried out in the solid state (Figure B.11) and, although the 
vibrations in the spectra of the expected metal-ligand complexes when compared to the ligand 
used as starting material are similar, they appear at slightly different wavenumbers (Table 
B.6).17 Accordingly, it can be observed that the band corresponding to v(C=N) is shifted in the 
metal-ligand complexes to a lower frequency. However, the coordination positions of the 
ligands with the metals cannot be elucidated using FT-IR, as the lowest recorded frequency is 
650  cm-1, and these would appear at smaller wavenumbers. 
 







Table B.6. Band assignment for the FT-IR spectra of compound 29 and products from reactions 16 
and 12 (Figure B.11).  









668 C-S st 
Reaction 16 
3199 N-H st 
2973 C-H st 
1569 C=N st 
672 C-S st 
Reaction 12 
3214 N-H st 
2966 C-H st 
1560 
C=N st  
1438 
650 C-S st 
 
UV/visible spectroscopy was carried out in order to compare the properties of the tripodal 
thiosemicarbazide ligands with those of the products from the reactions with metals (Figure 
B.12). The spectrum of compound 26 shows a sharp peak at 262 nm. The spectra of the solids 
from some reactions carried out using this compound (1, 4, 9 and 10) are overlaid with the 
spectrum of compound 26. The products from reactions 4 and 10 have maximum intensity 
peaks at 261 nm, and the one from reaction 9 has its maximum at 270 nm. The three solids 
have a peak followed by a tail, which is likely due to the charge transfer band in the metal-
ligand complex. Solid 1 has relative maximums at 261 nm and 381 nm, and an absolute 
maximum at 359 nm. The shape of the spectrum for this product is peculiar and different to the 
other three, with two curves and three peaks. The spectrum of compound 27 shows a 
maximum intensity peak at 268 nm. The close wavelength might be due to the similar 
structures of compounds 26 and 27. When compared to the spectra of the products from 
reactions 14 and 15, which were carried out using this ligand as starting material, they have 
similar maxima, the latter two being at 270 nm. However, the shape of the peak is different in 
each case; the spectra of the two solids have a tail, likely due again to the charge transfer band 
in the complex. In general, there are wider peaks in the spectra of the potential synthesised 
complexes than in those of the ligands. Fluorescence spectroscopy was carried out but the 






Figure B.12. Normalised UV/visible spectra of compounds 26 (red) and 27 (black), and products from 
reactions 1 (blue), 4 (purple), 9 (green), 10 (yellow), 14 (light green) and 15 (dark red). 
 
NMR spectroscopy analyses were carried out on these solids but the results were not 
conclusive: in some cases, only peaks due to solvents and water could be observed, while in 
other cases the spectra presented similar resonances to those in the spectra of compounds 
26, 27, 28 and 29. For some products, new resonances appeared in the spectra of the resulting 






Numerous attempts to grow crystals of these molecules for single crystal X-ray diffraction 
analysis were carried out, all of them unsuccessfully.  
 
Looking at all the data collected to analyse these potential metal-ligand complexes, 
conclusions can be made. While mass spectrometry does not show evidence of the formation 
of the complexes, other analysis such as UV/visible spectroscopy show peaks that indicate 
that a metal is present in the product and coordinated to a ligand. Moreover, IR spectroscopy 
shows signals corresponding to the ligand used as starting material for each reaction, which is 
coherent as the organic part is the one that can be seen in the IR spectra and this remains 
unchanged from the ligand. Raman spectroscopy suggests the same, with some visible peaks 
assignable to the stretching of bonds in the ligand. In summary, the formation of complexes 
with metals possibly worked, but the structure of the final products could not be identified. 
When complexes could be synthesised, even without having the desired analytical information, 
they could potentially be air and water sensitive. This is not desired for an in vivo imaging 
agent. Moreover, all the solids resulting from the reactions with the metals were highly insoluble 
in aqueous and organic solvents, therefore not suitable for in vivo or in vitro studies. Finally, 
the formation of polymer-like structures, with many units of the ligand and metal ion used, 
should also be considered, as it has been seen to happen in the crystal structures through 
hydrogen bonding. This would hinder even more the characterisation of the products. 
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